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Cough is common but has been under-researched. In tuberculosis cough is probably of 
particular relevance in transmitting infection.  
This thesis explores several interlinking areas. Regarding how best to measure cough, 
coughs are shown to be recognizable to the human ear, but automated cough 
monitors can disagree with auditory cough counting. A novel approach to testing 
cough reflex sensitivity is described, E62.5.   
There was no evidence to support the hypothesis that cough has unique characteristics 
in tuberculosis, in terms of symptoms, frequency and clustering. A significant reduction 
of cough frequency in tuberculosis is demonstrated overnight. Clinical correlates of 24-
hour cough frequency were explored; female sex in unexplained chronic cough, and 
sputum smear status in tuberculosis were important, and possibly transfer factor in 
pulmonary fibrosis and duration of symptoms prior to treatment in COPD 
exacerbations. Cough frequency correlated poorly with symptoms. 
There seem to be both generic and disease-specific mechanisms associated with 
cough. This was further suggested by a faster reduction in cough frequency with 
treatment in pneumonia than in acute asthma and COPD exacerbations, correlating 
with C-reactive protein decline only in pneumonia. A serial reduction in 24-hour cough 
frequency in tuberculosis during the whole course of treatment was demonstrated, a 
potentially novel approach to measuring treatment response.  
The role of genetic polymorphism in the cough receptor gene TRPV1 was explored, 
but, at least in chronic cough was not demonstrated to predict coughing. 
Regarding the infectiousness of coughs, an airborne particle counter was shown not to 
be sensitive enough for measuring droplets released during coughing in room air. 
However, I demonstrate for the first time a significant association between 24-hour 
cough frequency in TB and household infection. 
This work has set a foundation for the further investigation of the mechanisms, 
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FVC – forced vital capacity 
FFP – filtering face piece 
HEPA - high-efficiency particulate arrestance 
HRCT – high-resolution computed tomography 
HUH – Homerton University Hospital (NHS Foundation Trust) 
ICC – intraclass correlation coefficient 
IGRA – interferon gamma release assay  
ILD – interstitial lung disease 
IPF – idiopathic pulmonary fibrosis 
IQR – interquartile range 
KCO - lung transfer factor for carbon monoxide per unit lung volume 
LCM – Leicester Cough Monitor 
LCQ – Leicester Cough Questionnaire 
Lone cough – a cough separated in time from other cough sounds from the same 
individual by ≥ 2 s   
LTBI – latent tuberculosis infection 
MIRU-VNTR - mycobacterial interspersed repetitive units  - variable number of tandem 
repeats 





PEFR – peak expiratory flow rate 
PTC - phenylthiocarbamide 
q – quantum, the lowest dose of Mycobacterium tuberculosis required to cause new 
infection 
QFT – QuantiFERON® 
RH – relative humidity 
SD – standard deviation 
SNP – single nucleotide polymorphism 
TB – tuberculosis 
TLC – total lung capacity 
TLCO – total lung transfer factor for carbon monoxide  
TRPV1 – transient receptor potential vannilloid 1 
UIP – usual interstitial pneumonia 
URTI – upper respiratory tract infection 












1 Background and aims of thesis 
1.1 Definition of cough 
Cough is an onomatopoeic word, in English as well as many other languages . The 
distinctive sound is produced by the rapid release of air through the opening vocal 
cords which have been held closed against a forced expiratory movement.1 
Correspondingly, the definition of cough proposed by the British Thoracic Society is a 
‘forced expulsive manoeuvre, usually against a closed glottis and which is associated 
with a characteristic sound’.2 
There has been debate about whether a ‘true’ cough is only that which is preceded by 
an inspiratory phase in contrast to an expiration reflex which is not.3 On this basis a 
burst of cough sounds preceded by a single breath would be classed only as a single 
cough. However, the majority of doctors with an interest in cough seem to classify 
each typical sound within a cluster as an individual cough.4 Presumably the lay person 
or patient experiencing cough would classify a cough likewise. To avoid ambiguity, 
particularly when the frequency of coughing is being discussed, individual cough 
sounds are often distinguished from bouts, peals, series or epochs of coughing.5,6 A 
cough epoch has been defined, arbitrarily, as more than one closely-spaced cough 
sounds, each of which occurs no later than 2 s than the one preceding it.5 Throughout 
this thesis a ‘cough’ has been taken to refer an individual cough sound while a cough 
bout refers to the equivalent of a cough epoch following the definition above. In turn, 
a cough ‘episode’ refers to either a single cough or a coughing bout (see  
1.2 The physiological role of cough 
The purpose of cough is defensive, for removing particles, mucus and other potentially 
harmful material from the airways.1 It is a physiological phenomenon that is shared 
with other species, but it perhaps more important in humans as our upright posture 
leads to an increased risk of aspiration.7 Sensory receptors are located mainly in the 







Figure 1.1. Basic anatomy of the cough reflex. 
 
mechanical and chemical stimuli including smoke, hypotonic and hypertonic saline, 
acidic and alkaline solutions, bronchoconstriction and heat.9 The importance of an 
intact cough reflex is demonstrated by an increased risk of aspiration pneumonia 
where it is impaired, for example in old age10,11 and stroke.12 Also, in some 
Sensory afferent cough receptors, predominantly located in the central airways and larynx, input via the vagus nerve 
(orange) to the brainstem, which in turn triggers coughing via efferent relay (green) to the diaphragm and 
intercostal muscles. Note the involvement of the cerebral cortex in sensation and the volitional control of cough. 





circumstances, voluntarily suppressing cough is thought to lead to chronic pulmonary 
infection.13 Conversely, the use of angiotensin-converting enzyme (ACE) inhibitors, 
which enhance the cough reflex,14 has been associated with a reduced risk of 
pneumonia.15  
1.3 Mechanisms of coughing 
The current paucity of effective anti-tussive treatments reflects the poor state of 
knowledge of the mechanisms of cough.16,17 The basic anatomy of the cough reflex has 
been elucidated mainly from animal studies, predominantly involving the guinea pig 
and is illustrated in Figure 1.1.9 The vagus nerve communicates  with the nucleus 
tractus solitarius to trigger the characteristic pattern of muscular activity.9,18,19 Input 
from the cerebral cortex is also clearly important, as demonstrated by the ability to 
cough at will or to voluntarily suppress coughing.20 Effective placebo treatments for 
cough probably operate via this route.21  
Sensory afferents include rapidly adapting Aδ fibres and unmyelinated C-fibres which 
interact, but broadly speaking are more responsive to mechanical activity and chemical 
stimuli respectively Figure 1.2.8,22–24 Although the large majority of the work leading to 
the characterisation of these different fibre types has been done in animal models of 
cough (predominantly the guinea pig), a very similar innervation pattern also seems to 
be present in humans.25 The exact purpose of different types of afferent nerve 
continues to be investigated, but is has been suggested that C-fibres could be mainly 
involved in the regulation of cough, whereas the role of Aδ fibres is in cough 
initiation.26 










Figure 1.2. Sensory afferents of the cough reflex. 
1.3.1 Cough receptors 
1.3.1.1 C-fibres 
The receptors associated with C-fibres have been better characterized than those 
triggering the rapidly-adapting Aδ fibres. In particular, the transient receptor potential 
(TRP) ion channels have attracted attention.27 TRP channels compose a large group 
I l lustration of the two main afferent nerve types thought to be involved along with their 



























involved in sensory transduction in response to a number of stimuli in a variety of cell 
types but in the lung appear to have an important role in cough.27–31 For example, 
resiniferatoxin elicits the cough reflex and iodoresiniferatoxin inhibits it by acting on 
the transient receptor potential vanniloid-1 receptor (TRPV1).29,32 TRPV1 is also 
activated by heat, particles and other irritants including capsaicin, the extract of chi llies 
used experimentally for measuring cough reflex sensitivity, as discussed below (Section 
1.6.2.1).31 TRPV1 channels are more abundant in the airways of patients with chronic 
cough compared to healthy controls28,33 and have been shown to be upregulated by 
rhinovirus infection of a human cell culture.34 TRPA1 also appears to have an important 
role, by activating the cough reflex directly and indirectly.35 TRPA1 responds to 
tussogenic irritants which do not activate TRPV1, such as acrolein which is present in 
cigarette smoke and industrially-polluted air.36 
TRPA1 is activated by paracetamol.37 Epidemiological evidence has linked frequent 
paracetamol use to asthma,38 and could perhaps also be associated with cough, 
potentially via TRPA1, although this has not previously been explored.  
TRPM8 responds to menthol and cold temperatures and also seems to be associated 
with C-fibres in animal models.39  
Despite the clear roles of TRPV1, TRPA1 and TRPM8 in the cough reflex, inhibitors of 
these receptors have yet to show clinical utility. For example, in a small study in 
unexplained chronic cough, the TRPV1 antagonist SB-705498 led to a reduction in 
sensitivity to capsaicin on cough challenge testing, but no changes in daily symptoms 
or 24-hour cough frequency.40 
1.3.1.2 Aδ fibres 
Another TRP channel, TRPV4, is also widely-expressed in the respiratory tract.41 
Recently-published work has demonstrated that hypo-osmolar solutions and TRPV4 
ligands cause firing of Aδ fibres, vagus nerve and cough in a conscious guinea  pig 
model, independent of C-fibre activation, and all blocked by TRPV4 inhibitor.42 TRPV4-





gated ion channel present in airway nerves.42 This finding is of particular interest given 
the substantial reduction in cough frequency observed in a subset of patients with 
unexplained chronic cough in a recent small phase 2 trial of AF-219, an inhibitor of 
P2X3.43 
The mechanisms of cough are clearly complex and probably involve several inter-
linking peripheral and central pathways. The lack of efficacy of TRPV1 receptor 
antagonism on cough frequency compared to the results seen with blocking P2X3 
support the idea of a more subtle regulatory role in the cough reflex for C-fibres, in 
contrast to a role of Aδ fibres in cough initiation.  More preclinical and clinical work in 
this area is required. 
1.3.1.3 Taste receptors 
Other sensory receptors in the respiratory tract may also be important in cough. One 
such group are bitter taste receptors. Their evolutionary role is presumably to detect 
toxins and initiate their expulsion, and they have been found in human airway smooth 
muscle,44,45 where they may have a role in asthma.46,47 For example, the G-protein 
coupled T2R bitter taste receptors may promote bronchodilatation.44,48 This would aid 
airway clearance of noxious particles, but it is not known if T2R receptors are directly 
involved in the cough reflex. Conversely sweet tasting substances have been used 
traditionally as cough remedies. One study showed a reduction in cough reflex 
sensitivity after rinsing the mouth with sucrose solution, while a bitter substance had 
no effect.49  
That cough is linked with taste sensation is also suggested by the gustatory side effects 
observed alongside cough suppression with P2X3 inhibition,43 presumably a result of 
inhibition of P2X receptors which are known to have an important role in taste.50 
One simple way of gaining further insight in this area could be through correlating 
variation in taste sensation in the population, such as exists for phenylthiocarbamide 





1.3.2 Genetic influences on coughing  
The genetic influence on cough patterns has been investigated rarely. Angiotensin 
converting enzyme receptor polymorphism may be important for developing ACE 
inhibitor-induced cough51 but probably not for chronic cough of other causes,52 
although if may affect cough reflex sensitivity.53  Polymorphism in the tachykinin gene 
NK-2R has been associated with cough reflex sensitivity to capsaicin but not with 
symptoms of chronic cough.54 There appear to be very few other studies comparing 
objectively-measured cough to genetic variation.  
Single nucleotide polymorphisms (SNPs) of the TRPV1 and TRPA1 gene have been 
described.55 Several SNPs of TRPV1 have been associated with cough symptoms in a 
large observational study involving two independent populations whereas TRPA1 SNPs 
did not have this association.55 It is not known whether SNPs of TRPV1 influence 
objectively measured coughing patterns. 
1.4 Pathological and other causes of excessive coughing 
Cough is extremely common, being one of the most common reasons for medical 
consultation in the UK and other countries.2 Excessive coughing is associated with a 
range of pathological states affecting the upper respiratory tract, lower airways, lung 
parenchyma and pleura.56 Gastro-oesophageal reflux disease (GORD) is also stated to 
be a common cause56 although this is debated,57 the purported cause being direct 
vagal activation of the cough reflex via cough receptors in the oesophagus, or laryngeal 
irritation by gastric contents.58 
The majority of coughs are short-lived, self-limiting and due to upper respiratory tract 
infections. Chronic coughs are defined arbitrarily as those persisting longer than eight 
weeks.2 It is estimated that approximately 10% of individuals in the community 
experience chronic cough.59 Up to 40% of patients referred to respiratory clinics with 
chronic cough may have symptoms that are unexplained in spite of investigation and 
trials of treatment,60 although rates this high have mainly be reported from tertiary 





cough reflex, possibly a neuropathic disorder caused by upregulation of cough afferent 
pathways.61,62  
Trials of treatment are often used empirically in chronic cough. While often successful, 
a problem with this approach is that where cough has not been measured objectively, 
it is difficult to confirm or refute the level of response. Furthermore, chronic cough can 
improve spontaneously,63,64 and responds to behavioural training,65,66 and placebo, as 
in randomized controlled trials of proton pump inhibitor therapy.67 The true 
epidemiology, burden and causes of chronic cough have therefore not been 
adequately defined in longitudinal cohort studies. 
Infectious organisms and the substances they produce may stimulate cough chemo- 
and mechanoreceptors,68 as may components of the host immune response including 
increased mucus production and inflammatory mediators.19 Infectious diseases and 
other causes of cough also seem to affect the overall sensitivity of the cough reflex, as 
seen in causes of acute,34,68,69 and chronic cough.34,68–71  
Aside from pathological causes, excessive coughing is associated with smoking,2,72 and 
environmental occupational irritants.73 This probably results from both the direct 
activation of cough receptors by inhaled particles and chemicals, and via the resultant 
inflammatory response which follows. ACE inhibitors cause cough through the 
accumulation of the pro-tussive peptides bradykinin and substance P in the lung.74  
Female sex influences cough in some respects; women appear to have a more sensitive 
cough reflex than men,70 unexplained chronic cough is more common in women than 
men, and women with this disorder have a higher cough frequency.75 Sex also seems 
to affect cough frequency in asthma,76 but not in idiopathic pulmonary fibrosis77 or 
COPD,78 and data in acute cough due to upper respiratory are conflicting.79,80 Reasons 
for an effect of sex are unclear but there is a suggestion of a link between idiopathic 
chronic cough and predisposition to autoimmune disease, which also shows a female 





1.4.1 Variation in cough with pathological cause 
Variations in cough with pathological cause have been studied rarely. Effect on quality 
of life by coughs due to stable asthma, COPD, asthma and bronchiectasis and 
unexplained chronic cough in one study of 147 patients did not significantly vary with 
the underlying cause.83 The relative subjective appreciation of coughing between 
diseases appears to have been little studied elsewhere. This could be relevant for the 
transmission of infection as will be further discussed. 
One method of investigating cough mechanism is measurement of the minimal dose of 
the tussogenic compounds capsaicin or citric acid required to cause a certain number 
of coughs, as discussed below (Section 1.6.2.1).5 However, cough reflex sensitivity 
measured in this way is variable and is not always distinguishable between health and 
disease,69,70,78,84 although a new approach to the capsaicin cough challenge may be 
more useful in this regard.85   
As will be discussed later (Section 1.6.2.2), ambulatory cough monitoring is a relatively 
recent development.86 Where cough frequency has been objectively measured, 
variability between individuals within the same disease group is high.75–78,80,87,88 
Although the mechanisms for cough may vary between disease it is therefore not clear 
if there are significant differences in overall cough frequency between diseases. Cough 
seems to be less frequent at night than during the day,89–91 but it is also unknown if 
there are significant differences in diurnal variation in cough between diseases. It is 
plausible, for example, that early morning coughing in asthma is more pronounced 
than in other diseases to coincide with the diurnal variation in lung function, and 
therefore presumable disease activity, in this disease.92  Another difference between 
diseases which needs further investigation is the way in which coughs are clustered 
within bouts. For example, repeated short bursts of coughing might be more efficient 
than recurrent single powerful coughs at clearing mucus 93,94 or aerosolizing pathogens 





The Manchester cough research group has reported predictors of objectively-
measured daily cough frequency in several diseases. In chronic obstructive pulmonary 
disease (COPD) cough frequency seems to relate to current and previous cigarette 
smoking and sputum neutrophila.78 In idiopathic pulmonary fibrosis (IPF) the cause of 
cough is unclear and cough frequency correlates poorly with lung function.77 Cough in 
asthma also does not relate well to pulmonary function but perhaps to measures of 
airway inflammation.76,95 In cystic fibrosis cough associated with airway inflammation, 
sputum production and lung function impairment.96 Loudon and Brown in the 1960s 
reported that in pulmonary tuberculosis overnight cough frequency increased with 
radiological extent of disease.88 
Further work in this area across disease groups, through clinical observation and 
ambulatory cough monitoring, should give further insights into the associations 
between pathological processes and cough.  
1.4.1.1 Cough sounds 
The notion of there being different types of cough in different disease is consistent 
with the range of terms used to describe coughs by medical textbooks and the 
layperson alike.97 The sound of the cough is said to predict pathology, a brassy cough 
for example equating with malignant tracheal compression and a bovine cough 
associated with laryngeal palsy.97 The practical utility of these terms is unclear as there 
is no evidence that health professionals are able to make diagnoses based on cough 
sounds, at least when they are heard in isolation for COPD, asthma, pulmonary fibrosis 
and bronchiectasis in adults.98 As will be discussed later (Section 1.6.2.4), attempts 
have been made to compare cough sounds between diseases, both in terms of the 
duration of component phases of the cough sound and, more promisingly, composite 
acoustic frequencies. The presence of airway mucus,99 pulmonary consolidation100 and 





1.4.2 Respiratory mucus 
Dry versus productive might be one of the commonest ways of describing coughs by 
both doctors and the general public, to refer to the absence or presence of associated 
sputum production respectively, which does seem to be easily recognizable.98 
Although one of the roles of cough is the clearance of respiratory secretions,102 sputum 
production correlates more with cough in some diseases, such as cystic fibrosis,96 and 
COPD79 than in others such as asthma.103 Airway mucus may not only influence the 
presence of cough but also patterns of cough: sputum expectoration in COPD has been 
observed to follow bouts of coughing rather than less closely-associated individual 
cough sounds.93 
The mucociliary escalator functions continuously to remove respiratory secretions of 
relatively low volume and viscosity. Any impairment of ciliary function, for example by 
smoking or infection, will require the airway to be cleared by coughing.104,105 Both the 
quantity and characteristics of respiratory secretions are also likely to be important 
determinants of cough; any significant increase in mucus production or viscosity will 
also overwhelm ciliary clearance.104 Mucins are the large glycoproteins responsible for 
the properties of respiratory mucus.105 They are stimulated by toxins, inflammatory 
states, and viruses (including respiratory syncytial virus, influenza and rhinovirus) and 
bacteria (including Staphylococcus, Streptococcus, Pseudomonas, Haemophilus and 
Mycoplasma).104,106  
MUC5AC and MUC5B are the principal secreted mucin components of respiratory 
mucus.104 MUC5B appears to have a particularly important role in host defence 
through the functioning of the mucociliary escalator. The corresponding MUC genes 
exist as variants in the human population107 and a large population study has shown 
single nucleotide polymorphisms (SNPs) of MUC5AC to be associated with self-
reported respiratory diagnoses including bronchitis and asthma.108 It is not clear if 





cough frequency in health and disease due to effects on mucus quantity and 
composition but this requires investigation. 
1.5 Cough and the transmission of disease 
In the public consciousness ‘coughs and sneezes spread diseases’.109,110 There is a 
natural aversion to the coughs of others and it is considered good etiquette to avoid 
coughing openly in company, particularly if unwell.111 Despite this, it is unclear exactly 
how much coughing contributes to the transmission of infection and which 
characteristics of cough are likely to be more infectious. 
1.5.1 Aerosol transmission of disease 
Many infectious diseases are spread by the airborne route, either as the only mode of 
transmission or one of several modes available to an organism.112 True airborne 
transmission is distinguished from droplet spread, the latter involving larger particles 
which quickly fall to the ground under the influence of gravity.113 Large droplets have 
the potential for infection only if a susceptible individual is positioned in close 
proximity to the source, said to be less than 1 m,114 unless secondarily doing so via 
objects in the environment acting as fomites. Airborne microorganisms, by contrast, 
have the potential to travel a far greater distance.115 To overcome gravity, particles 
probably need to measure around 5 µm or less, in order that frictional forces are of 
sufficient relative magnitude as predicted by Stokes’ law.113 Airborne particles, or 
droplet nuclei, may have started off as larger droplets on release from the respiratory 
tract, depending if there has been enough time for evaporation to lead to shrinkage 
down to an airborne size range before reaching the ground, as discussed further in 
Chapter 10. Further particle movement and changes in composition and size will be 
affected by ambient conditions such as air circulation, temperature, humidity, 
ultraviolet light, the presence of other particulate matter, and duration of transit 
through the air.113,115,116 The relative importance of the airborne route of infection 







Tuberculosis (TB) is possibly the only communicable disease which is almost 
completely transmitted by the airborne route.112,117 Aerial infection was demonstrated 
convincingly by Riley in the 1950s when tuberculosis was induced in laboratory-reared 
guinea pigs by air vented into otherwise sterile incubation chambers from a TB ward 
below.118   
Evidence for the dominance of the airborne route in TB transmission comes from 
epidemiological data, particularly where outbreaks have occurred. For example in the 
1960s almost half of the crew of 306 on board the USS Byrd became tuberculin skin 
test positive after sharing the ship with a case of pulmonary TB. The air on this ship 
was completely recirculated. The chance of contracting the infection was no higher 
amongst sailors who had had direct contact with the source case than those who had 
not, suggesting transmission by large droplets or direct contact was relatively 
insignificant.117,119 Another TB outbreak was studied in a juvenile correctional facility 
where the daily movements of the residents were closely monitored. The apparently 
random pattern of new acquisition of infection amongst the two wings of the building 
where the boys slept would have been very difficult to explain if direct contact were 
necessary for TB transmission, but much better favoured airborne spread.120  
Further support for the aerial infection comes from what is known about the initiating 
events in new infection. It was shown in the 1940s in rabbits that inhaled particles 
need to be small enough to reach the alveoli; bacteria deposited more proximally in 
the airways do not seem to cause tuberculosis.121 Interaction between Mycobacterium 
tuberculosis and alveolar macrophages seems to be a necessary early step in new 
infection.122,123 Respiratory particles containing M. tuberculosis (Mtb) are expelled 
from infected hosts during talking, singing and coughing.120,124–126 To reach the alveolus 
they need to measure <10 µm in diameter,127 ideally probably <2 µm,128 as larger 
particles will be deposited in the upper airway or more centrally due to their physical 





unless they evaporate quickly to a size small enough to resist gravity and become 
potentially capable of reaching the alveolus of a new host. 
1.5.1.2 Measles 
Transmission of measles seems to occur via virus-containing particles expelled from 
the respiratory tract. Droplet spread over short distances is probably the predominant 
mechanism, as the virus gains entry through the upper respiratory tract.129 
Epidemiological studies have also shown the airborne route to be important. For 
example in one school outbreak in Illinois, 69 cases occurred in a very low prevalence 
area several days after exposure to a strongly symptomatic individual. Because only 
22-65% of the pupils were likely to have had close contact with the source case whilst 
changing classrooms, droplet spread was unlikely to have been the only means of 
transmission.130 In 1991, 16 cases of measles were directly traced to attendance at an 
sporting event in which the index case was one of the athletes.131 10 of the cases had 
no known direct contact with the index and two of them were spectators sitting >30 m 
above the athletes’ entrance to the indoor stadium.  
Indirect evidence for airborne transmission of measles comes from the pre-vaccine 
era.117 The effectiveness of ultraviolet air decontamination at controlling measles 
epidemics in the 1940s was observed by comparing test schools with controls in 
Pennsylvania. Over a five year period there were significantly fewer cases in the UV-air 
disinfected schools. Other evidence from measles outbreaks, and data from air travel-
acquired cases,132 also support the airborne route of measles transmission. The 
relative contribution of airborne compared to droplet spread however is unclear.  
1.5.1.3 Influenza 
Influenza RNA has been detected in the air of clinical environments.133 The virus can 
retain its infectiousness to laboratory animals in airborne particles for periods of at 
least 24h depending on ambient conditions,134 and also possibly on disease strain.135 
Mice and ferrets can infect each other when separated by distances up to 2.5 m,136 too 





and other animals experimentally by exposure to aerosolized virus 137 and the dose 
required seems to be lower than that necessary to cause infection if applied directly to 
the nasal mucosa.135,138 Although airborne transmission of influenza therefore can and 
probably does happen,139 the majority of epidemiological evidence suggests that 
droplet spread or direct contact is the predominant mode of infection.135 For example 
hospital clusters show that nurses having direct contact with an index case have a 
much higher chance of infection than others in the same vicinity.135 The comparative 
effectiveness of the ventilation systems in two aeroplane influenza outbreaks was 
associated with no significant difference in viral transmission, and contact or droplet 
control measures (e.g. cohorting, isolation rooms and gloves) seem to be the most 
effective ways of limiting new infections in healthcare settings.140 Influenza probably 
enters the body via the conjunctiva and gastrointestinal tract as well as the upper and 
lower respiratory tract141 allowing transmission via larger droplets or fomites.  
1.5.1.4 Other pathogens 
Rhinovirus probably is transmitted predominantly by hand contact and self-
inoculation,142 although droplet spread seems to be important and airborne 
transmission possible.143 The same seems to be true for respiratory syncytial virus.144 
Smallpox is an opportunistic airborne transmitter,117 and so may be Neisseria 
meningitides.145 Pneumococcus does not appear to be particularly contagious and is 
probably transmitted by direct contact with respiratory secretions, entering via the 
upper respiratory tract.145,146 For pneumococcal pneumonia and bacterial meningitis, 
acquisition of the responsible organism may not be as important a step in new 
infection as the transition between asymptomatic carriage in the upper airway and 
invasive disease.145 Chickenpox, norovirus, rotavirus and Aspergillus may also be 
opportunistically spread by the airborne route.115 Pertussis has also been shown 
convincingly to be capable of airborne transmission in a baboon model, although again 





There therefore remains a significant lack of knowledge about the extent to which true 
airborne transmission of infection occurs although the evidence for tuberculosis is 
strongest by far. 
1.5.2 Particle production during respiratory activities 
The relative importance of respiratory activities  in the production of infectious 
particles has been little studied. Relevant factors are likely to include the relative 
frequency and force of each activity and the size, quantity and composition of particles 
at the point of expulsion from the body.127 There are some data in tuberculosis, but 
most work on particle production has been done in healthy volunteers. 
1.5.2.1 Particle size 
Following on from the discussion above, the ultimate size of particle released during 
respiratory activities will be an important determinant of its potential mode of 
transmitting infection, with the cut off often made between predominantly airborne 
transmission for particles <5 µm in diameter and mainly droplet spread if >5 µm.114 As 
mentioned for tuberculosis, a particle’s size will also be a major determinant of its 
potential to reach and interact with particular target sites within the new host, for 
example a diameter of <10 µm is required for the possibility of reaching the 
alveolus.128  
Several studies have attempted to measure the range of sizes of particles produced 
during normal respiratory activities through a variety of techniques.127 Older studies 
predominantly used the method of particle impaction against a surface and light 
microscopy.148 This work is now thought to have been insensitive to smaller particles 
as the average measured diameter of particles produced by coughing and talking  was 
50-150 µm.127 More recent studies have used aerodynamic particle sizers, charge 
separation methods or laser diffraction methods,127,149,150 and generally agree that the 
predominant particle size during breathing, coughing and talking is in the range 0.01-5 





particle sizes than talking.150 When healthy individuals cough openly perhaps 97% of 
particles are smaller than 1 µm and 99% smaller than 10 µm.149 
To my knowledge only one study has looked at particle production during singing, 
using an impaction technique, and found the predominant size range to be similar to 
that for coughing.124 There appears to be no recent study measuring particles 
produced by sneezing, but the fact that a large number of emitted droplets are visible 
by eye with stroboscopic photographic techniques151 suggests that the mean size is 
larger than that of those produced by other respiratory manoeuvres, although of 
course there will presumably also be a large number in the microscopic size range. 
1.5.2.2 Particle number 
Few studies have attempted to compare the number of particles produced by different 
respiratory manoeuvres and differences in methodology makes comparing studies 
difficult. Older studies used particle impaction methods and light microscopy, and 
therefore had a relative high limit of detection. Gerone et al. reported a single sneeze 
from one volunteer produced 1.6 million particles compared to around 200,000 for a 
single cough in an individual with a viral upper respiratory tract infection.152 Loudon 
and Roberts estimated that 3 healthy volunteers produce a mean of approximately 
7,000 particles by coughing 15 times and 1,800 when talking loudly (counting from 1 to 
100).148 
More recent studies have used a variety of methods. Papineni and Rosenthal used two 
methods, an optical particle counter and impaction onto glass with electron 
microscopy with 5 healthy volunteers. There was wide variation between subjects but 
the mean numbers of particles per L produced by coughing, mouth breathing, nose 
breathing and talking were 483, 72, 27 and 113 respectively.153 Xie et al. used a solid 
impaction method and reported an average of 108 particles were produced by seven 
healthy individuals both by talking (counting from 1 to 100) and voluntarily coughing 
20 times, although the predominant particle size measured was 50-75 µm.154 





15 healthy volunteers. The concentration of particles produced by vocalizing during a 2 
minute period (alternating an “aah” sound for 10 s with breathing normally for 10 s) 
was greater than that by voluntarily producing ‘mild throat clearing coughs’ for around 
30 s (0.75 compared to 0.48 particles/cm3). Breathing, whispering and talking (voiced 
counting) produced lower concentrations (c. 0.05, 0.08 and 0.28 particles/cm3 
respectively).150  
It is therefore difficult to make conclusions about absolute numbers of particles from 
these limited and varied studies, but the relative numbers of particles produced during 
coughing and talking seems to be of the same order of magnitude, and higher than 
those produced during normal breathing. Although this applies for healthy individuals, 
the relative numbers of particles produced by different activities in disease is not 
known. 
1.5.2.3 Particle composition 
Infectious particles obviously need to contain viable microorganisms. The other 
components will also presumably have an effect on a particle’s potential to cause 
infection by influencing its size and its movement, both through the air and within the 
respiratory tract of a potential secondary host, and by promoting the viability of 
organisms contained within, through effects on protection from desiccation, ultraviolet 
light and first lines of defence of the secondary host. There have been few studies 
specifically exploring this. However, Zayas et al. recently used a cough simulator 
machine and a mucus simulant solution to show that increasing the cohesivity of the 
solution decreased the number of particles expelled and aerosolized during a 
‘cough’.155 
The composition of mucus varies with disease,105 smoking,156 and possibly genotype.108 
The origin within the respiratory tract of an expelled particle will affect both its 
content of mucus and microorganisms. Particles originating in the mouth will contain a 
higher content of saliva whereas those from the airways will contain more mucus. 





influenza and measles, will presumably occur in higher concentrations in the upper 
airway whereas those causing lung disease, such as pneumonia and tuberculosis, will 
be at their highest concentrations in the lower airways. The predominant site of origin 
of resultant respiratory particles will vary with respiratory activity. Sneezing is initiated 
by receptors in the nasal mucosa157 and the majority of particles produced seem to 
originate in the mouth and nose whereas cough presumably more efficiently expels 
particles from the lower respiratory tract.102 
1.5.2.4 Expiratory flow 
The number and size of particles formed during expiratory manoeuvres will be 
influenced by the speed with which air moves outwards over respiratory epithelia. In 
turn, the range and behaviour of aerosolised particles in the environment will be 
affected by the force at which they are released.  
Peak flow rates during expiratory manoeuvres will vary depending on lung size, 
physical fitness, gender and other factors including disease.158,159 The maximum 
velocity of air expelled by coughs from healthy volunteers in one study using 
shadowgraph imaging was 2.2-5.0 m/s for women and 3.3-14 m/s for men.160 The 
same authors report that for these values are similar for sneezing (4.5 m/s) and higher 
than for breathing, either through the mouth (1.3 m/s) or nasally (1.4 m/s).161 Using a 
laser particle detection technique another group measured the initial air velocity in 
healthy volunteers during coughing to be 15.3 m/s in men and 10.6 m/s in women; 
during speaking these figures were 4.07 m/s and 2.31 m/s respectively.162 Blowing on 
certain musical instruments may produce particularly high expiratory flow velocities.163 
1.5.2.5 Activity frequency 
Given that all expiratory manoeuvres have the potential to release infectious particles, 
the relative importance of each respiratory activity in disease transmission will clearly 
in part depend on the frequency with which it occurs. In individuals free of disease 
coughing and sneezing are rare events. Sneezing is a symptom of the common cold and 





usual in pneumonia and bronchitis, and is the cardinal symptom of pulmonary 
tuberculosis. Persistent coughs in particular are typical of TB, so much so that the 
presence of chronic cough is used as a screening strategy for tuberculosis in endemic 
parts of the world.164 Talking, shouting, playing wind instruments and singing will vary 
with personal and social factors but will presumably be diminished in frequency in 
those who are unwell. The frequencies of respiratory activities in infectious diseases 
have been rarely reported.  
1.5.3 The importance of cough in the transmission of tuberculosis 
Mechanisms of bacterial aerosolization deserve special attention in TB since it is 
perhaps the only infection to be spread entirely by the airborne route. Coughing was 
first shown experimentally to be capable of spreading tuberculosis  in the 1890’s, at 
least from humans to guinea pigs, by Carl Flügge, a key early proponent the role of 
respiratory particles in TB transmission.165–167 Coughing is likely to be of prime 
importance for TB transmission for the reasons above: cough frequency is increased in 
TB, coughing clears material from the distal airways and coughs produce large 
numbers of particles at high velocity, the majority of a size small enough to be carried 
as true aerosols and reach the alveoli of susceptible hosts. 
1.5.3.1 Determinants of the infectiousness of tuberculosis 
For the transmission of TB there are several broad stages: (1) the clearance and release 
of bacilli from an index case, (2) the aerial passage of viable bacilli through the 
environment, (3) inhalation into the alveoli of a new potential host and (4) initiation of 
new infection. Variability in TB transmission clearly exists. This is demonstrated by the 
outcomes of routine contact tracing, where overall probably fewer than half of sputum 
smear-positive cases of pulmonary disease pass infection on to household 
contacts,168,169 and is suggested by  TB outbreaks, in which unusually large numbers of 
secondary infection are related to a particular epidemiological setting and individual 
source case.170,171 This variability must be explainable by factors affecting one or more 





the acquisition of infection through effects on the innate immune system.172 Other 
personal epidemiological risk factors for tuberculosis, such as very young age,173 
alcohol misuse,174 malnutrition,175 diabetes,176 and HIV infection,177 probably act 
mainly on the adaptive immune system, thereby influencing progression of latent Mtb 
infection rather than its acquisition. Relevant environmental variables for transmission 
include UV light,178 and factors leading to the shared air:179 crowding,180 and 
ventilation of indoor space,181 whilst social factors relate to the number, duration and 
nature of episodes of contact with others.119 Features of the organism strain are also 
of interest, potentially affecting every stage of transmission and disease in ways that 
are yet to be ellucidated.182–185  
A large part of the variability in the transmission of tuberculosis is related to features 
of the source case. This has been shown most clearly by the classic experiments of 
Riley mentioned above (Section 1.5.1.1), in which the majority of infections in exposed 
guinea pigs were caused by only a small percentage of patients with untreated smear 
positive tuberculosis.118,186 Similar studies have been conducted recently with very 
similar results.187  
Expectorated bacillary load, measured as the presence and number of mycobacteria 
visible on microscopy of sputum smears before culture (sputum smear status) is  
probably the factor most commonly used to estimate the infectiousness of source 
cases.188,189 Various studies have showed that compared to community controls the 
rates of tuberculin positivity are increased by 30-50% in contacts of smear positive 
individuals and by around 5% in contacts of smear negative, culture positive cases.119 
For example, in one study of 4,445 TB contacts in Edinburgh, 18% of close contacts of 
smear positive cases had active TB compared to <2% of contacts of smear negative 
pulmonary disease.190 Despite this, only <50% of smear positive source cases seem to 






The presence of visible lung cavities in the source case is also linked with tuberculosis 
transmission. This is at least partly because cavities are associated with higher 
bacterial loads, both in the lung itself191 and in sputum,192 presumably leading to an 
increased chance of releasing infectious particles into the environment. However, 
cavitary disease may be associated with infectiousness independently of the presence 
of a high sputum bacillary content.193–196 This might be because cavities are a marker 
of more advanced disease and a longer period over which transmission could have 
occurred. Alternatively, cavities themselves might promote coughing and the 
aerosolization of Mtb. This has not been directly explored as far as I am aware. 
Another possibility is that exposure to air in cavities might promote a phenotypic 
change in TB bacilli which improves their ability to resist exposure to the open 
environment once released into aerial transit.197 The type of bacilli which end up in 
sputum are not necessarily the same as those which are released into the air in droplet 
nuclei.  
Airborne particles  separated by inertia l  mass . Adapted from ref 201. 






1.5.3.2 Aerosolization of Mycobacterium tuberculosis 
The ability to produce aerosols of a respirable size which contain viable TB organisms is 
a prerequisite for transmission.121,198 This fact received little direct attention for many 
years until the recent work of Fennelly and colleagues.126,199,200 The group has 
developed apparatus involving an Andersen cascade impactor201 for separating out 
particles released during voluntary coughs into sizes based on inertial mass (Figure 1.3) 
which are collected on selective media for mycobacterial culture.126 The majority of 
particles from which TB was cultured were in the diameter range 0.65-4.7 µm,126,199 
the optimum size for aerial transmission. Positive cough aerosol cultures of M. 
tuberculosis were achieved in only 28 of 101 patients with culture-positive pulmonary 
tuberculosis. Individuals on TB treatment and with a longer time to positive sputum 
culture were less likely to produce aerosol cultures; those with a higher sputum 
bacillary content and a salivary as opposed to a purulent appearance of the sputum 
were more likely to be aerosol culture positive.199 Further work correlated positive 
cough aerosol cultures with transmission by individuals with smear positive pulmonary 
tuberculosis.200 As was the case in the earlier study, <50% of patients with smear 
positive disease produced cough aerosols, although some had received several days of 
TB treatment. The only predictor of infectiousness, as measured by conversion to a 
positive from a negative test for latent TB amongst 110 household contacts of culture-
positive tuberculosis, was  a higher number of colony forming units in the aerosol 
culture of the index case, even though other factors including source sputum smear 
grade and radiographic extent of disease, age and BCG vaccination status of the 
contact and house size were taken into account.200 Correlating with epidemiological 
evidence mentioned above, the presence of bacteria in the sputum did not necessarily 
equate with the ability to aerosolize and transmit tuberculosis, even though this has 
been considered the most important determinant of infectiousness. 
Even though Fennelly’s work is a significant step forward from evaluating sputum 
smears as the sole method of estimating the infectiousness of individuals with TB it has 





tuberculosis does not necessarily equate with whether the composition and other 
characteristics of the particles are sufficient to resist transit through the air until 
reaching a new potential host. Also, the production of infectious particles when 
coughing voluntarily into a collection system on one occasion does not necessarily 
equate to what individuals with pulmonary tuberculosis do normally over the course of 
their illness prior to treatment. The frequency of coughing in tuberculosis is 
presumably important, and certain types of cough might be better at aerosolizing 
bacilli. These factors have rarely been investigated.  
1.5.3.3 Features of cough in tuberculosis 
The effect of objectively-measured cough frequency on TB transmission has to my 
knowledge been studied only once. In a Texas hospital in the 1960s, Loudon and Spohn  
measured coughing frequency between the hours 11 pm and 7 am in patients yet to be 
started on treatment for pulmonary tuberculosis.125 This was compared to the 
proportion of 130 household contacts aged 14 years or less with cutaneous reactions 
to tuberculin. They demonstrated only a small and statistically insignificant effect of 
nocturnal cough frequency on the infectiousness of untreated pulmonary TB on 
univariate analysis (p < 0.20). Source case sputum smear status and radiological extent 
of disease were better predictors of tuberculin skin test result in contacts, and no 
attempt at multivariate analysis was made to look for independent effects of any of 
the variables. The study was also limited by the short duration of cough recordings due 
the technology available at the time. Cough in other diseases is more prevalent during 
waking hours.89,91 The relevance of objectively-measured daytime cough frequency in 
tuberculosis transmission has therefore not been investigated, nor has the significance 
of patterns of cough in terms of clustering of coughs into epochs.  
The force of coughing was assessed subjectively by Fennelly et al. and shown to relate 
to a higher chance of producing culturable cough aerosols in tuberculosis .199 This has 
not been addressed elsewhere although is also presumably relevant. The observation 
of the same authors that salivary rather than mucoid sputum in better at producing 





machine,155 but other work by Fennelly et al. failed to show a direct association 
between salivary characteristics and TB transmission.200 Further work is needed here; 
pharmacologically modulating sputum properties may be a way of reducing TB 
transmission in cases of drug resistant disease where conventional medication has 
little effect.  
Individuals’ awareness and interpretation of their coughs must also be important in 
the transmission of TB in terms of modifying behaviour such as cough hygiene, 
reducing social contact, wearing a mask and seeking medical attention for TB 
treatment. For example, there is evidence that smokers may delay seeing a doctor 
about symptoms of TB,203 presumably because coughing is less of an unusual 
occurrence than in non-smokers.72 As in other diseases, cough frequency probably 
correlates poorly with subjective awareness of coughing in tuberculosis,88 but the 
strength of correlation has not been compared with that in other diseases as far as I 
am aware. Other TB symptoms which accompany cough are probably important in 
reducing social contact and seeking medical advice, as shown in a recent study in 
Tanzania.204  
Given the central role that cough has in tuberculosis it has been investigated very 
infrequently. The characteristics of cough, particular patterns which associate with 
transmission and direct mechanisms are largely unknown. Much of the variation in 
transmissibility between individuals, and also perhaps between strains of tuberculosis, 
may be explained by variation in coughing patterns which promote the efficiency of 
aerosolization of viable bacilli into the environment. A better understanding of 
tuberculosis transmission will help global efforts to control the disease as drug 
resistance becomes an increasing threat.205 The efficiency of contact tracing would be 
much improved if it could be estimated with greater accuracy which individuals are 
likely to have transmitted the most disease. The use of isolation measures in hospitals 
could also be utilized more efficiently for the same reason, particular in areas of the 





1.5.4 The aerial movement of particles released by coughing: a theoretical discussion 
Human-to-human transmission of infection depends on characteristics of one or more 
of the disease-causing organism, the infecting source case, the environment, and the 
secondary host (Section 1.6.2.5). For aerially-transmitted disease such as tuberculosis, 
infectiousness of a source case relates largely to the nature of infectious particles and 
the way in which they are released into the air. The number and size of infectious 
particles are important for infectiousness, but so is the initial horizontal distance 
travelled on release from the respiratory tract before the particle enters Brownian 
motion, as I shall now discuss.   
1.5.4.1 Space, time and quantity: relevant variables in the aerial release of 
Mycobacterium tuberculosis 
Modelling the aerial transmission of TB in confined spaces often assumes complete 
mixing of the air and ignores the proximity of the source case to other individuals.206 
However, epidemiological studies of TB transmission in aeroplanes and other contexts 
have shown that the spatial distribution of individuals in an enclosed space is 
important,206–208 as infectious particles are at a higher concentration closer to the 
infector.209 For example, 31% of 13 passengers seated within two rows of an index 
case of untreated smear-positive pulmonary tuberculosis during a nine-hour flight 
developed positive tuberculin skin tests compared to 3.6% of passengers seated 
elsewhere208 (although laminar air recirculation patterns in the aircraft may have 
effectively divided cabins into sections210).  
It is of interest to consider the size of the zone of highest concentration of airborne 
bacteria surrounding an infecting individual, and in particular how rapidly and how far 
infectious particles move at head height before falling to the floor or entering random 
Brownian motion. Such considerations are perhaps not so important for longer 
durations of contact with an infectious source case, particularly in small, enclosed and 
poorly-ventilated locations, but are of most relevance for situations in which brief 





classically assumed, particularly in high-incidence settings, as molecular 
epidemiological studies suggest.211–216 For brief contact to result in infection, the rapid 
direct propulsion of an ejected bacillus in the airstream of a cough towards the nose 
and mouth of a new potential host will much more likely achieve this than Brownian 
motion.  
The time during which Mtb remains capable of causing infection after release into the 
open environment is highly relevant. For example, if bacilli were to be rendered non-
viable within seconds of exiting the mouth, even prolonged contact between two 
individuals may not necessarily result in transmission, even if the source case was 
coughing out large numbers of initially viable bacilli. Over 99% of artificially aerosolized  
Mtb from broth culture became non-culturable almost immediately after entering the 
airborne state in one study.217 It is not clear how closely this represents bacilli released 
during coughing, and the half-life of M.tb in open air is uncertain,202 although it is 
variable and affected by ambient conditions, including ultraviolet and ionising 
radiation,178,218 and possibly features of the organism itself.184,219 For example live 
bacillus Calmette-Guérin (BCG, a strain of Mycobacterium bovis) is light sensitive and 
supplied in dark glass vials for vaccination, and when reconstituted it is recommended 
that it be used within six hours,220 and probably 30 min if not kept out of the light. A 
time limitation on the infectious potential of airborne bacteria nevertheless reduces 
their effective range, strongly influenced by the speed of release into room air. 
A crude indication of the importance of the effects of space and time on the airborne 
movement M. tuberculosis is given by a comparison of the results of studies which 
have sampled room air from TB wards with those from collecting aerosols at the point 
of exit from the mouth in pulmonary TB. Experiments with artificially-produced 
aerosols,121 and studies exposing guinea pigs to air from TB wards (Section 1.6.2.5.1)118 
have shown that, at least in animal models, a single infectious dose is sufficient to 
cause infection with a single pulmonary lesion. This dose probably equates to a single 
viable bacillus, although this has not been proven without doubt.121,221 Through 





pig infections, and calculation of the total air volume breathed by the animals, Riley 
and Wells, and later others, have estimated the rate of addition of infectious doses (or 
‘quanta’ (q)) to ward air by patients with smear-positive pulmonary TB.118,187,218,219,222 
Recent molecular techniques have linked source cases to the number of guinea pig 
infections.219 For one particularly infectious case, the rate of release of aerially-
transmittable particles exceeded 200 q/h although the median (IQR) rate in patients 
causing infection in guinea pigs was about 12 (4.3-39) q/h.219 In Fennelly et al.’s cough 
aerosol sampling work (Section 1.6.2.5.2), the smear-positive TB cases who released 
cultivable aerosols into the collection system produced a median of 16 (5-30; 
maximum 710) Mtb colony forming units over only 10 min when asked to cough 
repeatedly,199 although these subjects may have coughed a lot more frequently in the 
10 min period than they would have done under normal condtions.126 However, part of 
the reason for higher viable Mtb aerosol numbers close to the source case than reach 
further parts of room air in normal circumstances might be explained by what happens 
to airborne particles, and the bacilli contained within, as they travel through air. 
1.5.4.2 Droplets and droplet nuclei: modelling the aerial movement of respiratory 
particles 
The aerial movement of respiratory droplets is complex and has been discussed 
surprisingly infrequently since the classic (largely theoretical) work of William 
Wells.113,223 Important factors are the size, speed, and composition of the droplet, the 
size of the mouth at the point of exit, and the relative humidity (RH), temperature, 
pressure, movement and quality of the ambient air, as I shall summarise, largely taken 
from the recent paper by Xie et al.223 
The size of a newly-formed respiratory droplet will decrease on contact with the 
external environment due to evaporation of its aqueous content. As originally 
theorised by Wells,113 a droplet of pure water released at a height of 2 m above the 
ground will either fall to the ground or evaporate completely before doing so, 
depending partly on its starting size. The critical size determining the droplet’s fate will 





and the velocity at which it is released from the mouth. For example, evaporation is 
slower with greater RH, leading to further vertical movement under the influence of 
gravity. Respiratory droplets clearly do not consist entirely of pure water, but contain 
glycoproteins, ions and, of interest to this discussion, microbes. Complete evaporation 
therefore does not occur but results to the formation of ‘droplet nuclei’ consisting of 
microbes and solute residue.113 As previously discussed (Section 1.5.2.1), for M. 
tuberculosis such infectious particles measure approximately 0.5-5 µm, as can be 
inferred from the dimensions of the bacterium itself and the anatomy of the distal 
airways which they must reach to cause infection.121 Direct measurements with an 
Andersen cascade impactor within a cough aerosol collection system have confirmed 
this directly (Section 1.5.3.2).126,202  
For the current discussion of infectiousness within the close proximity of a source case 
of tuberculosis, droplet movement in the horizontal direction from the mouth is of 
most interest. The closer the starting diameter of an expiratory droplet is to that of an 
airborne droplet nucleus, the less vertical movement there will be due to gravity after 
release from the mouth. Aerially suspended particles resist gravity due to the relatively 
large frictional force acting on them in movement, as explained by Stokes’ law.113  The 
temperature of the air within a cough air jet relative to ambient conditions will 
determine whether the jet is isothermal, with a linear trajectory, or non-isothermal, 
with a trajectory that is slightly curved, hotter air for example moving upwards. At the 
same time, droplets with greater starting speeds have greater momentum and take 
longer to leave the cough air jet to become suspended in air, although they also take 
longer to shrink by evaporation and escape the pull of gravity, due to larger Reynolds, 
and therefore Sherwood numbers.  
The Reynolds number of the airborne particle, Rep, is the ratio of inertial forces to 
viscous forces defined as 
Rep =







where ρg is air density, dp, the particle diameter, ?⃗? p and?⃗? g, particle and air velocity, 
respectively, and µ the dynamic viscosity of air. Where inertial forces dominate, the 
Reynolds number is high and flow is turbulent, whereas laminar flow occurs at low 
Reynolds numbers where viscous forces dominate. 
The Sherwood number, Sh, is the ratio of the total rate of mass transfer to the rate of 
purely diffusive mass transport, and is defined as  
Sh = 1 + 0.3Rep
1/2Sc1/3  
where Sc is the Schmidt number, the ratio of momentum diffusivity (viscosity) and 




where D is the diffusion coefficient of vapour through air. The size of the mouth 
opening affects properties of the air jet and therefore of droplet evaporation and 
movement such that a larger cross-sectional area increases the propulsive distance of 
a cough. 
Together, airborne droplet movement can be estimated from the following 
simultaneous differential equations for evaporation and deceleration. The rate of 










where C is a correction factor due to temperature dependence of the diffusion 
coefficient, Mv, the molecular weight of vapour, D∞, the diffusion coefficient of vapour 
far from the droplet, ρp, the particle density, R, the universal gas constant, T∞, the 
ambient temperature, p, total air pressure, pva, vapour pressure at the droplet surface, 
and 𝑝𝑣∞ , ambient vapour pressure. Droplet deceleration can be estimated as  
𝑑?⃗? 𝑝
𝑑𝑡











where 𝑔  is gravitational acceleration, and Cd, the drag coefficient. In turn droplet 
displacement is given by 𝑑𝑥 𝑝 = ?⃗? 𝑝𝑑𝑡. 
From this, it is estimated that with an ejection velocity of 20 m/s, in a cough air jet of 
initial temperature 33 °C, through an oral aperture of diameter 4 cm into a room of 
ambient temperature 20 °C and RH 50%, the horizontal distance moved before 
commencing Brownian motion would be greatest (3.5 m) for a droplet of starting 
diameter c. 40 µm. Assuming a constant deceleration, it would take 0.35 s to cover this 
distance. For a slower cough air jet speed of 10 m/s, the same particle in the same 
conditions would move about 2.3 m in 0.46 s, or about 1.4 m in 0.28 s if the mouth 
opening was 2 cm in diameter. 
Therefore, according to the modelling of Xie et al., the most infectious individuals (who 
spread infectious particles quickly over a relatively large distance) will be those with 
higher cough velocities and larger mouth openings during coughing who produce large 
numbers of respiratory droplets of initial diameter 40-60 µm. For example, men would 
be expected to be potentially more infectious than women on this basis, due to larger 
mouths and higher cough velocities (3.3-14 vs. 2.2-5.0 m/s, respectively, in one 
study160). For a stationary individual repeatedly coughing openly with velocity varying 
up to 10 m/s into a still room of RH 50% and temperature 20 °C, it is therefore possible 
to imagine a zone following the cough air jet extending up to 2.3 m containing rapidly 
moving shrinking droplets of high concentration, surrounded by zones of ever smaller 
concentrations of droplet nuclei, some of which will contain viable microbes. 
The above estimated distances and speeds of droplets are of course approximate and 
the modelling of Xie et al. ignores many variables of importance. These include droplet 
composition (assumed above to be 0.9% saline), fluid flow within droplets, physical 
interactions between multiple droplets in an air jet, electrostatic charges, room air 
purity and room air currents, and body movements of the source individual, including 
covering of the mouth while coughing. Airborne droplets in motion are also assumed 





Although droplets presumably start off spherical, during evaporation an airborne 
droplet nucleus containing a single bacillus may approach the same shape, therefore 
altering the Reynolds number and drag coefficient compared to a sphere of the same 
volume and increasing the potential range. The difficulties of visualizing moving 
respiratory droplets clearly makes verification of such theoretical models a problem. 
This is an important area for further theoretical and experimental research. 
Mathematical modelling can therefore predict the movement of respiratory particles 
in air on release from the mouth and the influence of various variables. It might be 
possible to test some of these predictions by measuring particles in air. 
1.6 Clinical evaluation of coughs 
Cough is one of the most common medical presentations to be assessed by clinicians. 
A simple line of enquiry would include the duration of the cough, any associated 
symptoms, and perhaps the daily pattern, relieving and exacerbating factors and the 
presence of mucus along with smoking habit and known respiratory disorders.2 Where 
the cough is more prolonged, particularly despite investigation and trials of treatment, 
a more detailed assessment of the characteristics of the cough is helpful.5  
1.6.1 Subjective assessment 
As well as asking patients to describe the frequency, severity and other characteristics 
of their cough, tools have been developed to help document subjective cough severity. 
Asking individuals to score the severity of their cough out of ten or to mark a line on a 
visual analogue scale (VAS) are the simplest ways.5   
Cough severity visual analogue scales are widely-used in cough research, although 
predominantly in chronic cough.63 In stable COPD the VAS score is generally consistent 
after an interval of two weeks and, in studies of chronic and acute cough, it is 
responsive to clinical improvements.5,79,80,224 The minimum clinical important 
difference of a 0-100 mm cough severity VAS has not been formally defined but is 





1.6.1.1 The Leicester Cough Questionnaire 
There are cough-specific quality of life questionnaires, the most frequently-used of 
which is the Leicester Cough Questionnaire (LCQ, Appendix).226,227 It is composed of 19 
questions, each with seven possible responses on a Likert scale, concerning the effect 
of cough on physical, social and psychological domains , and has a total possible quality 
of life score of 3-21.  
The LCQ was originally developed in patients with cough of duration >3 weeks.226 The 
process involved the generation of an initial list of items following a literature review, 
multidisciplinary expert meeting, and discussion with 15 patients with chronic cough, 
and then reduced down after testing the questions on a further 104 patients. 
Concurrent validity of the final questionnaire was shown by correlation of responses 
with those to the St George’s Respiratory Questionnaire,228 the Short Form 36 item 
(SF36) health status questionnaire,229 and a cough severity visual analogue scale.  
Further evaluation demonstrated repeatability of LCQ scores in patients with stable 
symptoms, and responsiveness to reported improvements in cough.226 
Although used mainly in the context of chronic cough, where the minimum clinically 
important difference in the total score has been defined as 1.3,230 the tool has also 
been successfully evaluated for validity, repeatability and responsiveness in acute 
cough due to upper respiratory tract infection (with a minimum important difference 
in the total score of 2.5),231 bronchiectasis, 232 and COPD.233 The LCQ has also been 
used in asthma,76 idiopathic pulmonary fibrosis,77 and, on only one occasion to my 
knowledge (without validation), in tuberculosis.234 It has been translated into a 
number of languages.235–237 
The LCQ therefore seems to be a useful and versatile tool for assessing cough 
symptoms. A potential omission from the questionnaire, however, concerns urinary 
incontinence. This is a frequent and often distressing feature associated with chronic 
cough238 and is addressed in another specific cough assessment tool, the Cough 





frequent in women than men, meaning the LCQ would be less gender non-specific 
were it to specifically ask about urine incontinence. Furthermore, the impact of 
incontinence should be captured within responses to other questions in the LCQ 
concerning control, embarrassment, frustration and feeling fed up Appendix 
In unexplained chronic cough and asthma the strength of association between both 
LCQ score and cough VAS score and objectively-measured cough frequency is similar 
and statistically significant but mild to moderate.76,84,87,227 Early cough monitoring 
studies similarly noted the weak correlation between cough rates and patients’ 
appreciation of them.88,240 Cough frequency therefore only seems to explain part of 
cough-related quality of life in these conditions. Data in other diseases are lacking.  
1.6.2 Objective assessment 
The objective evaluation of cough is required for the adequate exploration of 
mechanisms of cough and the direct assessment of provoking or relieving factors. 
Different features of cough have the potential for measurement including coughing 
frequency, the force or intensity of cough, cough reflex sensitivity, characteristics of 
the resultant cough sound, associated lung or peripheral biomarkers and the potential 
of the cough to transmit disease in infections by production of particles.  
1.6.2.1 Cough reflex sensitivity 
Cough can be experimentally induced with a variety of agents, including citric acid, 
acrolein and ultrasonically-nebulized distilled water, but the most commonly-used 
substance in cough challenge testing is capsaicin.241 Cough reflex sensitivity to 
capsaicin has been shown to be repeatable242 and responsive to improvements in 
cough symptoms.243 It is usually defined as the inhaled concentration of capsaicin 
required to produce 5 coughs (C5) within a specified time (usually 15 s),241 and there is 
expert consensus on the method of dose administration.5 The main role of capsaicin 
cough challenge testing has been in investigating potential antitussive treatments by 
measuring the effect on cough reflex sensitivity.244 However, as it is currently used, a 





disease due to wide inter-subject variability in capsaicin cough response.70 There is 
also poor correlation between C5 and 24-hour cough frequency.75,245  
A novel test protocol has been proposed which involves gradually escalating the 
concentration of capsaicin and noting the largest number of coughs produced in 15 
s.85,246 ‘Emax’, the maximum number of coughs evoked by any concentration of 
capsaicin, seems to be more predictive of 24-hour cough frequency than C5.85 
However, because the test protocol terminates at the maximum-tolerated 
concentration of capsaicin, it is not clear from the reported data how often Emax 
reaches a plateau for particular patients. Published data so far appear to only include 
<40 patients.85  Poor tolerance of higher doses of capsaicin could be a limitation to the 
wider use of this protocol. Another drawback of this proposed new approach is that it 
is time-consuming, requiring several repeated inhalations of each concentration of 
capsaicin solution. 
An alternative approach might be to compare the number of coughs produced after 
administration of a one-off relatively high concentration of capsaicin, or to measure 
cough latency, the time between dose inhalation and the first cough. This latter 
measure might reflect central processing and the influence of (semi-) conscious cough 
suppression. 
1.6.2.2 Cough frequency 
The number of coughs in a particular time period can only be assessed objectively. As 
cough is an episodic symptom with diurnal variation an estimation of cough frequency 
in health and disease requires measurement over hours or days. Direct observation 
over this time frame is clearly impractical hence methods for recording and playback of 
coughs have been developed.  
1.6.2.2.1 Recording coughs 
Different methods for recording cough activity have been tried, including video 





movement, and sound and vibration data from the chest wall or close to the 
patient.86,247–251 Video data probably do not add much to sound information: in one 
study almost exactly the same number of cough sounds were counted in each of eight 
8-hour recordings whether or not video information was shown.252 The cough 
monitors about which most has been published are based on prolonged sound 
recordings with either a single free-field microphone,253 or a combination of one free-
field microphone and another in contact with the chest wall.86 The potential advantage 
of the contact microphone is it picks up little background noise,254 making it easier to 
distinguish coughs of the individual being monitored from background noises, 
including other coughs. However, sound characteristics are altered when recording 
through the chest wall, which seems to alter the recognition of cough sounds.251 The 
problem of background coughs during cough monitoring will obviously vary with the 
environment in which recordings are performed. Cough monitoring a patient using 
only a free-field microphone on open respiratory ward, for example, may lead to over-
estimation of cough frequency if coughs of others are misinterpreted as belonging to 
the patient under observation. This potential problem does not seem to have been 
examined in detail but it could perhaps be minimized by placing the microphone close 
to the mouth of the subject and using a device with the capability of filtering out 
background noise. On listening to the recordings some background coughs may be 
obvious due to differences in sound quality (for example lower volume and clarity) and 
characteristics, particularly if the sex of the person coughing is recognizable and 
different to that of the subject being monitored. 
Whereas early attempts at prolonged monitoring of cough required bulky equipment 
and confinement of the subject to a  single room,240,255 digital technology and advances 
in sound recording have allowed devices to become small and portable enough to be 
worn during normal activities86 for continuous monitoring for 48 h or longer.256  
Monitoring over several days in the stable state of respiratory disease, or in health, is 
probably necessary to establish normal intra-individual variability in cough frequency, 





minimize any effect on cough frequency of the actual process of being monitored. It is 
possible that cough monitoring alters the subject’s awareness of his or her cough, 
leading to fewer or more voluntary coughs, or avoiding activities which produce more 
coughing such as smoking.72,240 Wearing a cough monitor over longer periods than 24 h 
might allow the subject to become accustomed to the device and not adapt behaviour 
as a result. 
1.6.2.2.2 Non-automated cough counting 
‘Manually’ counting coughs in patient audio recordings is the accepted standard for 
objectively determining cough frequency.252,253 Different basic units of cough for 
counting have been proposed87 but individual cough sounds seem to be 
preferred,6,78,253 in keeping with part of the definition of cough by the British Thoracic 
Society as a “characteristic sound”.2 However, it is assumed there is universal 
agreement on what a cough sound is, and while this may seems a safe assumption, 
cough sounds vary between patients and between diseases 257 and this assumption has 
been little-tested. Studies measuring observer consistency in cough counting have 
shown good agreement but only on comparing two different observers or the same 
observer on different occasions, and generally with individuals in research groups who 
have perhaps learned a particular method of classifying coughs from other sounds  
such as throat-clearing and other non-verbal vocalisations.96,247,248,253,258 Inter-observer 
agreement in cough is in need of further investigation. It would be a reflection of the 
ability both to discriminate individual coughs in bouts of repeated closely-spaced 
coughing and to differentiate between coughs and other sounds. 
A further matter in non-automated cough counting is the use of audio editing software 
to identify coughs by the visual appearance of their typical amplitude waveforms 
coincident with the cough sounds.87,259 While this method presumably simplifies the 
recognition and counting of coughs, it is not clear if the approach is valid if the 





the influence of the visual inspection of sound activity on cough counting, and the 
interaction of auditory and visual sensory inputs is complex.260 
A basic method for measuring cough frequency has therefore not been fully 
established and evaluated. This is important for the study of cough on the whole and 
to create a reference standard for the testing of automated coughing counting devices. 
1.6.2.2.3 Automated monitors 
Counting cough by ear is highly labour-intensive. The automated detection of coughs 
has been attempted several times and has been reviewed elsewhere.86,251 Challenges 
have been the development of software which will correctly recognize coughs across a 
variety of disease types, patients and environmental conditions and reject other 
sounds or respiratory events. Three recently-developed automated or semi-automated 
systems are described below. 
1.6.2.2.3.1 PulmoTrackTM 
To my knowledge only one automated cough monitor, PulmoTrackTM (KarmelSonix, 
now iSonea, Haifa, Israel) has been made commercially available.261 It records input 
from chest wall movement, a free-field microphone and two microphones in contact 
with the trachea and chest wall to give completely automated counts. The device has 
been tested in only one study which reported good agreement between its algorithm 
and non-automated cough counting.262 However, the evaluation was only carried out 
on 12 healthy individuals who were asked to voluntarily cough and make other noises 
during a 25-minute monitoring period. No published research into cough frequency in 
disease has been published using this device. Further confirmation of its accuracy is 
required. 
1.6.2.2.3.2 VitaloJAKTM 
VitaloJAKTM (Vitalograph, Buckinghamshire, England) has been developed by the cough 
group in Manchester, currently only for their research purposes.263 It is a semi-





microphone to produce ambulatory recordings of up to 24h in length. The software 
algorithm compresses 24-hour recordings down to approximately one hour or less by 
removing silences and all non-cough audio data but retains information about the time 
of occurrence of the preserved sounds.264 The resultant digital sound file then requires 
human analysis for counting coughs. There have so far been two published reports on 
the evaluation of this algorithm in a total of 30 individuals comprising 24 patients (with 
chronic cough, asthma or COPD) and 6 healthy controls.263,264 The developers report an 
almost zero error rate of the algorithm in transferring the original cough sounds to the 
condensed recording apart from in one patient with asthma and apparently muffled 
cough sounds.263 The overall cough rates in the individuals tested did not seem 
particularly high and the background conditions of the recordings were not described. 
Although the algorithm has been used in clinical studies of cough frequency78,79 more 
published evidence on its performance in a greater range of patients is required. 
1.6.2.2.3.3 The Leicester Cough Monitor 
The cough monitoring system for which there are the most published data is the 
Leicester Cough Monitor (LCM).253 The device consists of a portable digital voice 
recorder and lapel microphone which can record continuously for over 48h.256 
Recordings are analyzed by a software algorithm using techniques similar to those for 
speech recognition.265 It requires human calibration by classifying a selection of 
candidate noises as coughs or non-coughs. 
Initial evaluation of the system by the developers compared its performance to cough 
counting by ear in 6-hour sequences from 15 patients with chronic coughs due to 
asthma, gastroesophageal reflux, eosinophilic bronchitis, viral infection or an 
idiopathic cause. The sensitivity of detecting cough sounds was reported as 86% and 
sensitivity 99% with a median false-positive rate of 1.0 sound/hr.253 Further evaluation 
by an independent researcher from another institution compared non-automated 
cough counts in 24h recordings from 7 patients with idiopathic chronic cough to 





similar (mean ± SE: 23±7, compared to 24 ± 6 coughs/patient/h respectively; intra-class 
correlation coefficient  0.98).266 
More recent testing of the Leicester Cough Monitor in 24-hour recordings from 20 
individuals (8 healthy volunteers and 12 with chronic cough) showed a sensitivity of 
the system of 83.8% in patients and 82.3% in healthy volunteers with a specificity of 
99.9% in comparison to counting by ear.89 Indirect evidence of the accuracy of the LCM 
is the strong similarity between its reports of 24-hour cough counts in patients with 
chronic cough compared to those calculated by ear by the Manchester group in 
recordings from similar patients.75,89 The two research groups with different methods 
of counting cough also report similar cough counts in patients with acute cough.79,80 
Reports of coughs frequency using the LCM are consistent with subjective cough 
severity in chronic cough as measured by questionnaire89 and improvement in LCM-
calculated cough frequency correlated with the primary endpoint of improvement in 
cough-specific quality of life score in a recent randomised controlled trial of 
gabapentin in chronic cough.267 
Data supporting the accuracy of the LCM are therefore accumulating and it would 
seem to be a useful tool for the automated measurement of cough frequency. 
However, the total number of patients in whom the system has been rigorously 
evaluated remains low. There are no reported data for use of the device in lung cancer, 
bronchiectasis, pneumonia, acute exacerbation of COPD, acute asthma or tuberculosis 
and possible differences in cough sounds between diseases might be relevant. Because 
the Leicester Cough Monitor relies on one single lapel microphone for audio input, 
background coughs may be represented, but this has not been adequately tested. This 
is less likely to be important for VitaloJAK because of the simultaneous input from a 
chest wall contact microphone. 
Automated cough detection systems therefore remain in development but are much 
needed for acquiring data about cough in respiratory disease and to enable the use of 





1.6.2.3 Cough intensity 
The intensity of coughing, in terms of the force of chest wall movement, intrathoracic 
pressure changes, and resultant expiratory flows, are probably important in terms of 
symptom severity and also the transmission of infection. This does not seem to have 
been addressed very often. Using measurements of oesophageal and gastric pressure, 
and peak cough flow rate, one study of 49 subjects showed that cough intensity was 
higher in individuals with chronic cough than healthy volunteers.268 The expiratory flow 
rate of a cough is related to the volume of air within the lungs prior to its onset, such 
that repeated coughs within a single breath become sequentially weaker and therefore 
probably less effective at clearing debris from the airways.94,269 The force of a 
spontaneous or involuntary cough may be different to when coughing 
involuntarily.268,270 No study appears to have yet attempted to measure the intensity 
of force of ‘normal’ coughs over a 24-hour period in an ambulatory setting. Using 
cough peak flow may not be practical over 24h, but electromyography or the 
measurement of oesophageal pressures94 might be. Alternatively, the force of a cough 
could be inferred from characteristics of its sound. This has been considered but 
requires further investigation.271   
1.6.2.4 Cough sound analysis 
Coughs have been analyzed acoustically by either measuring the duration of the 
component phases of coughs or the frequency composition of their sounds. There 
have been few developments in this area since the literature was reviewed several 
years ago.272 The three phases of a cough sound have been described as (1) the ‘initial 
burst’, explosive phase or first phase, corresponding to the opening of the vocal cords, 
(2) the middle, intermediate or second phase, corresponding to the flow of air through 
the open larynx, and (3) the ‘final burst’ or third voiced phase as the vocal cords re-
oppose at the end of the cough sound (Figure 1.4).5,257,273–275 This third phase is only 
present some of the time, for example in only 53% of 234 voluntary coughs from 24 
healthy non-smokers in one study.274 Data are few but in children it is perhaps more 





often in 33 voluntary coughs from 5 children without asthma than in 81 coughs from 
12 children with the disease.273  
 
Figure 1.4. Phases of the cough sound, corresponding to, (1) opening of the vocal cords, (2) air flow through the 
open larynx, and (3) re-opposition of the cords. 
 
This same study found the first phase in children to be shorter in asthma than in 
health.273 In contrast Piirilä and Sovijärvi found the first phase cough in adults to be 
longer in asthma than bronchitis, fibrotic pulmonary disease or tracheobronchial 
collapse syndrome. An average of 12 spontaneous coughs from each of 31 adults with 
respiratory disease were looked at here, although the definition of ‘first cough sound’ 
was not given.101 Hashimoto et al. observed that in voluntary coughs from 15 patients 
with chronic productive cough the first phases were relatively shorter and second 
phases relatively longer then in 9 individuals with dry cough.275  
The same group observed a significant lengthening of the second phase in 10 voluntary 
coughs productive of sputum compared to 10 coughs which were non-productive in 
each of 5 patients with chronic bronchitis. The length of the second phase was also 
greater than for 5 healthy controls in each case.99 They also correlated sputum physical 
characteristics with the duration of the intermediate cough phase which was longer 
when the sputum was more plastic and transportable by cilia.275  Others have noted 





The most extensive measurements of phases of the cough sound in respiratory 
diseases have probably been carried out by Smith et al. In a median of 46 spontaneous 
coughs from each of 35 patients with COPD, asthma, IPF or cystic fibrosis there was no 
evidence of difference in phase lengths between diseases, variation being higher 
within diagnostic groups.254,276 However, the authors did not appear to control for 
whether coughs occurred individually or as part of a coughing bout. Coughs occurring 
later during an expiratory breath occur at smaller lung volumes and with lower flow 
rates,94,269 and might therefore have a different distribution of phase lengths. 
In terms of analysis of the acoustic frequencies of cough sounds there seem to be 
differences between individuals based on anatomy, gender and voice.274,277,278 In 31 
patients with respiratory diseases Piirilä and Sovijärvi looked at the frequency at which 
the maximum intensity component of the cough sound occurred.101 They found there 
to be a wide variation, particularly for chronic bronchitis and no significant difference 
between diseases. They also looked at the upper frequency limit of the cough sound: it 
was lower for asthma than chronic bronchitis and tracheobronchial collapse syndrome. 
Knocikova et al., carried out a more detailed analysis of one voluntary cough from each 
of 26 healthy controls, 17 people with stable asthma and 22 with COPD.279 They 
observed that the highest amplitude component of the cough sound in asthma was of 
a higher frequency than that in healthy controls. COPD coughs had greater amplitude 
in the low frequency range and asthma more components of high frequency. By 
including other parameters the authors report an ability to discriminate 85-90% of the 
cough sounds in asthma, COPD and controls according to disease.279  
In probably the largest and most clinically relevant study of its kind Abeyratne et al. 
recently report a method for discriminating childhood pneumonia from other acute 
respiratory illness based only on acoustic analysis of cough sounds.100 From bedside 
recordings in an Indonesian hospital an average of 6.7 spontaneous coughs from each 
of 66 children with pneumonia or another diagnosis including asthma, bronchitis and 





prospectively on a further 25 coughs from each of another 17 patients with pneumonia 
and 8 children with other acute respiratory illnesses by a researcher blinded to the 
physician-made diagnosis. In comparison to this reference standard the reported 
sensitivity of the algorithm for diagnosing pneumonia was 94% and sensitivity 75%. 
The term tussiphonography has been coined to refer to the study of cough sounds .257 
There is need for more work in this area. Just as auscultation of the chest reveals 
information about underlying pathology,280 analysis of cough sounds, in terms of both 
cough phase length and acoustic frequency profiles, might do so likewise. For example, 
cough sounds in tuberculosis may relate to infectiousness, due perhaps to properties 
of mucus, vibration frequencies associated with particle generation, or force of the 
release of air, but this has not been explored. 
1.6.2.5 Measurement of the infectiousness of cough in tuberculosis 
Coughing is probably more important for spreading infection in tuberculosis than in 
other disease (Section 1.5.3). This is because of the need to expel aerosols of a 
particular size and composition to transit through the air and reach the alveolus of a 
new host. Where droplet spread and entry to the new host via the upper respiratory 
tract or conjunctiva are significant, as in influenza, direct contact and sneezing are 
more significant as previously discussed (Section 1.5). 
Not all people with pulmonary tuberculosis and cough transmit disease. Studying the 
characteristics of cough that associate with infectiousness requires a method of 
measuring the spread of infection. Unfortunately, attempts to directly capture and 
culture airborne M. tuberculosis from a room in the vicinity of a coughing individual 
have been unsuccessful,202 and the perfect method for assessing TB transmission does 
not exist. All current techniques provide only indirect evidence for the infection of one 





1.6.2.5.1 Guinea pig air sampling 
The guinea pig air sampling model is probably the most direct way of observing the 
transmission of tuberculosis as it occurs. As previously described, laboratory-reared 
animals free of disease inhale air that is vented from the vicinity of patients with TB. 
The guinea pigs then require serial tuberculin skin tests to detect infection and autopsy 
for confirmation of disease.118,187,222 The technique  has been extremely valuable is 
providing the first clear evidence of aerial transmission in tuberculosis,118 and has 
given the strongest indication of the variability of TB infectiousness between 
patients.186,219 It has recently also been used to evaluate the effectiveness of 
interventions to limit TB transmission, such as the use of surgical masks,222 and UV 
irradiation or ionization of indoor air.178 Problems of this method are the expense and 
time involved, hence one of the reasons it took so long from the 1950s to be 
reemployed.168 Also, as this is an animal model the differences in the process of 
inhaling and becoming infected with M. tuberculosis between humans and guinea pigs 
may be a source of error.281 The method is also only practical in a health care setting, 
and in particular types of patients who require hospitalization for prolonged periods of 
time. The majority of transmission of TB clearly occurs outside of this context hence 
the model is removed from real world situations.  
1.6.2.5.2 Cough aerosol culture 
Another technique is the measurement of expectorated airborne bacilli , as carried out 
recently by Fennelly et al. as described above (Section 1.5.3.2).126,199,200 Only the 
minority of individuals with TB produced cough aerosols in the sampling system from 
which positive cultures were obtained.199 This remained the case even if studying only 
sputum smear-positive disease,200 and the technique appears to produce better 
predictions of infectiousness than considering only sputum smear status.200 However, 
the types of cough in these studies may not be typical. Coughing into a mouthpiece on 
demand might alter usual airflow patterns and therefore the aerosolization of bacteria. 





bacteria which do not involve a mouthpiece.282,283 Although resultant coughing might 
be more representative of usual behaviour, only limited pilot data in TB have been 
reported so far.282,283 Again though, coughing on demand may not be typical of how 
people with TB cough normally. It would be more preferable to attempt to identify M. 
tuberculosis from a space which had been occupied by an individual coughing 
normally. Unfortunately it is very difficult to culture TB from an open area due to 
overgrowth with fungi and environmental bacteria.202  
1.6.2.5.3 Detection of aerosolized DNA of Mycobacterium tuberculosis 
One way around this problem is to measure TB DNA in the vicinity of a patient by 
polymerase chain reaction-based techniques (PCR). This appears to have been done 
rarely.284–286 Limitations of these studies for estimating aerial transmission are several. 
Firstly, the presence of TB DNA does not prove the presence of living organisms 
capable of causing infection. The source bacilli may have died some time previously or 
may lack the appropriate phenotype necessary to cause new infection. Secondly, the 
proximity of the collection system in two studies did not differentiate droplet-sized 
particles from those capable of aerial spread. Thirdly, qualitative techniques about the 
presence or absence of DNA gives no indication about the potential inhaled 
concentration of TB.287 PCR techniques therefore may have high sensitivity but will 
have lower specificity for estimating infectiousness, although more recent approaches 
are quantitative in nature,286,288,289 and may be complementary to other approaches 
for estimating infectiousness. 
1.6.2.5.4 Quantifying aerosolized particles  
Collecting aerosol for TB culture has the disadvantage of requiring a closed system. A 
technique for quantifying the aerosolized particles in an individual’s vicinity during 
routine activity might indicate infectiousness, even if it is difficult to prove that the 
particles contain viable tuberculosis. Most of the work on particle counts during 
expiratory manoeuvres involves closed collection apparatus of various types as 





of measuring particles from ‘open bench coughs’, perhaps more generalizable to 
normal situations than coughing into a mouthpiece, but still produced on demand so 
probably not reflective of normal patterns.149 However, the advantage of this system is 
the ability to study the effectiveness of masks and other cough etiquette techniques in 
impeding the release of particles into the environment.290  
Airborne particle counters have been developed for measuring air quality with high 
sensitivity in industrial settings, particularly where cleanrooms are required. This 
technology has yet to be established as a method for monitoring aerosolized particle 
production by individuals with tuberculosis or other respiratory infections, although 
very recent preliminary work has tested its use in pulmonary TB.283,291 Depending on 
the background air quality it may be a useful method for predicting infectiousness.  
1.6.2.5.5 Evidence of new human infection  
A rise in the local rate of TB infection coincident with a new diagnosis of active 
tuberculosis is the most commonly-used method for estimating transmission, 
particularly if a close genetic relationship between infecting organisms can be 
proven.214,292 The main limitation of this approach is that coincident cases of active 
disease are generally rare with households, at least in the UK, and contact tracing 
reveals many more cases of latent TB infection than active disease.188,293,294 By 
definition, it is not possible to culture or detect TB DNA in latent disease from clinical 
samples, hence the origin of infection is impossible to determine with certainty. The 
local incidence of tuberculosis and an individual’s other risk factors for TB will affect 
the likelihood of latent infection having come from a particular source case. New 
infection in the very young gives clear indication of recent infection, and conversion in 
the immune response from negative to positive on repeat testing with tuberculin or an 
interferon gamma release assay is suggestive.295 Another limitation of detecting latent 
infection is the accuracy of tests for diagnosis; where the presence of bacteria can be 
confirmed (i.e. in active TB), the sensitivity of interferon gamma release assays is about 





Due to the limitations of any one approach, studies using TB infectiousness as an 
endpoint either need to involve a large number of patients or should involve more 
than one approach.    
1.6.3 The diagnostic utility of cough 
Differences in coughs between respiratory conditions have been little studied (Section 
1.4.1). Certain clinical features such as duration of cough, production of mucus, 
associated symptoms, timing of day and exacerbating and relieving factors are used to 
help diagnose the underlying cause.2,56 Further study of cough will reveal if there are 
specific characteristics of coughs that are unique to particular clinical situations. The 
frequency of coughing, diurnal variation, amount of clustering of coughs into epochs 
and features of the cough sound might all be relevant. 
Cough can be due to serious disease but because it is commonplace its potential 
importance may be ignored.298 For this reason the UK Government recently launched a 
publicity campaign to encourage people with a persistent cough to seek medical 
attention.299 A way of analyzing coughs in more detail may improve diagnosis, 
particularly in resource-poor areas if the technology were simple. Cough sound 
analysis may improve the diagnostic rate of childhood pneumonia in developing 
regions.100 Combining very basic clinical information (the presence or absence of fever) 
in the study of Abeyratne et al. improved the diagnostic algorithm based on analysis of 
the cough sound (Section 1.6.2.4).100 
Tuberculosis is also prevalent in low income countries and diagnosis is often 
delayed.205 This is due to the reliance on sputum microscopy as the main diagnostic 
test which is often unavailable. Even when accessible it has sensitivity of <60%, or less 
in individuals with HIV.300 New relatively low-cost microbiological and molecular 
techniques are promising,301 but simpler diagnostic methods could have a large impact 
on TB control.  
Cough is the most common symptom of pulmonary tuberculosis.302 A recent large 





cough would detect 60% of cases of active TB but with a specificity of only 2%.303 It is 
not known if certain features of cough are more likely to be present in tuberculosis but 
if this were the case the potential diagnostic usefulness of cough would clearly be 
enhanced.  
1.6.4 The prognostic utility of cough 
Serial cough monitoring may be a novel objective laboratory-free method of following 
the course of respiratory disease. In tuberculosis current methods for assessing the 
response to treatment are inadequate due to a lack of sensitivity and specificity.304 
They include clinical parameters (improvement of symptoms, control of fever and 
weight gain), radiographic monitoring (resolution of chest X-ray changes) and 
microbiological criteria (conversion of sputum smear and cultures). Other tools are 
needed to guide clinicians through the treatment of individual cases, particularly those 
with drug-resistant disease. 


























































n = 2 0
n = 1 1
n = 1 5
n = 2 0
n = 2 0
n = 1 2







Figure 1.5. Reduction in nocturnal cough frequency during treatment of pulmonary tuberculosis. 
 
Cough clearly improves as TB infections resolve; the resolution of the symptom 
correlates with treatment success.305 This has only been shown objectively in only one 






study to my knowledge,125 although another describes the early development of a 
cough detection algorithm for this purpose.259 In the 1969 study by Loudon and Spohn 
nocturnal cough counts were repeated on a weekly basis during the treatment of 20 
individuals with pulmonary tuberculosis.125 There was a drop in 65% in the first two 
weeks, followed by a continued slower decline in cough frequency from then on 
(Figure 1.5). It is not known how improvements in cough frequency correlate with 
other indicators of response to TB treatment and whether monitoring coughs over 
shorter periods than eight hours and more frequently than once a week would be 
predictive of response to treatment.  
Serial cough monitoring has been carried out in acute upper respiratory tract infection 
to describe the normal range of resolution of cough frequency in this context, useful 
for the future evaluation of potential anti-tussive medications.79,80 In chronic 
conditions such as COPD78,306 and idiopathic pulmonary fibrosis77 serial cough 
monitoring may reveal information about the trajectory of the disease, perhaps with 
greater sensitivity although probably less specificity than changes in lung function.307 
This also needs further exploration. 
1.7 Study aims 
This thesis aims to describe the patterns and significance of cough in tuberculosis with 
reference to other respiratory conditions. The more specific objectives were as follows. 
1. To assess and compare the subjective appreciation of cough in respiratory 
diseases.  
2. To evaluate methods of objectively measuring cough frequency. 
3. To assess the temporal patterns of cough frequency in respiratory disease, 
observe the response of cough frequency in tuberculosis  and other conditions 






4. To investigate the influence of single nucleotide polymorphisms of TRPV1 on 
objective measures of cough. 
5. To investigate the infectiousness of coughs by measuring airborne droplets and 
the association of cough frequency with household infection in tuberculosis.  
The thesis addresses some of the areas in which there is a significant lack of knowledge 
regarding variability, mechanisms and implications of cough in TB and other 





2 Comments on methodology and 
analysis of data 
2.1 Introduction 
A variety of methodological approaches were employed to fulfil the aims of this work. 
Detailed descriptions of the methods follow in the corresponding chapters but 
common approaches are set out below. This was an observational clinical study, 
predominantly of a cohort design, with cross-sectional elements. 
2.2 Setting 
The principal recruitment site was Homerton University Hospital NHS Foundation Trust 
(HUH), a district general hospital (DGH), in Hackney, North-East London, UK, where 
individuals were sought with all diagnoses. Patients with pulmonary tuberculosis were 
also recruited from Whipps Cross University Hospital, Shrewsbury Road Chest Clinic, 
and Mile End Hospital, East London. The work on capsaicin cough reflex endpoints 
(Chapter 6) and TRPV1 genotyping in chronic cough (Chapter 9) took place at King’s 
College Hospital, Denmark Hill, South London. Recruitment took place between 
January 2013 and June 2015. 
2.3 Ethics 
Ethical approval was granted for the majority of this study by the London Riverside 
Research Ethics Committee as part of the project “Cough in respiratory disease” 
(reference 12/LO/1923). In Chapters 6 and 9 capsaicin challenge testing was carried 
out (at King’s College Hospital) with pre-existing ethical approval given by East London 
and The City Research Ethics Committee as part of another study, “The assessment of 
cough intensity with a novel cough monitor” (10/H0703/6). Approval to test for 
genetic polymorphism related to cough (Chapter 9) was given separately by the 
London Stanmore Research Ethics Committee (“Genetic variation and cough: the 





14/LO/0164). The Research and Development departments of the participating 
hospital trusts granted approval for the conduct of the research under their 
jurisdiction. All study subjects provided written consent to participate. 
2.4 Data cleaning 
Data entry was checked primarily by verifying the values of outliers and unexpected 
results, range checking for continuous data, and verification that all values for 
categorical data were one of the pre-specified alternatives.308 
2.5 Statistical analysis 
Data were analyzed using Prism version 6.04 (GraphPad Software Inc., San Diego, 
California) and Stata 13.0 (Stata Corp, College Station, Texas).  
Parametric tests were used with all continuous data, unless otherwise stated, after 
testing that distributions were approximately normal with either the Shapiro-Wilk W 
test (Stata) or D’Agostino-Pearson omnibus normality test (Prism). Log-transformation 
of continuous data to achieve normality was used where appropriate. Comparisons of 
means were made with Student’s t-tests, paired or unpaired as appropriate, or one-
way analysis of variance (ANOVA) for two or more groups of data, respectively. Non-
parametric data are expressed as medians and inter-quartile range (IQR). Differences 
in non-normally distributed untransformed groups of data were tested with Wilcoxon 
rank-sum (Mann-Whitney) or Kruskal-Wallis tests for two or more groups of data, 
respectively. Dunn’s tests were applied for multiple pairwise comparisons.  
Categorical data were compared between groups with Fisher’s exact tests, with odds 
ratios calculated with the Mantel-Haenszel method. Associations between two 
continuous variables were tested with Pearson’s coefficient (r) or Spearman’s rank 
correlation coefficient (ρ [rho]), for parametric and non-parametric data, respectively.  
Multivariate analysis were performed using multiple regression. Candidate explanatory 
variables were selected on the basis of associated p values < 0.15 from univariate 





of magnitude of associated p values from univariate analyses (smallest to largest) until 
the addition of an extra variable was not statistically significant.308  
All statistical tests were two-sided and statistical significance (α) was taken as p ≤ 0.05. 
Power calculations were performed with the aid of an online tool.309 
2.6 Acknowledged contributions 
Necessary applications to ethics committees and research and development 
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The majority of patients (>97%) involved in this research were recruited by the author. 
The remainder, all inpatients at HUH with acute respiratory disease, were recruited by 
Dr Metin Yalcin. All other aspects detailed in the methods in the following chapters 
were carried out by the author with the exception of DNA extraction and genotyping 
from saliva samples (Chapter 9) which was carried out by the Barts and the London 
Genome Centre. Data entry and statistical analysis was also performed by the author, 
with advice from Dr Richard Hooper. Further details of individuals contributing to this 








3 Study participants 
3.1 Introduction  
The majority of the data in this thesis were obtained from the voluntary participation 
of human subjects, the large majority of whom were patients with respiratory disease. 
This chapter will describe the criteria for study participation, case definitions and 
subject characteristics. 
The main interest was cough in tuberculosis, with the hypothesis that there may be 
special features in TB associated with the role of cough in the transmission of infection. 
Other disease groups were included partly as controls against which to compare cough 
patterns in TB, but also in attempt to observe particular patterns associated with 
different types of pathology. Aspects of the pathology of other respiratory conditions 
are shared to varying degrees with tuberculosis. For example, as well as occurring in 
TB, chronic sputum production is characteristic of bronchiectasis and chronic 
bronchitis; fibrosis is a common feature of interstitial lung disease, granulomatous 
inflammation the mechanism of sarcoidosis, and bacterial infection with consolidation 
is the hallmark of community acquired pneumonia. Conversely, the airway disease of 
COPD and asthma is not a feature of tuberculosis, malignant parenchymal and airway 
invasion by tumour is unique to lung cancer, and individuals with latent TB infection 
and no respiratory condition, by definition, should cough only as much as anyone else 
without lung disease. Isolated chronic cough probably represents a group of individuals 
who cough excessively, or are more aware of their cough, in response to stimuli which 
to others would be relatively innocuous.62  
3.2 Subject selection and enrolment 
Individuals were invited to participate in the study if they fitted into one of the 
following categories: isolated chronic cough, stable COPD, stable asthma, 
bronchiectasis, pulmonary fibrosis, lung cancer, COPD exacerbation, acute asthma, 





Exclusion criteria were age <16 years, an inability to consent to the study, very severe 
acute illness (leading to artificial ventilation or palliation), or more than one of the 
following respiratory diagnoses: isolated chronic cough, COPD, asthma, bronchiectasis, 
pulmonary fibrosis, community-acquired pneumonia. Patients with lung cancer were 
not excluded on the basis of co-existent COPD due the common co-occurrence of 
these two diagnoses.310,311 Individuals with latent TB infection were excluded if they 
had any one of the other respiratory diagnoses investigated in this study. Smoking and 
the use of medication with a possible influence on the cough reflex (in particular ACE 
inhibitors and opiates or opioids), were not exclusion criteria. Other than for 
individuals with isolated chronic cough, subjects were invited to participate regardless 
of whether or not cough was reported. 
Patients were recruited both as hospital inpatients and outpatients, from respiratory 
wards, an acute medical admissions unit, and specialist respiratory clinics. These 
included a cough clinic, for patients referred from primary care with isolated chronic 
cough, and TB clinics. For stable COPD, recruitment also took place at pulmonary 
rehabilitation sessions.  
3.2.1 Isolated chronic cough  
Participants with isolated chronic cough had cough as the only or predominant 
symptom for ≥8 weeks.312 At the time of enrolment they were visiting the cough clinic 
for the first time after referral from general practice. Their symptoms at that point had 
not been attributed to a particular diagnosis but the referrer had deemed there to be a 
low probability of thoracic malignancy.  
3.2.2 Stable COPD   
The diagnosis of  COPD (chronic obstructive pulmonary disease) was confirmed on the 
basis of chronic respiratory symptoms (including cough and dyspnoea) and a post-
bronchodilator ratio of forced expiratory volume in one second (FEV1) to forced vital 





had not experienced one or more exacerbations requiring medical treatment within 
the previous four weeks (section 3.2.7).315 
3.2.3 Stable asthma 
Participants with asthma had had their diagnosis confirmed by a consultant respiratory 
physician. In keeping with national guidelines, in all cases there had been a 
‘characteristic pattern of symptoms and signs and the absence of an alternative 
explanation for them’ and demonstration of variable airflow obstruction.316 Patients 
were considered to have stable disease if, within the previous 10 days neither of the 
following had occurred: use of a short-acting bronchodilator inhaler ≥4 times/day on 
two consecutive days, or waking due to symptoms of asthma on two consecutive 
nights.317  
3.2.4 Bronchiectasis 
Bronchiectasis had been diagnosed on the basis of current or previous symptoms of 
persistent cough and sputum production in conjunction with a confirmatory high 
resolution computed tomography (HRCT) which had been interpreted by a thoracic 
radiologist.318 Patients with cystic fibrosis were not included, mainly because they did 
not attend clinics at Homerton University Hospital (HUH).  
3.2.5 Pulmonary fibrosis 
This category included patients with several underlying interstitial lung diseases (ILDs), 
including idiopathic pulmonary fibrosis (IPF), sarcoidosis, and connective tissue 
disease-related ILD.319,320 All had evidence of pulmonary interstitial fibrosis  on HRCT, 
including architectural distortion, honeycombing, and reticulation.321  
3.2.6 Lung cancer 
Patients in this category had either a tissue or clinico-radiological diagnosis of lung 






3.2.7 COPD exacerbations  
This group comprised patients with COPD, as defined above (section 3.2.2), but were 
recruited within 48 h of hospital admission for symptoms of increased breathlessness, 
possibly accompanied by worsening cough and increased sputum volume and 
purulence, not explained by pneumonia or another cause.323   
3.2.8 Acute asthma 
Participants with acute asthma had a known previous diagnosis of asthma (section 
3.2.3) but were recruited within 48 h of hospital admission for symptoms of increased 
breathlessness, possibly accompanied by worsening cough and wheeze not explained 
by pneumonia or another cause, but accompanied by a decline in the baseline or 
predicted best peak expiratory flow rate (PEFR).316 
3.2.9 Community-acquired pneumonia 
Community-acquired pneumonia (henceforth referred to simply as pneumonia) was 
defined as an acute illness (of duration ≤21 days) with symptoms consistent with a 
lower respiratory tract infection (including cough, fever, sputum production, 
breathlessness, wheeze, chest pain) accompanied by new shadowing on a chest x-ray 
not attributed to another cause (e.g. pulmonary oedema or infarction) in patients 
admitted to hospital from the community.324,325 
3.2.10 Pulmonary tuberculosis 
The diagnosis of pulmonary TB was ultimately clinical, made by an experienced 
physician, based on risk factors, symptoms, physical examination, radiology and 
sputum microbiology.326 Sputum culture-negative cases were included. Patients were 
often invited to participate before the diagnosis was confirmed, and at times were 
retrospectively excluded if they had not officially been notified, or were later de-
notified, with the public health authority as a case of pulmonary tuberculosis. Patients 





3.2.11 Latent tuberculosis infection (LTBI) 
Subjects with LTBI had immunological evidence of exposure to Mycobacterium 
tuberculosis (Mtb) on the basis of a positive interferon-γ release assay (IGRA) and/or 
Mantoux test, but a normal chest x-ray and no clinical evidence of active 
tuberculosis.327 They had been screened for tuberculosis either as close contacts of 
cases of active TB, because of recent arrival to the UK from a high TB-incidence 
country, routine occupational screening prior to working in a health or social care 
setting, or prior to starting on biological therapy for systemic rheumatic disease or 
other autoimmune disorder.  
The IGRA used in most cases was the QuantiFERON® test (Cellestis, Australia), 
following manufacturer’s instructions, with a positive test equating to a interferon-γ 
response to TB antigen ≥0.35 IU/ml above the negative control.328 The Mantoux test 
was performed in the standard way, by the intradermal injection of 2 TU/0.1 ml 
tuberculin (PPD RT23, Statens Serum Institut, Copenhagen), and was considered 
positive if the skin induration at 48-72 h measured ≥6 mm, or ≥15 mm in the context of 
prior BCG vaccination.329 Discordance between IGRA and Mantoux results was 
interpreted by an experienced clinician in light of epidemiological and clinical variables 
and the greater specificity of IGRAs compared to the Mantoux test.330 
Individuals with LTBI were included specifically as a negative comparator group to 
those with respiratory disease. It was assumed that coughing in individuals with LTBI 
should be relatively infrequent, but individuals with acute coughs (and a normal chest 
x-ray) and smokers were not excluded. 
3.3 Demographic and routine clinical data collection 
From clinical records, both electronic and paper, it was verified that subjects fulfilled 
the diagnostic inclusion criteria. Age, gender, co-morbidities, routine medication use, 





For patients with tuberculosis, sputum microbiology results were recorded, including 
acid-fast bacilli counts on smear microscopy, graded as +/-, 1, 2 or 3+.331 X-ray 
appearances in TB were noted, including the presence of visible cavities, as reported 
by a radiologist, and the extent of disease, measured as the number of chest 
radiograph zones affected, from 0 to 6. M. tuberculosis complex lineage was also 
documented, as inferred from routine molecular typing (mycobacterial interspersed 
repetitive units, variable number of tandem repeats; MIRU-VNTR), carried out by the 
local mycobacterial reference laboratory.332,333 From published literature on 
associations with virulence particular interest was in the Beijing strain,182,184 from local 
(unpublished) cluster data, the Cameroon strain, and from a possible negative 
association with cough in one study, the Haarlem strain.234  
For patients with COPD, asthma, bronchiectasis, pulmonary fibrosis and lung cancer, 
the most recent lung function report from the preceding 12 months was used if 
available. For pneumonia the CURB-65 score was calculated as an indicator of disease 
severity from the component variables on hospital presentation of confusion, serum 
urea concentration, respiratory rate, blood pressure and age.325 
3.4 Routine management of respiratory disease 
What follows is a description of the routine management of conditions relevant to the 
patients in whom repeated measurements were made. 
3.4.1 Acute respiratory disease 
Patients admitted to hospital with pneumonia, acute asthma and COPD exacerbations 
were usually commenced on treatment in the emergency department, transferred to 
the acute general medical admissions ward, and then a respiratory or other medical 
ward for continued care. Because an exclusion criterion to the study was very severe 
acute illness, patients admitted to the intensive care unit were not included. 
Supportive care included intravenous fluids and oxygen therapy as indicated.334 
Disease-directed treatment followed national guidelines. For pneumonia this included 





part, on clinical severity of disease.325 For acute asthma and COPD, treatment included 
inhaled bronchodilators, usually delivered initially by nebulizer, and systemic 
corticosteroids.313,316  
3.4.2 Pulmonary tuberculosis  
Treatment for TB was started by an experienced respiratory physician on suspicion or 
microbiological confirmation of the diagnosis in line with national guidance.327 The 
standard regimen of four drugs (rifampicin, isoniazid, pyrazinamide and ethambutol) 
was given, unless there was confirmation or suspicion of drug resistance (e.g. previous 
TB treatment or a history of contact with drug-resistant pulmonary tuberculosis), in 
which case an alternative regimen was used.327 Treatment of drug-sensitive TB was for 
six months, the final four months with only rifampicin and isoniazid, unless there was 
drug intolerance, poor medication adherence or a failure of adequate clinical response, 
in which case treatment was prolonged, possibly with alteration of the regimen. 
Common alternative regimens included streptomycin and/ or moxifloxacin as 
component drugs. Routine clinic appointments with the respiratory physician were 
scheduled at 0, 2, 8 and 26 weeks during treatment of non-complicated cases. Patients 
undergoing directly-observed therapy at the HUH TB clinic (usually due to previous TB 
treatment, previous poor adherence, or social risk factors for reduced treatment 
adherence) attended daily or on alternate week days. Chest x-rays were performed at 
baseline and repeated at 8 and 26 weeks in uncomplicated cases. Sputum was sampled 
at baseline, two and five months during standard treatment, produced either 
spontaneously or induced by inhaling hypertonic (3%) saline, and sent for 
mycobacterial microscopy and culture.  
3.5 Participant characteristics 
A summary of the baseline characteristics of the study participants is shown in Table 
3.1. Ethnicity varied between diseases: compared to the whole study population, 
patients with TB were less likely to be white, as were participants with LTBI. In 





Table 3.1. Summary of baseline characteristics of study participants 













Chronic cough 143 98 (68.5)§a 54 (37.7) 64 (44.8)† 51 (39-65)‡ 5 (3.5)§d 13 (9.1) 4 (2.8)* 
Stable COPD 18 9 (50.0) 15 (83.3)§c 16 (88.9)§c 67 (62-73)§b 6 (33.3) 6 (33.3)‡a 2 (11.1) 
Stable asthma 5 4 (80.0) 2 (40.0) 3 (60.0) 64 (58-73) 0 0 0 
Bronchiectasis 9 6 (66.7) 2 (22.2) 3 (33.3) 71 (60-74)‡ 0† 0 2 (22.2) 
Fibrosis 15 6 (40.0) 5 (33.3) 5 (33.3) 72 (63-74)§ 2 (13.3)* 5 (33.3)‡a 1 (7.7) 
Lung cancer 9 2 (22.2)a 5 (55.6) 6 (66.7)* 64 (58-73)‡ 4 (44.4) 0 2 (22.2) 
COPD 
exacerbation 
25 13 (52.0) 19 (76.0)§b 19 (76.0)§b 71 (60-77)§ 12 (48.0)a 7 (28.0)‡ 5 (20.0)a 
Acute asthma 18 13 (72.2)† 5 (27.8) 14 (77.8)§ 35 (23-44)a 6 (33.3) 1 (5.6) 0 
Pneumonia 17 8 (47.1) 12 (70.6)‡a 14 (82.4)§a 54 (43-65)* 10 (58.8) b 5 (29.4)† 0 
TB 44 13 (29.5)b 10 (22.7)a 9 (20.5)a 40 (30-43)d 24 (54.5)d 0 4 (9.1) 
LTBI 17 7 (41.2) 2 (11.8) 4 (23.5) 31 (29-34)d 2 (11.8)† 1 (5.8) 0 
ALL 302 172 (57.0) 129 (42.7) 153 (50.7) 53 (40-67) 69 (22.8) 40 (13.2) 21 (7.0) 
 
 
TB – pulmonary tuberculosis; fibrosis – pulmonary fibrosis due to any interstitial lung disease; AECOPD – acute exacerbation of 
chronic obstructive pulmonary disease; LTBI – latent tuberculosis. ACEi  – current ACE inhibitor use. 
Va lues are n (%) or median (IQR). 
* p ≤ 0.05, † p ≤ 0.01, ‡ p ≤ 0.001, § p ≤ 0.0001, for di fferences compared to TB (Fisher’s exact tests, except Dunn’s multiple 
comparisons test for age). Differences otherwise not s tatistically s ignificant. 
a p ≤ 0.05, b p ≤ 0.01, c p ≤ 0.001, d p ≤ 0.0001, for di fference in proportions compared to the whole group (Fish er’s exact tests, 
except Dunn’s multiple comparisons test for age). Differences otherwise not statistically s ignificant.  







community-acquired pneumonia was white than in the whole study population and in 
those with TB. A similar pattern was seen for country of birth, although there were 
more significant differences on comparing TB with other groups  
Patients with TB and lung cancer were more likely to be male, and participants with 
isolated chronic cough more likely to be female. Age was higher in stable COPD and 
COPD exacerbations, and lower in TB, LTBI and acute asthma than in the whole group. 
Current smoking was more prevalent amongst patients with TB than with isolated 
chronic cough, bronchiectasis, fibrosis and LTBI, but not significantly different from 
subjects with COPD exacerbations, pneumonia and acute asthma. ACE inhibitors were 





used in TB than in the whole study population. Opiate medication was used 
significantly less frequently in patients with chronic cough than TB. 
Apart from the 302 patients who consented to participate in the study, 32 declined. 
Their diagnoses were TB (n = 11), isolated chronic cough (n = 6), LTBI (n = 6), 
pneumonia (n = 3), pulmonary fibrosis (n = 2), asthma (n = 2), COPD (n = 1) and lung 
cancer (n = 1). 
3.5.1 Isolated chronic cough 
143 patients were recruited with isolated chronic cough. Final underlying diagnoses 
were as in Table 3.2, with asthma (30.8%), gastro-oesophageal reflux disease (16.1%) 
and unexplained chronic cough (16.1%) the most common. Four participants had >1 
diagnosis and 18 participants had no diagnosis, due to loss to follow up (n = 8), a 
decision to be discharged before finding a cause for the cough (n = 6) and ongoing 
clinic management at the time of the end of the study (n = 4). The median duration of 
cough symptoms at entry to the study was 6 (3-12) months. 
 
Table 3.2. Final diagnoses of participants with isolated chronic cough. 
Diagnosis n (%) 
Asthma  44 (30.8) 
Gastro-oesophageal reflux  23 (16.1) 
ACE inhibitor-associated 12 (8.4) 
Upper a irway pathology 10 (7.0) 
Post-infective  8 (5.6) 
Smoking 4 (2.8) 
Lower respiratory tract i nfection 2 (1.4) 
Voluntary coughing / throat clearing 1 (0.7) 
Bronchiectasis 1 (0.7) 
Sarcoidosis 1 (0.7) 
Unexplained chronic cough 23 (16.1) 
No diagnosis 18 (12.6) 
 
 
The general characteristics of patients referred to the HUH cough clinic and the 
outcome of the diagnostic approach at the time of the current study have been 
described elsewhere.335 






3.5.2 Stable COPD 
Eighteen patients had stable COPD. All were recruited from pulmonary rehabilitation 
sessions. Lung function, exacerbation frequency and regular medication are 
summarized in Table 3.3.  
Table 3.3. Characteristics of participants with stable COPD. 
Characteristic  
Post-bronchodilator FEV1 (% predicted) 59.9 (± 19.0) 
Exacerbation frequency (yr-1) 6 (3-6) 









3.5.3 Stable asthma 
Only five patients had stable asthma, all recruited from a secondary care asthma clinic. 
They all had severe asthma as demonstrated by fixed airflow obstruction, high 
frequency of exacerbations of symptoms requiring oral corticosteroids and high level 
of background medication use (Table 3.4). Only one patient had a smoking history, 
having stopped >20 years previously. 
Table 3.4. Characteristics of participants with stable asthma. 
Characteristic  
Post-bronchodilator FEV1 (% predicted) 66.8 (± 35.0) 
Exacerbation frequency (yr-1) 6 (3-6) 















Table 3.5 shows the characteristics of the nine patients with bronchiectasis.  
Values are mean (± SD), median (IQR) or n (%). Exacerbation defined as acute worsening 
of respiratory symptoms requiring antibiotics and/or systemic corticosteroids. n = 18. 
Values are mean (± SD), median (range) or n (%). 
Exacerbation defined as acute worsening of respiratory 
symptoms requiring systemic corticosteroids. 









3.5.5 Pulmonary fibrosis 
The characteristics of the 15 study participants with established pulmonary fibrosis 
due to ILD are shown in Table 3.6. All the cases of IPF had radiological diagnoses, one 
of which had been confirmed with histology.  
Table 3.6. Characteristics of study participants with pulmonary fibrosis. 
Characteristic  
Underlying diagnosis 
idiopathic pulmonary fibrosis 



























Table 3.5. Characteristics of study participants with bronchiectasis. 
Characteristic  
Cause of bronchiectasis 
idiopathic/ post-infective 








Number of affected lobes on CT 2 (2-3) 
Lung function  
FEV1 (% predicted) 












Exacerbations/ yr*  4 (2-7) 
 
Va lues are n (%), mean (± SD) or median (IQR). 
*Exacerbation defined as acute worsening of respiratory symptoms 
requiring specific antibiotic treatment. 
n = 9. 
 
 
Va lues are n (%), mean (± SD) or median (IQR). 
*a l l given as % predicted, other than FEV1/FVC ratio (actual 
va lues). 
TLC – tota l  lung capacity; DLCO – tota l diffusing capacity of the 
lung for carbon monoxide; KCO – di ffusing capacity of the lung 
for carbon monoxide per unit alveolar volume 






3.5.6 Lung cancer 
Only one of the nine patients with lung cancer recruited to this study had received 
anti-cancer treatment at the time of recruitment, palliative radiotherapy >12 months 
earlier. There was no evidence of associated pulmonary fibrosis in this, or any other 
patient. None had undergone surgery. Lung function was only available for four 
participants: FEV1 range 46-95% predicted, FEV1/FVC ratio range 41-74%. One patient 
did not have any CT imaging due to residence abroad. The characteristics of the group 
are shown in Table 3.7. 
Table 3.7. Characteristics of patients with lung cancer included in the study. 
Characteristic  




























Co-existent COPD 3 (33.3) 
 
3.5.7 COPD exacerbations 
The characteristics of study participants with COPD exacerbations are shown in Table 
3.8. All were commenced on treatment with antibiotics, oral corticosteroids and 
nebulised bronchodilators on the day of hospital admission. 
 
Values are n (%). 
RUL, RML, RLL: right upper, middle, and lower 
lobe, respectively. 





Table 3.8. Characteristics of study participants with COPD exacerbations at the time of recruitment. 
 
3.5.8 Acute asthma 
Table 3.9 shows the characteristics of patients with acute asthma. 
Table 3.9. Characteristics of patients with acute asthma at the time of study recruitment. 
Characteristic  





ora l  corticosteroid 
 
14 (78.0) 




Exacerbation frequency (yr-1) 0.5 (0-3.3) 
Days  from onset of symptom worsening 3 (2-5) 
PEFR on admission (% best or predicted) 42.4 (±15.1) 
 
3.5.9 Community-acquired pneumonia 
Characteristics of the 17 patients recruited with community-acquired pneumonia are 
shown in Table 3.10.  
Table 3.10. Characteristics at time of recruitment of study participants with community-acquired pneumonia. 
Characteristic  
Day from onset of symptoms  6 (5-14) 
Cl inical severity on admission 
bi lateral chest x-ray involvement 
C-reactive protein (mg/L) 









Baseline FEV1 (% predicted)* 44.5 (±16.8) 
Exacerbations frequency (yr-1) 3 (1-4) 
Days  from onset of symptom worsening 




Va lues are mean (±SD) or median (IQR). *data only 
ava ilable for 24 patients. n = 25. 
Va lues are median (IQR) or n (%). 
n = 17. 
Va lues are n (%), median (IQR) or mean (±SD). 






Forty-four patients were recruited with pulmonary tuberculosis prior to starting anti-
TB treatment (Table 3.11). Two patients also had COPD; no other participant had other 
chronic respiratory diagnoses. Of the four patients taking regular opiates, the 
medication used was methadone. Forty patients were recruited at Homerton 
University Hospital, and four from the other hospitals in East London.  
13 of the 44 patients were female (Table 3.1), 10 of whom were sputum smear positive 
(77%), compared to 18 of 31 males (58%), a non-significant difference (Fisher’s exact 
test, p = 0.314). 17 males had disease involving <2 x-ray zones (55%) compared to 7 
females (54%; p = 1.000). Three women had co-incident extra-pulmonary disease 
(EPTB; 23%) compared to 4 men (13%; p = 0.404). 
3.5.11 LTBI  
Of the 17 participants with LTBI, reasons for TB screening had been contact with a case 
of active TB (n = 12), recent arrival to the UK from a high TB-incidence country (n = 3), 
pre-employment as a healthcare worker (n = 1), and consideration of biological 
treatment for rheumatoid arthritis (n = 1). One participant had an acute cough of three 
days’ duration at the time of recruitment, presumably due to an upper respiratory 










































Previous pulmonary TB 4 (9) 








Coincident extra-pulmonary TB 7 (16) 
Referral from screening  2 (5) 
Chest x-ray appearances 


















time to positivity (days) 
organism drug sensitivity 
ful ly sensitive 




































Values are n (%) or median (IQR). 







The ethnic origin (43% white) and region of birth (51% western Europe) of the 
participants in the study overall was similar to those of the wider population of 
Hackney (52% white, 61% UK-born).336 Patients with TB were particularly likely to be 
born overseas and be non-white, in keeping with national data indicating the 
importance of imported infections.337 Patients with COPD, both stable disease and 
with exacerbations, were more likely to be white than the general study population, 
but were also older. The prevalence of COPD increases with age generally;338 the 
ethnic  difference was probably a reflection of the fact that white people make up a 
relatively larger proportion of the local older population compared to younger age 
groups.336 In keeping with global figures, individuals with tuberculosis were generally 
of relatively young age. The relative youth of subjects with LTBI perhaps reflected UK 
practices of offering preventative anti-TB treatment primarily to those under the age 
of 35,327 leading to over-representation of this age group with LTBI in TB clinics. 
The male predominance amongst the recruited patients with tuberculosis is 
representative of wider trends in TB which have a variety of explanations, biological 
and social.339 A female over-representation amongst patients with isolated chronic 
cough has been often reported, and may be representative of a mechanism of the 
cough reflex (Section 1.4)340 although women are more likely than men to seek advice 
about many symptoms other than cough.341 Smoking is associated with TB,172 COPD,310 
and pneumonia,342 and this was reflected in the relatively high proportion of current 
smokers amongst study participants with these conditions. Smokers were under-
represented amongst patients with isolated chronic cough, perhaps because smokers 
are less likely to seek medical attention for coughs,343 or they are less likely to be 
referred by general practitioners (GPs) to secondary care for isolated cough, as 
symptoms are attributed solely to tobacco use. 
ACE inhibitor use was relatively higher in those with COPD and pulmonary fibrosis and 
lower in TB, presumably reflecting differences in age and the likelihood of the 





prescribed. The baseline differences in general characteristics between disease groups 
were therefore predictable and the study participants were representative of the local 
population. Detailed analysis of differences in baseline characteristic between groups 
is however limited by sample sizes, particularly for stable asthma, bronchiectasis and 
lung cancer, in which fewer than 10 participants were recruited in each case.  
Disease-specific baseline characteristics within groups also varied. This is most clearly 
seen for tuberculosis and isolated chronic cough, the largest groups, where baseline 
variation should make the findings this research more widely applicable to other 
settings. Studying TB in London is probably unique for the large diversity of host and 
bacterial strain genotypes.337 
The underlying attributed diagnoses in isolated chronic cough were similar to those 
seen in other settings,9 although comparison with the literature is difficult as many 
published series contain large proportions of patients referred from primary, as well as 
secondary care.224,243,344 It is also a problem for objectivity that diagnoses in isolated 
chronic cough are to a large extent made on the response to trials of treatment,2 when 
cough can also resolve spontaneously,64 with behavioural training,65 and in response to 
placebo.67  
Most other disease groups were small, which may limit the generalizability of specific 
findings in these conditions. The patients with stable asthma had severe disease, as is 
not uncommon in those attending a secondary care asthma clinic, whereas the 
recruitment of individuals with stable COPD from pulmonary rehabilitation sessions 
had more moderate pathology. The interstitial lung diseases have varied in their 
classification with time, and subdivisions in theory and practice are often difficult.319 
This was one of the reasons for grouping together all patients with established lung 
fibrosis regardless of the attributed underlying cause, in order to observe the effect of 
chronic lung scarring on cough. Umbrella terms are more commonly used in other 
areas of respiratory medicine to lump together patients with differing pathology and 





obstruction might be the only unifying criterion that associates different diseases 
resulting from, for example, cigarette smoking, longstanding uncontrolled asthma, or 
the effects premature birth.345  
3.7 Conclusion 
This Chapter has set out the study recruitment criteria and characteristics of the 
included participants. It is in this context that cough in tuberculosis and other 












4 Subjectively-described cough across 
respiratory conditions 
4.1 Introduction and objectives 
Cough is a common symptom of many respiratory disorders, either on its own, or in 
association with other clinical features. There have been few attempts to compare 
cough in different conditions in the same study.83,88,89,91,101,276 This chapter will focus 
on cough as reported by the patient, i.e. the subjective report of cough symptoms, 
rather than an attempt at objective description of measurable physiological and 
pathological characteristics of cough, which will  be discussed in Section 3.  
The hypothesis was that subjectively-described cough varies between respiratory 
conditions. This might be because of different ‘types’ of cough, relating to differences 
in underlying pathology (Section 1.4.1), or differences in the noticeability of cough, 
either due to its relative novelty across diseases of varying chronicity, relative severity 
in comparison to other co-existing symptoms, or other factors. As suggested earlier, it 
would be to the evolutionary advantage of Mtb if the subjective effect of cough in TB 
were relatively mild so as not to impact significantly on social mixing and reduce 
opportunities for transmission (Section 1.5.3.3). Patient-reported cough in TB might 
therefore be particularly distinct.  
4.2 Clinical procedures 
4.2.1 Study participants 
Two cohorts of patients were included. A prospective cohort with various diagnoses, 
and a retrospective cohort with pulmonary tuberculosis. The recruitment criteria, 
collection of routine clinical data, participant characteristics, and routine clinical 
procedures for the prospective cohort are described in Chapter 3. The retrospective 
cohort comprised all patients who had been treated for pulmonary tuberculosis at 





4.2.2 Measurement of cough symptoms 
4.2.2.1 Prospective data across respiratory diseases 
At recruitment, if participants reported cough they were asked to rate the severity of 
their cough over the previous two weeks with a 0-100 visual analogue scale (VAS),63 
and to describe the impact of the cough on quality of life over the same time period 
with the Leicester Cough Questionnaire (LCQ; Section 1.6.1, Appendix).226 The possible 
range of total scores for the LCQ is 3-21. If participants reported an absence of cough, 
the VAS score was taken to be zero and the LCQ score to be 21, the maximum possible 
for cough-related quality of life (QOL). 
Both the total LCQ scores and the component scores for each of the physical, social 
and psychological domains were used for analysis. For isolated chronic cough the 
minimum important difference over time for the same patient for the total LCQ score 
has been shown to be 1.3,230 and for the cough VAS is probably 17 mm.225 For the 
acute respiratory conditions and TB, these values were taken to be 2.5 and 13 mm, as 
established for acute cough.231 
Self-reported sputum production was documented by taking the response from 
Question 2 of the Leicester Cough Questionnaire, ‘In the last two weeks have you been 
bothered by sputum (phlegm) production when you cough?’.226,346 Possible responses 
ranged from 1 to 7 on a Likert scale of frequency from ‘every time’ to ‘never’, 
respectively. 
4.2.2.2 The Leicester Cough Questionnaire in tuberculosis 
As no method appears to have been validated to quantify cough symptoms in TB, the 
use of the LCQ in participants with this diagnosis was evaluated. The face validity of 
the LCQ was evaluated by structured interviews with five patients, selected by 
convenience, and a multi-disciplinary team of a general respiratory physician, two 
respiratory physicians with specialist interest in tuberculosis, three TB specialist nurses 
and a TB case worker. Internal reliability of the questionnaire was tested by measuring 





VAS score with LCQ score, and responsiveness by improvements in LCQ score during 
treatment of TB.  
4.2.2.3 Retrospective data on cough in TB 
Because of a particular interest in cough in tuberculosis, and due to the limited 
literature in this area, further data were gathered retrospectively about the local 
prevalence of cough symptoms in this disease. From clinical records, the absence or 
presence and, if present, the duration of a cough at initial presentation were noted 
amongst the retrospective cohort of patients with TB. Gathering this information was 
made easier by the routine use of a standardized clinical data sheet in the local TB 
clinic for all patients which included information about cough.   
4.3 Analysis of data 
Non-parametric data are expressed as medians and inter-quartile range (IQR). Baseline 
patient characteristics were compared between groups with Fisher’s exact tests  and 
odds ratios. Baseline cough scores were compared across diagnostic groups with 
Kruskal-Wallis tests, and Dunn’s tests for multiple pairwise comparisons (or one-way 
ANOVA and Tukey’s tests for parametric data). Univariate analysis were performed on 
VAS scores, component and total LCQ scores across disease groups with Wilcoxon 
rank-sum (Mann-Whitney) tests for binary predictor variables and Spearman rank 
correlation for age. If appropriate, multi-variate analysis was performed of VAS and 
LCQ scores with linear regression models after the appropriate transformation of non-
normally distributed data. The strength of correlation between total LCQ and VAS 
scores was also tested. Inter-relatedness between items of the LCQ in TB was assessed 
with Cronbach’s α. 
For the retrospective data, multivariate analysis was performed of possible predictors 
of the reported presence of cough in pulmonary TB using logistic regression with a 






4.4.1 The subjective impact of cough in respiratory disease 
4.4.1.1 Diagnosis, cough severity and cough-related quality of life 
Summary statistics for patient-reported cough severity (VAS score) and cough-related 
quality of life (total LCQ score) from the prospectively-recruited patient cohort are 
shown in Table 4.1 and Figure 4.1. 
Table 4.1. Patient-reported cough severity and cough-related quality of life according to respiratory 
diagnosis.  
Group n Cough 
severity 
(VAS) 
Cough-related quality of life (LCQ score) 
 Phys ica l  psychological  socia l  Tota l  
Isolated chronic 
cough 
143 70 (50-88)* 3.8 (3.1-4.8) 2.9 (1.9-4.0) 2.3 (3.0-4.5) 9.5 (7.9-12.9)* 
Stable  COPD 18 40 (9-70) 5.3 (3.4-5.6) 4.8 (3.0-6.4) 5.3 (3.4-6.5) 15.4 (9.5-18.3) 
Stable asthma 5 44 (36-87) 3.1 (2.6-4.6) 3.3 (2.9-3.9) 3.5 (3.0-4.3) 9.9 (8.8-12.4) 
Bronchiectasis 9 69 (64-81) 3.3 (2.9-4.3) 3.6 (2.8-4.2) 4.1 (2.5-4.6) 11.1 (8.5-12.5) 
Fibrosis 13 43 (35-74) 4.5 (3.8-6.0) 3.4 (1.7-4.1) 3.0 (2.5-4.5) 10.9 (8.7-14.6) 
Lung cancer 9 56 (40-63) 3.9 (3.4-5.9) 4.0 (3.3-5.6) 4.8 (3.8-6.5) 13.4 (10.9-18.0) 
COPD 
exacerbation 
25 74 (50-100)* 3.8 (3.0-4.2) 3.1 (2.6-3.8) 4.0 (2.6-5.1) 10.8 (8.8-13.2) 
Acute asthma 18 74 (37-89) 3.4 (4.8-5.8) 3.7 (2.6-6.0) 3.0 (2.5-6.0) 10.3 (7.7-17.0) 
Pneumonia 17 72 (50-92) 3.4 (2.4-4.8) 3.7 (2.3-4.3) 3.8 (2.3-4.5) 9.9 (8.1-13.4) 
TB 44 40 (9.5-62.5) 4.5 (4.0-6.5) 4.4 (2.8-6.3) 5.3 (3.0-7.0) 13.6 (8.8-19.2) 
LTBI 17 0 (0-0)* 7.0 (7.0-7.0)* 7.0 (7.0-7.0)* 7.0 (7.0-7.0)* 21 (21-21)* 
Values are median (IQR). 






























































































































































VAS – vi sual analogue scale (top); LCQ – tota l Leicester Cough Questionnaire score (bottom); LTBI – latent TB 
infection. AECOPD – COPD exacerbation. * p<0.05 for di fference between groups (Dunn’s multiple comparisons 
test; cough severity in LTBI s ignificantly lower than in all other groups). Vertical dashed lines separate acute and 
chronic respiratory diseases and LTBI. 






Amongst the disease groups (i.e. excluding LTBI), there was evidence of a difference in 
cough severity (VAS score) only between TB and isolated chronic cough (p < 0.05), and 
between TB and COPD exacerbations (p < 0.05). For cough-related quality of life (LCQ 
score) there was evidence of difference only between TB and isolated chronic cough (p 
< 0.05; Figure 4.1). Cough-related quality of life and cough severity were worse in 
isolated chronic cough than tuberculosis. Cough symptoms were a lot milder in LTBI 
than in all the disease groups (p < 0.05 to < 0.0001); almost all participants with LTBI 
reported an absence of cough, although the participant with the likely upper 
respiratory tract infection (Section 3.5.10) had a cough VAS score of 30 and total LCQ 
score of 17.1.   
Taking the three domains of the LCQ separately (physical, social and psychological), on 
multiple pairwise comparisons with Dunn’s test there was evidence of a difference 
from the other groups only for LTBI, for all domains, and between isolated chronic 
cough and stable COPD, for the psychological domain, where quality of life was worse 
in isolated chronic cough (median scores 2.9 [1.9-4.0] vs. 4.8 [3.0-6.4]; p<0.05). 
Self-rated cough severity (VAS scores) and cough-related quality of life (LCQ scores) 
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VAS – visual analogue scale; LCQ – total Leicester Cough Questionnaire score. 






overall were correlated (ρ = -0.73, 95% confidence interval -0.79 to -0.67, p < 0.0001; 
Figure 4.2). 
4.4.1.2 Non-disease related factors and cough symptoms 
Wilcoxon rank-sum tests revealed no statistically significant associations between 
gender, ethnicity, county of birth, smoking status, current ACE inhibitor or opiate use 
and either VAS or total LCQ scores across all disease groups overall (data not shown). 
Spearman’s rank correlation coefficients (ρ) provided evidence of almost no 
association between age and cough severity (ρ = 0.13; p = 0.039), and no evidence of 
association between age and cough-related quality of life (ρ = -0.038, p = 0.56). Neither 
was there any evidence of an association between these variables and cough 
symptoms when looking at each of the disease groups individually, or together as 
chronic respiratory conditions (stable asthma, stable COPD, bronchiectasis, pulmonary 
fibrosis and lung cancer) or acute conditions (acute asthma, COPD exacerbation and 
pneumonia). This was even true in each of TB and isolated chronic cough, the groups 
of largest sample size displaying particularly wide variation in symptom scores, 
particularly VAS.  Similarly, there was no evidence of association between the 
individual domains of the LCQ score and any of these same variables (analyses not 
shown).  
4.4.1.3 Cough and sputum 
There was no evidence of a difference in the self-reported effects of sputum 
production between diseases on any pairwise comparison (Tukey’s multiple 
comparisons tests, all p > 0.05). The association between sputum symptoms and cough 
symptoms appeared strongest for lung cancer, fibrosis, stable asthma and stable 
COPD, although confidence intervals for Spearman’s rank correlation coefficients were 






 Subjectively-described cough in tuberculosis 
4.4.1.1.1 Reported cough in tuberculosis (retrospective data) 
There were 197 cases of pulmonary tuberculosis treated at HUH between 2010 and 
2013; clear details about cough were available for 176 of them (Table 4.4). 141 (80%) 
reported cough at initial presentation, of median duration at diagnosis 2 (1-5) months, 
which on univariate analysis was positively associated with smoking, sputum smear 
positivity, visible lung cavities, and radiographic extent of disease. Reported cough was 
negatively associated with coincident extrapulmonary disease, and screening as the 
initial source of referral to the TB clinic. On multivariate analysis, absence of coincident 
EPTB, sputum smear positivity, and referral from screening retained a significant 
relationship with the presence of cough. 








Correlation with cough severity (VAS score) 
Spearman’s  rho  p P’ 
TB 44 4.6 (±2.2) -0.43 (-0.71 to -0.04) 0.028 0.276 
Chronic cough 143 3.8 (±2.1) -0.28 (-0.53 to 0.01) 0.055  
Stable COPD 18 4.1 (± 1.8) -0.80 (-0.95 to -0.37) 0.0024 0.024 
 
Stable asthma 5 3.8 (± 1.9) -0.70*  0.233  
Bronchiectasis 9 2.6 (± 1.4) -0.27* 0.477  
Fibrosis 13 4.4 (± 2.1) -0.82 (-0.95 to -0.48) 0.0006 0.006 
Lung cancer 9 3.1 (± 1.6) -0.877* <0.0001 <0.001 
COPD 
exacerbation 
25 3.1 (± 2.2) -0.16 (-0.66 to 0.45) 0.553  
Acute asthma 18 3.9 (± 1.9) -0.19 (-0.72 to 0.48) 0.528  
Pneumonia 17 3.7 (± 2.2) -0.47 (-0.84 to 0.20) 0.132  
 
Va lues are mean (± SD). 










4.4.1.1.2 The Leicester Cough Questionnaire in pulmonary TB 
The multi-disciplinary team and patients thought the LCQ to be relevant, well-written, 
comprehensive and useful in tuberculosis. The five patients were all non-native English 
speakers (having been born in Angola, Brazil, India, Pakistan and Somalia, respectively); 
two were female and two white, of median age 41 (range 27-50); four with a diagnosis 
of smear-positive disease, compared to one had smear-negative, culture positive TB. 
However, it was commented that there were no questions relevant to symptoms of 
Table 4.3. Factors associated with the reported presence of cough in pulmonary tuberculosis on clinical 
presentation (retrospective data set). 
 Total no.* No. (%) 
with cough 
Univariate analysis Multivariate analysis 
 odds  ratio (95% 
CI) 
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pulmonary TB other than cough (e.g. weight loss, haemoptysis), and that there were 
no items on the questionnaire relating to patients ’ concerns of infectiousness when 
coughing. Internal reliability of responses was high (Cronbach’s α = 0.93), and 
concurrent validity was shown by strong correlation between VAS and LCQ scores in 
pulmonary TB (Spearman’s ρ = -0.81 [95% CI -0.91 to -0.62], p < 0.0001).  
4.4.1.1.3 Predictors of cough symptom severity in tuberculosis (prospective data) 
As in the other disease groups, there was wide variation in the cough symptom scores 
in pulmonary TB. On Mann-Whitney tests for associations between binary variables 
and cough symptoms, there was statistical evidence for an association of an absence 
of coincident extrapulmonary TB (EPTB) with LCQ score, and strong trends (with p ≤ 
0.10) of associations of sputum smear positivity, culture positivity, and absence of 
EPTB with VAS score, and of an absence of current smoking and culture negativity with 
LCQ score (Table 4.4). There were too few patients with HIV infection (n = 2) or who 
had been referred from screening (n = 2) to test for any effect of these variables on 
symptoms. On multivariate analysis, in a model including EPTB and sputum smear 
status there were independent trends for each variable of an association with VAS 
scores (p ≤ 0.20), whereas for LCQ scores, there were trends for independent 






   
  




































































































































































































Va lues are median (IQR). 
Univariate p values relate to Mann-Whitney tests, apart from *, Kruskal-Wallis test. Multivariate p va lues relate 
to l inear regression analysis. 









This chapter set out to document cough symptoms in acute and chronic respiratory 
conditions. Wide variability in subjectively-measured cough in patients with respiratory 
disease was demonstrated which was significantly worse than in controls with latent 
TB infection. Cough symptoms in pulmonary TB were milder than in isolated chronic 
cough, but very few other differences were observed between diseases. There were no 
non-disease factors associated with cough symptoms across the group as a whole. In 
tuberculosis there were trends for the reported presence of cough with sputum smear 
and culture results, and for subjectively-described impact of cough with positive 
sputum microbiology and (an absence of) coincident extrapulmonary TB.  
4.5.1 Cough symptoms and diagnosis 
Cough symptoms in all disease groups were highly variable. This was particularly 
evident for stable COPD and TB, where the impact of cough in the majority of patients 
ranged from negligible to severe. A statistically significant difference was shown in 
both subjective measures of cough (visual analogue scale and Leicester Cough 
Questionnaire) only between isolated chronic cough and pulmonary TB.  
The presence of an observed significant difference only between isolated chronic 
cough and TB could be due to greater statistical power than associated with other 
groups: these were the two largest disease groups (n = 143 and 44, respectively). 
Estimating appropriate sample sizes for investigating an association between diagnosis 
and cough symptoms a priori was difficult due to the lack of explicit data in the 
literature about the mean and variance of LCQ and cough VAS scores, particularly in 
conditions other than isolated chronic cough. It is now possible to retrospectively 
calculate the power of this part of study. For example in COPD (where both VAS and 
LCQ values approximated a normal distribution), the mean ± SD VAS and LCQ scores 
were 42 ± 33 mm and 14.2 ± 4.9, respectively. The relatively larger minimum 
important difference (MID) for VAS compared to LCQ scores (which has at least been 





sizes were more likely to show clinically meaningful differences between groups using 
VAS than LCQ scores. 224 patients would have been needed in each group to test for a 
difference in LCQ score of magnitude ≥1 x the MID compared to that observed in COPD 
with a power of 0.80; the equivalent sample size using VAS measurements would be 53 
(assuming α = 0.05).309 However, 14 patients would be needed in each group to test 
for a difference in LCQ score of ≥4 x the MID (total score 14.2 vs. 9.0), or 9 patients for 
≥5 x the MID (14.2 vs. 7.7). Conversely, two groups of 14 patients would be adequate 
with α = 0.05 and 80% power to test for a difference in VAS score of ≥2 x the MID from 
that measured in COPD (41 vs. 7 mm).309  
This study was therefore adequately powered in the large part to test for clinically 
meaningful differences in VAS scores between disease groups. Apart from stable 
asthma (n = 5), bronchiectasis (n = 9) and lung cancer (n = 9), where sample sizes were 
particularly small, the lack of large observed differences in VAS scores (≥2 x the MID) 
between disease groups are likely to be representative of what might be found in a 
larger study. However, a larger study would be required to exclude the possibility of a  
clinically significant difference in LCQ scores between disease groups.   
These comparative observations between diseases are not dissimilar to those reported 
from the only other study of which I am aware to have compared cough symptoms 
between diagnostic groups. Polley et al. observed no differences in LCQ score between 
the included diseases, stable asthma (n = 20), bronchiectasis (n = 26), COPD (n = 18) 
and isolated chronic cough (n = 79).83 However, that study was also likely to have been 
under-powered as the observed mean ± SD LCQ scores were very similar to those 
measured in the current work (e.g. 13.2 ± 4.4 in COPD in the previous study compared 
to 14.2 ± 4.9 in this Chapter). 
Amongst the individuals with chronic respiratory diseases it is not unexpected that 
cough symptom scores were numerically most severe in isolated chronic cough, given 
that this group was defined solely by the subjective presence of cough.2 In contrast, 





reported coughing. However, the particularly strong psychological impact in isolated 
chronic cough (at least in comparison to COPD) suggests that in this group there might 
have been a greater subjective awareness of coughing. This hypothesis will be tested in 
Chapter 6 by comparing the subjective impact of cough to objective measurements 
across disease groups (Section 7.4.3). 
As expected, almost all participants with LTBI reported no cough symptoms; they were 
free of respiratory disease and in the majority were non-smokers. Indeed, LTBI was 
selected as a diagnostic group to act as a negative comparator to those with disease. 
However, the one participant in this group with an upper respiratory tract viral 
infection served as a reminder that coughs in any individual are not always necessarily 
caused by the main diagnosis of interest.  
4.5.2 Cough and sputum 
No difference was observed in self-reported sputum production between diseases, and 
an apparently stronger association between sputum production and cough symptoms 
in pulmonary fibrosis and lung cancer than in COPD exacerbations and isolated chronic 
cough. Bronchiectasis is strongly characterized by cough productive of sputum, and the 
cough of pulmonary fibrosis is classically described as dry.319 Although there is a 
precedent for the method used in the current study for measuring sputum production 
(Question 2 of the Leicester Cough Questionnaire),346 its use has not been validated, 
and it is not clear how responses to the question correlate with objectively-measured 
sputum production. The method of estimating sputum production could therefore be a 
reason for a failure to differentiate between diseases on the subjective sputum score. 
Another shortcoming with the use of Question 2 is that it cannot be easily compared 
with total LCQ score as the two variables are non-independent; the questionnaire has 
a high level of inter-relatedness between component items.226 Sputum scores were 
therefore compared only against VAS scores, not the LCQ score. 
In COPD, the use of an alternative method of estimating sputum production seems to 





“Over the past 4 weeks I have brought up phlegm (sputum): not at all, only with 
respiratory infections, a few days a month, several days a week or most days a week?,” 
from the St George’s Respiratory Questionnaire228 to be a predictor of 24-hour cough 
frequency.78 Despite this, responses to this question similarly do not appear to have 
been compared to objective measures of sputum production in respiratory disease. In 
contrast,  the UK Medical Research Council (MRC) validated another a set of questions 
used in epidemiological studies of chronic bronchitis in relation to objectively-
measured morning sputum volumes and the proportion of mornings on which sputum 
is produced.347 The MRC questions related to the number of months during the year in 
which ‘phlegm’ is usually brought up, and whether, if this occurs, just in the early 
morning, or during the whole day.  
Cough and sputum are clearly closely associated, particularly in COPD,348 
bronchiectasis and TB, yet respiratory mucus has been researched relatively 
infrequently (Section 1.4.2).105 It would be of interest to measure how self-reported 
sputum symptoms relate to objective measures of sputum in other conditions, and 
how objectively-measured sputum production is related to both cough symptoms and 
objectively-measured cough frequency across diseases. 
4.5.3 Subjectively-reported cough in tuberculosis 
There was no consistent evidence that coughing affected patients more or less in TB 
than in any other group, other than isolated chronic cough or latent TB infection. Given 
the wide variability in cough scores (Figure 4.1) it is unlikely that a larger study would 
show evidence for clinically significant differences between disease groups , at least for 
VAS scores (for which this study was more strongly powered compared to LCQ 
outcomes). 
Although in TB there was a trend towards a worse cough-related quality of life 
amongst smokers than non-smokers, no general non-disease related factors were 
quantitatively associated with cough symptoms overall. This may again be due to 





14.2, standard deviation 5.2), with two samples of 22 patients (total n = 44) this study 
had a power of 0.13 to detect a difference in LCQ score associated with a particular 
binary variable between groups of ≥1 x the MID (as determined in chronic cough) with 
α = 0.05, although a power of approximately 0.8  to detect a difference of ≥3 x the 
MID.309  
For specific disease-related factors in pulmonary tuberculosis, the only significant 
association with the severity cough symptoms was an absence of coincident extra-
pulmonary tuberculosis, at least on univariate analysis, for LCQ score. From the 
retrospective data, the reported presence of cough was independently associated with 
sputum smear positivity whereas an absence of cough was associated with screening 
as the source of patient referral and co-existent extra-pulmonary disease.  
The relevance of EPTB and screening is presumably that the associated pulmonary 
disease in both cases was clinically mild, patients having presented either with 
symptoms related to other anatomical sites of disease  (e.g. neck swellings in TB 
lymphadenitis, dyspnoea and systemic symptoms in pleural disease), or with only very 
few or no symptoms but an abnormal chest x-ray, respectively. The relative lack of a 
noticeable cough in screened patients may have been precisely why active medical 
care was not sought. Conversely, the associations of sputum smear and culture 
positivity with cough suggest that bacterial numbers are important in either the 
frequency or awareness of cough, or both. Other retrospective studies have also noted 
associations between sputum culture positivity, smear status and x-ray characteristics 
and the presence of cough, but it is not clear whether these associations were 
independent of each other.305,349  
Only one other study of which I am aware has studied cough symptoms in tuberculosis 
quantitatively, with the LCQ and a VAS (although scaled from 1-10 rather than 1-
100).234 Amongst 124 smear positive patients in Brazil, cough symptoms were possibly 
associated with M. tuberculosis genotype: there was a non-statistically significant 





may have related to less extensive disease as assessed by chest radiograph. Although 
the authors of the study suggest a pattern of more severe cough in those with cavitary 
disease, they do not state whether this association was statistically significant. There 
was also a trend for worse cough symptoms in patients with lung cavities (albeit in a 
group with smear negative as well as smear positive disease) which was not 
statistically significant (p = 0.14 for VAS, p = 0.27 for LCQ).234 
4.5.4 The measurement of cough symptoms in respiratory disease 
The current study has shown that the use of the Leicester Cough Questionnaire and a 
cough severity visual analogue scale is feasible in a range of respiratory diseases. Both 
of them, particularly the VAS, are straightforward to use.  
The Leicester Cough Questionnaire, as previously discussed,  is probably the most 
widely-use and best-validated method of quantifying cough-related quality of life 
(Section 1.6.1).225,227 Despite this, the large majority of the related published literature 
refers to isolated chronic cough rather than other diseases. The LCQ does not seem to 
have previously been used in lung cancer,350 pneumonia, acute asthma or COPD 
exacerbations, and has only been used very rarely in pulmonary fibrosis 77 and 
tuberculosis.234 The fact that good correlation with the VAS was demonstrated, 
particularly in TB, suggests concurrent validity of the LCQ in these other conditions.  
Concurrent validity of the LCQ in TB was also demonstrated by the strong trend for 
worse QOL scores in patients with higher bacterial loads, seen in those with culture 
positive, compared to culture negative disease. Face validity was shown by MDT 
discussion and interviews with patient. The comments from some individuals that the 
questionnaire did not give opportunity to comment on other symptoms reflect the fact 
that the LCQ is a cough questionnaire, applicable to a range of diseases and allowing 
comparison of cough symptoms across different types of patient. The absence of 
questions about perceived infectiousness of coughs also reflect the fact that the LCQ is 
not a TB-specific tool. There is a need to develop a general quality of life tool specific 





study therefore provides justification for use of the LCQ in TB that was lacking in the 
only other study to have used the Questionnaire in the disease.234 
The cough VAS and LCQ are complementary tools measuring crude subjective severity 
of cough, and a more detailed assessment of impact of cough on quality of life, 
respectively. The simplicity of the VAS is clearly an advantage but the LCQ has been 
more fully validated in cough against other clinical outcomes.225    
The subjective measurement of cough has clear limitations. As in the documentation 
of any symptom, there are varied associations with underlying pathological 
phenomena. From the earliest studies it has been clear that there is poor correlation 
between objective cough counts and patients ’ awareness of coughing (Section 
1.6.1).88,240 Patients’ awareness and interpretation of cough will depend on a variety of 
factors including personality, anxiety, experience, culture, education, social factors, 
and associated symptoms, both those resulting from coughing itself (pain, 
breathlessness, sputum production), and others caused by the underlying disease 
(including wheeze, fever, weight loss and malaise). Because it is almost impossible to 
separate objectively measurable phenomena from subjective experience when 
documenting symptoms on their own, I have made only limited conjecture on the 
reasons for an absence of differences in symptom scores between diseases (Section 
4.4.1.1), or the lack of an association across diseases between cough severity and 
quality of life with demographic and other non-disease related factors (Section 
4.4.1.2). 
Rather the documenting only the subjective experience of cough, the objective 
measurement of cough should therefore be much more instructive for determining 
mechanisms, causative factors, associated phenomena and response to treatment. 
This is the subject of the following Chapters.  
4.6 Conclusion 
Coughing is common in many respiratory disorders and subjectively-measured cough is 





isolated chronic cough, but no overall clear differences between other diseases were 
demonstrated, and few general factors appeared to be associated with cough 
symptoms. However, an initial validation of the Leicester Cough Questionnaire in 
tuberculosis was provided, and cough symptoms in pulmonary TB were shown to be 
associated with sputum smear status and an absence of extrapulmonary disease. A 
detailed examination of cough in respiratory disease requires objective measurement, 














5 The objective measurement of cough 
frequency  
5.1 Introduction 
While fully-automated cough monitors remain in development, counting coughs by ear 
remains the reference standard against which automated systems should be compared 
(Section 1.6.2.2.2).252 However, defining coughs essentially depends on the subjective 
experience of the listener.2 It is generally assumed the human ear can distinguish 
coughs from other sounds,352 but this seems only to have been tested within pairs of 
individuals involved in the research of cough.77,253,258 A broader consistency among 
larger numbers of people naïve to counting coughs has not been reported in the 
literature. 
Recent research of cough frequency has often used computer software to visualize 
changes in amplitude in sound recordings to help identify and count coughs.79,259,353,354 
This is despite the recommendation that cough be defined by its sound,2 and the effect 
of such visual assistance does not appear to have been evaluated.  
Automated cough monitors would greatly facilitate the measurement of cough 
frequency. Of the recent attempts at developing cough monitors, PulmoTrack® (iSonea 
(formerly KarmelSonix), Haifa, Israel) is one of the least tested devices  (Section 
1.6.2.2.3.2),262 yet at the time of this research it was marketed as a fully-automated 
ambulatory device for measuring respiratory sounds including cough.261 It was the only 
automated cough monitor available to me for evaluation. 
The following hypotheses were tested: 
1. untrained observers agree when counting coughs; 
2. visually representing audio data does not affect cough counting; 








A convenience sample of 13 patients from all those recruited to the wider study was 
selected (Chapter 3). All reported excessive coughing and had a range of diagnoses. 
5.2.2 Automated cough monitor 
Cough monitoring with PulmoTrack® took place in hospital over 16-24h. Clinic patients 
were admitted specifically for this purpose. The PulmoTrack® software (Version 6.5.0) 
used an algorithm to calculate cough counts expressed as ‘cough events’ and 
‘component coughs’ per min. These terms were not clearly defined in the product 
literature but it was presumed that they equated to bouts of coughing and individual 
cough sounds, respectively. The system allowed playback for non-automated cough 
counting. To test repeatability the recordings were analyzed with the software twice. 
5.2.3 Listeners 
The author counted cough sounds in a 4-hour section from each of the recordings 
where PulmoTrack® indicated the presence of the greatest number of coughs. Three 
sequences were then selected lasting 14-22 minutes based on the presence of a high 
density of coughs and differing underlying pathologies. These short sequences were 
played to 15 respiratory physicians who were asked to count all cough sounds.  
Listeners were asked about any known hearing problems and, in order to estimate 
their experience of listening to closely spaced sounds, the frequency with which they 
played a musical instrument, and their confidence in detecting fixed splitting of the 
second heart sound (minimum duration 0.02s355) when auscultating the praecordium 
during routine clinical examination. No specific training or instructions of how to count 
coughs were given other than asking listeners to count cough sounds, whether 






Listeners could pause and repeat playback of the sequences as desired. They were 
unaware of the cough counts of other auditors and of the interpretation of the 
machine.  
The doctors listened to the sequences on three occasions at intervals of 4 weeks. 
Visual data were not shown on the first two occasion, but on the final occasion a 
simultaneous visual representation of sound amplitude was provided using Audacity® 
open source audio editing software (version 2.0.2; see Figure 5.1).356 The method is 
summarized in  
 





Figure 5.1. Audacity® audio editing software representing four cough sounds from patient with unexplained 
chronic cough.  
5.2.4 Data analysis 
Intra-class correlation coefficients were used to describe agreement between 
observers and to evaluate PulmoTrack®. Mixed effects regression models and a 
Ini tial explosive phases (a) and final, voiced, phases (b) of each cough sound indicated where 
present (Section 1.6.2.4). [Reproduced with permission. Audacity® software i s copyright (c) 1999-





likelihood ratio test were used to explore the variation associated with each non-
automated counting method (using sound alone or sound with visual data). The two 
methods were also compared with a Bland-Altman plot.  
The intended study size was 15 observers. From initial data this number would give 
80% power at a significance level of 0.05 to detect a difference in total cough counts of 
7% when comparing listening alone to listening with the addition of visual data, or 50% 





Figure 5.2. Investigation of methods for determining cough frequency: study overview.  
 
  







Thirteen patients were included with sarcoidosis (n = 1), acute asthma (n = 2) COPD 
exacerbation (n = 2), stable COPD (n = 2), tuberculosis (n = 2), idiopathic pulmonary 
fibrosis (IPF; n = 1), community acquired pneumonia (n = 1) and unexplained chronic 
cough (n = 2), who all reported coughing excessively.  
5.3.2 Cough monitoring 
The setup of PulmoTrack WHolterTM took an average of nine minutes. Recordings were 
inadequate on four occasions owing to battery failure, on one occasion, and 
disconnection of recording sensors on three separate attempts. One patient with 
chronic cough agreed to undergo a second attempt at monitoring. The median 
duration of the 10 successful recordings was 19.6 h (range 9.3 to 24.5 h).  
 
Figure 5.3.  Intra- and inter-observer variation in cough counting with auditory information alone. 
Sequences from 3 patients were played to 15 doctors, to 7 of them on two occasions. O = counts by author. Error 





5.3.3 Intra- and inter-listener consistency 
Cough counts of the three sequences using only auditory information are shown in 
Figure 5.3. The selected sequences were from patients with COPD, sarcoidosis and 
asthma and lasted exactly 19, 14 and 22 minutes respectively. On the first attempt 
mean (± SD) cough counts were 78.7 (± 8.1), 44.6 (± 7.5) and 77.3 (± 4.7) respectively 
(total count for all sequences: 200.7 ± 14.6).  
Seven of the 15 doctors listened to the sequences on a second occasion without visual 
data. Intra-class correlation coefficients (ICCs) between individuals were 0.89 (95% 
confidence interval [CI], 0.65 to 1.00) on the first attempt and 0.86 (0.53 to 1.00) on 
the second. Within-individual ICCs were in the range of 0.96 to 0.99 between 1st and 
2nd attempts with a mean of 0.7% more coughs counted on the second attempt (95% 
CI, -4.7 to 6.1). 
Sequences were also analyzed as one minute segments. Those segments in which 
coughs were counted by any observer were compared as two equal-sized groups: 
segments with lower variation in counts against those with higher variation (SD of 
mean <1.15 or >1.15). The only factor strongly associated with higher variation was a 
higher count of cough sounds (mean 7.3/minute in high variation periods, 3.2/min in 
low variation periods, p = 0.03). Eight and 5 segments contained speech in the higher 
and lower variation groups respectively (p = 0.12). Sounds which were considered by 
the author to represent throat clearing did not affect count variation although they 
were only present in 8 segments. There were even fewer background noises to test 
their influence on cough counting. 
All doctors stated having normal hearing. Gender, doctor seniority, musical ability and 
ability to detect fixed splitting of the second heart sound did not affect the total 










Mean (±SD) total cough 
count 
p 
Gender Male 10 201.1 (± 14.1) 0.75 
Female 5 199.8 (± 17.1) 
Doctor seniority Cons  / SpR 10 202.3 (± 17.0) 0.56 
F1 / SHO 5 197.4 (± 8.76) 
Plays musical instrument > monthly 4 205.5 (± 18.4) 0.46 
Rarely / never 11 198.9 (± 13.5) 
Ability to hear fixed splitting of 2nd heart sound Yes  6 207.2 (± 15.6) 0.17 




Figure 5.4.  Comparison of auditory with visual and auditory cough counting. 
P-values from paired sample t-tests. Cons: consultant in respiratory medicine; SpR: specialist 
registrar in respiratory medicine; F1: Foundation Year one doctor (first year post-medical  school 




Sequences from three patients played to 15 doctors on two or three occasions. Mean cough counts from 
attempts using only auditory information compared to counts when visualizing a  display of sound amplitude 






5.3.4 Audio vs. audio-visual counting  
Thirteen of the 15 original listeners re-analyzed the sequences with simultaneous 
visual data. Mean counts of coughs sounds were lower than the corresponding 
average values from the two attempts without visual information, significantly so for 
the sarcoidosis and asthma sequences (Figure 5.4) ; mean [± SD] total cough count 
190.2 [± 3.4]). A mean of 3.1 (4.8%) [95% CI: 0.3 to 9.2, (0.6 to 9.5%)] fewer coughs 
were counted in each sequence with the visual display than when listening without it 
(p = 0.04). For all but two of the counts the differences between methods were within 
two standard deviations of the mean (Figure 5.5). The agreement between the 13 
doctors counting by ear and eye together was excellent (ICC=0.94, 95% CI 0.80-1.00). 
The apparent decrease in inter-observer variation between methods, as assessed by 
the regression analysis and likelihood ratio test, was not statistically significant (p = 
0.80). 
 
Mean count from listening alone minus count with additional visual data plotted against the average cough 
count from between methods for each listener for each sequence. Dotted lines: mean difference (3.1) ± 2SD 
(-15.3 to 21.5). 







The majority of participants stated that cough counting was quicker with the addition 
of the visual display.  
 
Figure 5.6.  Comparison of PulmoTrack® and non-automated cough counting. 
 
5.3.5 Automated cough counting  
PulmoTrack® took approximately 7 h to process a 24 h recording. Automatically 
detected numbers and timings of coughs were identical the second time all sequences 
were analyzed. A comparison of the number of sounds counted as coughs by the 
machine and the human observer in the 4-hour recording segments is shown in  
Figure 5.6. Almost 2,000 coughs were counted by the author. Even ignoring agreement 
over individual sounds, overall crude counts of cough sounds between auditory and 
 
Number of sounds counted as coughs by PulmoTrack® and a  human observer in 4-hour sequences from 10 
patients. Data presented in descending order of numbers of coughs counted by the investigator.  AECOPD – 
acute exacerbation of COPD; NTM – non-tuberculous pulmonary mycobacterial infection; UCC – unexplained 
chronic cough; COPD – chronic obstructive pulmonary disease; CAP – community-acquired pneumonia; IPF – 



















CAP UCC IPF Sarcoidosis TB
Sounds counted as coughs only by
PulmoTrack®
Sounds counted as coughs by both
methods






automated methods substantially differed (ICC = -0.23, 95% CI, -0.51 to 0.34, p = 0.87). 
On non-automated counting, mean cough rates in these sequences ranged from 19 to 
119 cough sounds/h. A median of 100 (range -29 to 465) fewer cough sounds were 
counted by PulmoTrack® than by the non-automated method in each 4-hour 
sequence.  
A total of 39% of the cough sounds across sequences counted by PulmoTrack® were 
identified as such only by the machine (Figure 5.6). The author recognized these most 
commonly as speech, swallowing, microphone interference, breath sounds and 
background noise (Table 5.2). 









automated cough counting as the reference standard, the overall positive predictive 
value (95% CI) of PulmoTrack® was 60.6 (57.5 to 63.6) % and sensitivity 32.1 (30.1 to 
34.3) %.  
5.4 Discussion 
The findings of the current chapter have demonstrated that untrained listeners are 
consistent in counting cough sounds, that simultaneously visualizing audio sequences 
Sound n 
 
% of total number of sounds 
classified as coughs 
speech 149 14.4 
swallow 71 6.9 
microphone interference 58 5.6 
background noise 28 2.7 
breathing 27 2.6 
throat clearing 25 2.4 
no sound 24 2.3 
sneezing 7 0.7 
belching 7 0.7 
Eating 4 0.4 
Other 7 0.7 





led to lower counts, and that the Pulmotrack® automated cough monitor disagreed 
with human cough counting.   
5.4.1 Consistency within and between listeners 
To my knowledge this is the first work to test consistency in cough counting among >2 
individuals. The overall relative standard deviation here of 7.3% (14.6/200.7) when 
listening alone and 6.4% (12.1/190.2) with both visual and auditory representation is 
of the same order of magnitude as studies comparing two listeners. Key et al. noted a 
9.5% difference in cough counts between two individuals experienced in cough 
counting when coughs from 30 min sequences in 19 patients with IPF occurred at 
9.4/h.77 The same group also reported a difference between two people of about 2.6% 
when analyzing 24-hour recordings from 10 patients with chronic cough due to a 
variety of conditions.258 The intra-class correlation coefficient for 11 listeners of 0.94 
concurs well with the 0.98 reported for studies comparing just two listeners.253  
Intra-observer consistency was high (ICC 0.96-0.99). Birring et al. reported an ICC of 
0.99 when one cough researcher counted cough sounds in 2-hour recordings from 9 
patients twice but the time interval between counting attempts was not stated.253  
There appeared to be no listener factors which affected cough counting. Disagreement 
was associated with higher cough frequencies and possibly the presence of speech but 
not the rarer presence of throat clearing or background noise. Further comment on 
causes of inter-observer variation is limited as it was so low. However, ‘unusual’ cough 
sounds are probably a cause of disagreement. For example, I have demonstrated 
elsewhere that there is less consistency between listeners counting coughs during 
bronchoscopy procedures than in the current study; the median (IQR) difference in 
total cough counts by three respiratory physicians from 24 procedure recordings was 
15.6 (6.1-31.0) %.357 The sound produced by coughs during bronchoscopy is 
presumably altered because the endoscope prevents apposition of the vocal cords, but 





The fact that untrained listeners demonstrated good agreement in the current study, 
and that there was no evidence for an effect of doctor seniority, suggests that 
experience and specific training in counting coughs might not be required. Not 
including listeners with experience of cough counting here allowed easier testing of 
the previously untested assumption that the ‘characteristic sound’2,352 of cough is 
universally distinguishable from other noises. 
5.4.2 The effect of visual data on cough counting 
Audio editing software simplified cough counting by eliminating the need to listen to 
periods of silence which are evident from visual inspection. Fewer coughs were 
counted with a visual display of sound amplitude simultaneous to audio playback. The 
appearance of the sound amplitude trace presumably led to dismissal of certain 
sounds which would have been counted by listening alone. This is suggested most 
clearly by the difference in cough counts between methods in the sequence from the 
patient with sarcoidosis (Figure 5.4). The finding that recognition of coughs depends 
partly on the appearance of the amplitude waveform has implications for the 
definition of a cough, about which there has been  debate.3,4 
It is not clear why there was only a significant difference in cough counts between 
methods of non-automated counting for two of the sequences (from the patients with 
asthma and sarcoidosis); there may be certain types of cough that are more 
consistently recognized by listening alone. The cause of the two outlying results in the 
comparison between methods (Figure 5.5) is uncertain. Distraction leading to missing 
coughs, double-counting or errors in transcribing results to the data sheet are 
possibilities. There was no other evidence that attention span or fatigue were 
significant problems, but these factors may become important with longer recordings.   
Although the addition of visual data to audio sequences appeared to improve inter-
observer agreement in cough counts this was not statistically significant. A type 2 error 
is possible as this part of the study was not powered to detect relatively small 





5.4.3 Pulmotrack® cough monitor 
PulmoTrack® provided useful ambulatory recording and playback of patient data and 
showed perfect consistency on repeated analysis of the same sequences. However, 
there were technical problems and agreement between PulmoTrack® and non-
automated cough counting was unsatisfactory.  
As Figure 5.6 shows, agreement between the machine and the human cough counter 
was poor across all recordings, but the extent of this disagreement was variable. In 
some recordings almost all the coughs counted by the investigator were missed by 
PulmoTrack (e.g. from the patient with AECOPD and IPF), whereas in others (asthma, 
sarcoidosis) a substantial number of ‘coughs’ classified the machine were thought to 
be other sounds by the listener. In a sample of patients of this size, and without 
knowing the nature of the algorithm used by PulmoTrack to detect coughs, it is only 
possible to speculate on reasons for this lack of consistency. The fact that the 
‘sensitivity’ of the machine for detecting coughs recognized by ear was substantially 
different in the two patients with unexplained chronic cough suggests that the nature 
of pathology might not be important for the functioning of the cough detection 
algorithm. There are a number of other factors which could have been important for 
cough detection, such as vocal characteristics, background noise, movement artefact 
causing interference with contact microphones, and features of the digital sound 
encoding technology and the microphones themselves. 
One study to evaluate PulmoTrack® showed high agreement with non-automated 
cough counting, but recruited 12 healthy volunteers who were asked to make 
voluntary coughs and other noises during 25-minute recordings.262 The evaluation 
undertaken in the current work was more representative of the circumstances in 
which such a system might be normally employed.  
The development of a completely automated system for counting coughs has been 
slow.86  The brain appears to identify a cough from both a complex distribution and 





advantage to the recognition of coughs. The best tested automated or semi-
automated cough monitors require human input either to help calibrate the 
system253,265 or to actively count coughs in sequences that have been condensed to 
remove silences and non-cough sounds.263,264 High cough rates, speech, background 
noise and the ability to perform across a range of types of patient and cough are 
particular challenges for automated cough monitors.  
5.4.4 Limitations 
The data are limited by the inclusion of only three short sequences for testing 
consistency between observers in cough counting. The roles of auditory fatigue or 
inattention in longer recordings were therefore not examined. However, the 
sequences were selected for their very high number of coughs, aiming to amplify any 
differences between counting methods or observers that might only have become 
evident by using longer sequences with lower cough frequencies. Short sequences 
were used deliberately to make involvement in the study more acceptable to the 
volunteering listeners.  
I cannot comment on the recognition of coughs by non-clinicians, although the 
absence of an effect of doctor seniority suggests that clinical experience is not 
important for distinguishing coughs from other respiratory sounds and counting them. 
Neither were there enough data to describe the effects of types of cough as possibly 
influenced by pathology, gender, age and anatomy, or the effects of background 
recording conditions. Nevertheless, consistency in cough counting was examined 
between and within observers more thoroughly than any other study of which I are 
aware. 
All of the recordings were made in a hospital inpatient setting due to limited access to 
the cough monitoring equipment. A more rigorous assessment of PulmoTrack® would 
also include recordings in the ambulatory setting to test the effect of background noise 
and the acceptability of wearing the device during routine activities. Cough were only 





agreement between the non-automated counts and those of the machine strongly 
suggests that a more extensive assessment is unlikely to have altered the conclusions. 
No other work of which I am aware has contradicted this. 
The Leicester Cough Monitor (LCM)80,253 and Vitalojak263,264 are the two automated 
cough monitors about which there is the most published research (Section 1.6.2.2.3). 
Neither were commercially available at the time of writing. I was not able to obtain 
access to Vitalojak but did have access to the LCM through collaboration with its 
developers, and was the device used to collect data for much of the rest of this thesis.  
5.5 Conclusion 
Cough counting is consistent among and within doctors without specific training. 
Audio-editing software simplifies the process and leads to lower counts, which may be 
more accurate than counting by ear alone. The fully automated PulmoTrack® cough 
monitor agreed poorly with non-automated counting. The optimum method for 
objectively quantifying cough is yet to be defined but any technique should be clearly 







6 Measurement of cough reflex 
sensitivity 
6.1 Introduction 
Inhalation cough challenges have been used for some time in research.358,359 Their role 
has been to attempt to quantify the sensitivity of the cough reflex, particularly when 
evaluating the efficacy of treatments  for cough (Section 1.6.2.1).244 Capsaicin is the 
most widely used agent,241 and the currently recommended protocol produces results 
which are repeatable within individuals in the stable state and responsive to 
treaments.5 However, as it has been used, the capsaicin inhalational challenge is poor 
at distinguishing healthy subjects from those with respiratory disease, and 
measurements  do not correlate well with daily cough frequency (Section 1.6.2.1).5,70   
The most widely used endpoints to the capsaicin challenge test have been C2 and C5, 
the concentrations of capsaicin required to produce two or five coughs, respectively.241 
These cut-offs have been defined arbitrarily and largely recommended by opinion 
only.5 It is not clear which of them should be preferred.241 The recommended duration 
of time following the inhalation of capsaicin during which coughs should be counted to 
quantify the evoked response also seems to have been set arbitrarily, at 15 s.5,241 The 
aim is to presumably count only coughs resulting from the capsaicin itself rather than 
coughs which would have occurred anyway due to underlying pathology, and other 
durations such as 10 s or 30 s have previously been chosen.244,360 Another debate has 
been whether C2 or C5 should be taken as the actual lowest administered 
concentrations producing ≥2 and ≥5 coughs, respectively, or whether values should be 
interpolated from administered concentrations with log concentration-response 
data.5,361  
An alternative approach to the capsaicin challenge recently proposed by Hilton et al. 
has produced results which separated patients from healthy volunteers, and were 





measuring C2 or C5, ‘Emax’ should be documented, the maximum number of coughs 
produced in response to any concentration of capsaicin.85,246 However, this newer 
protocol appears to be more time-consuming than that previously proposed, involving 
the administration of up to 12 concentrations of capsaicin 4 times for each patient. 
Participant tolerance also seems to be a limiting factor, potentially preventing 
inhalation of the dose that would evoke the highest number of coughs.85  
The highest concentration tolerated by the majority of patients in Hilton et al.’s study 
was 62.5 µM (16 of 20 with chronic cough, as opposed to only 8 who chose to proceed 
beyond this dose).85 Measuring the number of coughs produced by the same relatively 
high dose of capsaicin without first going through a dose escalation protocol might be 
quicker, easier, and more tolerable to study participants, and produce data that are as 
valuable or nearly as valuable as measuring Emax. 
I set out to evaluate alternative endpoints to the capsaicin inhalational challenge test 
with the following hypotheses: 
1. ‘E62.5’, the number of coughs evoked by the inhalation of a 62.5 µM dose of 
capsaicin solution, is a new useful endpoint; 
2. C5 is better correlated with 24-hour cough frequency in chronic cough than C2; 
3. interpolated log-transformed data are not superior to using actual administered 
concentrations for the values of C2 and C5; 
4. counting coughs within 15 s of administering capsaicin is more predictive of 24-
hour cough frequency than counts performed over 30 s.  
6.2 Methods 
6.2.1 Setting and participants 
The study was carried out at Kings College Hospital, South London. Sequential patients 
were recruited from a tertiary referral cough clinic, having been referred from both 
general practice and secondary care. All participants reported cough as the main or 





unexplained, unknown at the time of the study due to ongoing clinic work-up, or 
presumed secondary to an underlying cause. Chronic cough was only classed as 
unexplained following the exclusion of diagnoses known to cause cough (normal chest 
x-ray and ear nose and throat assessment, including nasendoscopy, a negative 
response to bronchodilator reversibility testing, and failed therapeutic trials of inhaled 
or oral corticosteroids and high dose proton-pump inhibitor therapy for ≥2 months 
[Section 3.2.1]).2 
Demographic and routine clinical data were documented, including spirometry values 
taken within the preceding six months. Age <16 y, inability to provide written consent, 
current smoking (within the previous two months), a pre-existing respiratory diagnosis, 
recent coryzal symptoms (within the last one month), haemoptysis, recent use of 
angiotensin-converting enzyme (ACE) inhibitor medication (within the previous two 
months), and current use of opiate medication were patient exclusion criteria. 
6.2.2 Capsaicin cough challenge 
Capsaicin inhalation cough challenge was carried out as described in international 
guidelines.5 
6.2.2.1 Preparation and dilution of capsaicin solution 
30.5 mg capsaicin powder (Sigma-Aldrich, Gillingham, UK) was dissolved in 1 ml 100% 
alcohol and 1 ml polyoxethylene sorbitan (Tween 80, Sigma-Aldrich, Gillingham, UK), 
and then mixed with 8 mL 0.9% saline solution to produce 10 ml of 0.01 M stock 
solution. This was kept in a refrigerator at 4 °C for up to one month before being used 
or discarded. On the day of performing cough challenges, the stock solution was 
serially diluted with saline to produce solutions of doubling concentrations 0.49-1000 
µM. 
6.2.2.2 Administration of capsaicin solution 
Capsaicin solutions were administered with a single breath method using a Koko 





flow regulator valve, limiting flow to 0.5 L/s regardless of inspiratory force.5,362 Patients 
were asked to “allow yourself to cough if you need to, and as much as you need to”. 
The concentration of capsaicin was increased until inhalation of solution produced five 
or more coughs or until the maximum concentration solution (1000 µM) had been 
administered. Each concentration of solution was administered only once. 0.9% saline 
was interspersed once or twice between the escalating concentrations of capsaicin 
solution. If the 62.5 µM solution had not yet been administered after evoking ≥5 
coughs, this was then given. An audio recording was made of the procedure (Philips 
DVT 3000 digital recorder and Philips ME15 microphone).  
6.2.3 24-hour cough frequency measurement 
24-hour cough frequency was measured with the Leicester Cough Monitor as further 
described later (Section 7.2.2).253 The audio recorder was set to record several minutes 
after completing the cough challenge and the device returned by mail.  It has been 
shown previously that the effect of capsaicin disappears rapidly and does not affect 
cough frequency in the following 24 h.245 
6.2.4 Analysis of data 
The number of coughs occurring within 15 s of each dose delivery were later counted 
with the assistance of Audacity audio editing software.356 For the 62.5 µM solution, all 
coughs occurring within 30 s were also counted, giving values for the 15s -E62.5 and 30s-
E62.5, respectively. C2 and C5 were defined in each of two ways, as the first actual 
administered concentrations producing ≥2 or ≥5 coughs respectively (C2a, C5a), or as 
values interpolated from log concentration-response curves (C2i, C5i). Cough ‘latency’ 
following inhalation of the 62.5 µM dose was also measured, defined as the time 
between the brief ‘click’ of the dosimeter indicating completion of dose nebulization 






The outcome variable was 24-hour cough frequency (CF24). The strength of correlation 
of CF24 with each explanatory variable was tested in turn (C2a, C5a, C2i, C5i, 15s-E62.5, 
30s-E62.5 and cough latency). Pearson’s r was used following normalization of the non-
parametrically distributed variables with log transformation. If log-transformation did 
not successfully normalize data then Spearman’s rank correlation was used. 
6.3 Results 
6.3.1 Study participants 
57 patients were recruited, with underlying diagnoses unexplained chronic cough (n = 
38), cough-variant asthma (n = 6), gastro-oesophageal reflux disease (n = 2), upper 
airways disease (n = 2), COPD (n = 1) and sarcoidosis (n = 1). In seven patients workup 
was ongoing at the time of writing. Participant characteristics are shown in Table 6.1. 
 
Table 6.1. Characteristics of study participants. 
 All patients  
(n = 57) 
Unexplained chronic 
cough (n = 38) 
Other diagnoses  
(n = 19) 
P 
















Age 60 (54-66) 60 (54-65) 61 (40-69) 0.863 
BMI (kg/m2) 27.6 (23.5-31.4) 27.8 (24.0-30.6) 27.4 (22.8-35.2) 0.863 
Duration of cough (months) 4.5 (3.0-12.1) 9.0 (3.3-14.5) 3.3 (1.1-10.0) 0.014 
FEV1 (% predicted) 92.6 (±18.3) 89.4 (±16.7) 99.4 (±20.2) 0.375 
FEV1/FVC ratio 77.0 (73.4-81.9) 76.2 (72.6-82.0) 78.3 (72.9-81.7) 0.673 
  





6.3.2 Capsaicin cough challenge  
24-hour cough frequency and measured values from capsaicin challenges are shown in 
Table 6.2. There were trends for differences between unexplained chronic cough and 
other underlying diagnoses for C5a, C5i, 15s-E62.5 and 30s-E62.5, and a significant 
difference in 24-hour cough frequency between groups.  
Correlation coefficients and R2 values for correlations between capsaicin challenge 
endpoints and 24-hour cough frequency are represented in Figure 6.1 and ranked in 
Table 6.3. 
C2 appeared to correlate better with 24-hour cough frequency than C5. For C2, the 
actual administered dose, C2a, seemed a better predictor of cough frequency than C2i, 
the interpolated value; for C5i and C5a the converse was true.  
Significantly more coughs were counted over 30 s than 15 s following inhalation of the 
62.5 µM capsaicin solution (Wilcoxon matched-pairs signed rank test, p < 0.0001). 24-
hour cough frequency seemed to correlate better with 30s-E62.5 than 15s-E62.5. 
However, there were wide confidence intervals for r values and also missing data for 
30s-E62.5 for 18 patients, due to a decision to make this measurement part way through 
the study. 23 of the 39 patients for whom there were data coughed 15-30 s after the 
administration of capsaicin; 16 coughed more than once (range 2-13 coughs). 
Table 6.2. 24-hour cough frequency and measured values from capsaicin inhalation challenge. 
 All patients  
(n = 57) 
Unexplained chronic 
cough (n = 38) 
Other diagnoses  
(n = 19) 
P 
C2a (µM) 7.8 (2.0-11.7) 7.8 (1.7-9.8) 7.8 (2.0-15.6) 0.956 
C2i (µM) 4.6 (1.3-8.2) 4.5 (1.1-8.0) 5.5 (1.6-9.1) 0.629 
C5a (µM) 7.8 (7.8-31.2) 7.8 (3.9-15.6) 15.6 (7.8-31.3) 0.140 
C5i (µM) 7.8 (3.9-15.6) 6.2 (3.8-12.5) 13.5 (5.9-24.4) 0.085 
15s -E62.5 10 (7-12) 10 (8-13) 8 (6-12) 0.120 
30s -E62.5* 11 (7-14) 12 (8-22) 8 (6-12) 0.052 
cough latency (ms) 690 (501-989) 695 (509-937) 663 (481-1,165) 0.968 
24-hour cough frequency 436 (181-700) 487 (309-780) 207 (109-617) 0.031 





There was no evidence of correlation between 24-hour cough frequency and cough 
latency following the administration of 62.5 µM capsaicin solution, which was highly 
variable (range 0.32-5.63 s).  
Figure 6.1. Correlation between capsaicin cough challenge data and 24-hour cough frequency in chronic 
cough. 
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Subscripts a and i denote actual and interpolated values of C2 and C5, respectively. 15s - and 30s -E62.5 – number 






Table 6.3. Correlation between capsaicin cough challenge data and 24-hour cough frequency in chronic cough. 
 Correlation coefficient (95% CI) R2 P 
30s-E62.5* 0.553 (0.259 to 0.753)1 0.306 0.0008 
15s -E62.5 0.482 (0.197 to 0.692)1 0.233 0.002 
C2a -0.376 (-0.605 to -0.089)1 0.141 0.012 
C2i -0.372 (-0.603 to -0.085)1 0.139 0.013 
C5i -0.292 (-0.539 to 0.001)1 0.085 0.052 
C5a -0.247 (-0.504 to 0.051)1 0.061 0.103 
cough latency  -0.080 (-0.398 to 0.255)2 - 0.968 
 
6.4 Discussion 
This is one of very few studies to compare the two most widely-used endpoints in the 
capsaicin cough challenge, C2 and C5, with 24-hour cough frequency, and I am 
unaware of previous work to have compared the actual vs. interpolated values of 
these values with reference to 24-hour cough frequency. I have also tested two other 
parameters, E62.5 and cough latency. 
6.4.1 C2, C5 and cough frequency 
In 62 patients with chronic cough of various causes Decalmer et al.245 and reported a 
correlation coefficient of -0.45 between C5 and cough frequency. However, these data 
are difficult to compare to the current study as the authors used citric acid rather than 
capsaicin as the inhalation agent, quantified cough frequency for a 10-hour period 
rather than over 24 h for correlation with cough reflex sensitivity data, and reported 
cough frequency as time spent coughing rather than numbers of coughs. They did not 
report values of C2. In another study of seven patients with various causes of chronic 
cough, Birring et al.84 reported correlations of daytime cough frequency over 6 h with 
capsaicin-related C2 and C5 of r = 0.8 and r = 0.9, respectively. Again, comparisons with 
the current study are limited, in this case due to the short duration over which cough 
frequency was determined and the very small number of patients. In the largest s tudy 
comparing (citric acid) cough reflex sensitivity to cough frequency, of 100 patients with 
chronic unexplained cough, correlations of 24-hour cough frequency with C2 and C5 
were r = -0.23 and r = -0.47, respectively.75  
Values are median (IQR). 1 – Pearson’s r (from log-transformed data); 2 – Spearman’s ρ 





The current study is therefore the largest of which I am aware to compare C2 and C5 
from the capsaicin cough challenge to 24-hour cough frequency in chronic cough. The 
wide confidence intervals in the reported r values give no evidence of a difference 
from correlations with cough frequency reported in other studies of a similar size in 
chronic cough using citric acid. The two agents, capsaicin and citric acid, are thought to 
act on the same pathway of the cough reflex,244 and are both agonists of the receptor 
TRPV1.27 There is therefore no difference to suggest a priori that cough challenge 
results from the two agents would have different relationships with 24-hour cough 
frequency. A larger study with more statistical power would be required to test this.  
C2 appeared to have a stronger correlation with 24-hour cough frequency than C5, the 
opposite finding to that of Kelsall et al. However, the wide confidence intervals in the 
correlation coefficients again suggest this difference between C2 and C5 is not 
statistically significant. It is not clear which should be the preferred endpoint as there 
are conflicting data about which is the most reproducible endpoint over time.2,242,243 
However, there is some evidence in the current study that C5 might be superior to C2 
in the fact that there was a trend for a difference in C5 but not C2 between patients 
with unexplained compared to other causes of chronic cough, coinciding with a 
significant difference in 24-hour cough frequency.  
6.4.2 Interpolated values or administered concentrations? 
Only one other study has compared the two methods of calculating data for C2 or C5, 
using actual administered concentrations or interpolating values from the log dose-
response relationship.361 Patients with chronic cough (n = 15) and healthy volunteers 
(n = 15) were recruited. As both methods were equally repeatable and the values 
strongly correlated, the authors concluded both methods to be equally valid.  
The current study does not give clear support for superiority of either of the two 
standard approaches, given that interpolated and actual values for C2 and C5 led to 
similar correlation coefficients with 24-hour cough frequency. However, using 





effectively creating a continuous variable from ordered categories (Figure 6.1). There is 
some support for this effect in the observed fall in p values for the comparisons against 
cough frequency of C5a vs. C5i or C2a vs. C2i between diagnostic groups (Table 6.2), and 
in comparing correlation coefficients for actual with interpolated values  in Table 6.3. 
6.4.3 E62.5: a useful new endpoint? 
E62.5, the number of coughs evoked by a 62.5 µM solution of capsaicin is a novel 
endpoint, and appeared to be superior to C2 or C5a as a predictor of 24-hour cough 
frequency.   
In a study which set out to characterize the capsaicin pharmacodynamic dose-response 
in the cough challenge, Hilton et al. measured Emax, the maximum number of coughs 
produced by any concentration of capsaicin.85 Patients with chronic cough (n = 20) and 
healthy volunteers (n = 20) underwent a dose-escalation protocol that increased the 
administered concentration of solution until no further doses were tolerated. Although 
Emax appeared to be more predictive of 24-hour cough frequency (r = 0.71) than E62.5 
was in the current study (r = 0.48 or 0.55), a meaningful comparison is limited because 
confidence intervals for r were not reported in the previous study. 
Emax is presumed to equate to the ‘maximum capacity of a subject to cough when 
inhaling increasingly potent stimuli’.85 However, unlike in animal studies, Emax can only 
be estimated in human subjects due to the necessity to terminate the dose escalation 
protocol once the limits of an individual’s tolerance of the test have been reached. This 
tolerance relates to coughing and throat irritation as no other adverse reactions have 
been previously reported during capsaicin cough challenges.363 Presumably, the 
number of evoked coughs does not always level off with a protocol of this kind, 
although the authors did not state the proportion of subjects in which a plateau effect 
was observed.85 
The highest tolerated dose in the majority of patients with chronic cough in the study 
of Hilton et al. was 62.5 µM, hence my choice of this dose as an alternative to estimate 





predict 24-hour cough frequency in chronic cough as Emax (as measured by Hilton et al.) 
but would have the advantages of relative simplicity of measurement and reduced 
dependence on subject tolerance. 
Other than whether or not the plateau cough response had been reached in the 
current work and the study of Hilton et al., participant characteristics may have 
accounted for the apparent better correlation of 24-hour cough frequency with Emax 
than E62.5. In particular, including healthy volunteers and subjects with mild to 
moderate asthma as well as patients with chronic cough in the previous study 
produced a larger variation in 24-hour cough frequency than in the current work. 
E62.5 appears to be a useful endpoint to the capsaicin challenge. As well as the strength 
of correlation with 24-hour cough frequency, it seemed to differentiate unexplained 
chronic cough from patients with other underlying diagnoses better than most of the 
other capsaicin challenge endpoints evaluated. Further investigation is needed, with 
studies including healthy volunteers, and comparison to other measures which might 
reflect the maximum cough response more accurately, for example ‘E125’. 
6.4.4 15 s vs. 30 s  
It is recommended that only coughs occurring with 15 s of dose delivery should be 
counted in inhalational cough challenges. This is because the response is ‘immediate 
and brief’.2 However, this duration of time appears to be arbitrary and chosen by 
extrapolation from earlier work in healthy volunteers359,364 or mild asthma,365 in which 
all evoked coughs occurred within this time. Conversely, after administration of the 
62.5 µM capsaicin solution in the current study of patients with chronic cough, a 
number of patients coughed between 15 and 30 s, with coughing bouts in several 
cases being truncated at the 15 s mark. 30s-E62.5 was significantly higher than 15s-E62.5, 
and for comparisons of values between patient groups there was an associated trend 
for a difference that almost reached statistical significance for 30s-E62.5 but not 15s-






It therefore appears that limiting the counting of coughs to 15 s may result in the loss 
of informative data. As counting coughs over 30 s is technically no more demanding 
than over 15 s, with the application of digital sound recording and playback with audio 
editing software (Section 5.3.4), I would suggest that cough responses be routinely 
measured over 30 as well as 15 s when performing inhalation cough challenges.  
A reason for keeping the counting period as short as possible appears to be to exclude 
coughs not directly attributable to the inhalation of capsaicin. In the current study, the 
median cough rate of 487 c/24h in unexplained chronic cough equates to 
approximately one cough per 3 min. Ignoring the effects of the capsaicin challenge, the 
chance of a cough occurring as a result of the background pathological process over 
any 30 s period follows a Poisson distribution but is approximately 0.17 as opposed to 
0.08 for any 15 s period, a small and probably clinically insignificant difference. It is 
also possible that extending the period of cough counting from 15 to 30 s increases the 
chance that some of the coughs following the inhalation of capsaicin are ‘voluntary’ 
rather than ‘involuntary’, thus reducing the reproducibility of the test. However, there 
is no evidence for this as far as I am aware, and voluntary effects on coughing can 
clearly occur within only 15 s of the administration of capsaicin.364  
6.4.5 Cough latency 
Latency of coughing in inhalational challenge tests has been rarely measured. In a 
previous study of healthy volunteers at the highest administered concentration of 
capsaicin, mean values were 1.65 ± 0.18 s, and longer with voluntary suppression (2.16 
± 0.34 s),364 although comparison of the actual values with the current study is of 
limited value due to the different techniques of capsaicin administration. Coughing is 
probably triggered when capsaicin solution interacts with cough receptors in the 
larynx.365 Once reaching the larynx, capsaicin must interact with cough receptors to 
generate an action potential in afferent airway nerves, which in turn is conducted 
along the vagus to the nucleus tractus solitarius, before stimulating the efferent limb 





taken for nebulized capsaicin solution to reach the larynx is likely to vary little between 
patients as the flow regulator valve of the Koko dosimeter limits the speed at which it 
is inhaled. Similarly, it is doubtful if signal transduction at the larynx and nerve 
transmission along afferent and efferent components varies by a measureable amount 
between individuals. Tachyphylaxis tends not to occur with increasing concentrations 
of capsaicin.85,358 Differences in cough latency between subjects is therefore probably 
due to central processing, which in the current study exceeded 5 s. 
The role of conscious and voluntary or semi-voluntary influences on coughing following 
capsaicin inhalation, and also more generally, is of particular interest.20 As shown by 
the study of Hutchings et al.,364 even when healthy volunteers are asked to actively 
suppress coughing, the effect on the latency and number of evoked coughs is very 
variable. Latency did not correlate with the number of coughs in 24 h in chronic cough, 
nor was there a difference between unexplained chronic cough and other causes. 
Further work in this area is required, for example by observing the effect on cough 
latency of behavioural training in chronic cough.65,66 
6.4.6 Cough measurements and diagnosis 
In a study of 134 healthy subjects and 88 patients with various diseases, C2 and C5 
from capsaicin inhalational challenge varied substantially in healthy volunteers and in 
general distinguished poorly between health and disease.70 There were, however, 
significant differences between patients with cough variant asthma, gastro-
oesophageal reflux-related cough and unexplained chronic cough and healthy 
volunteers. In the current work there were trends for differences in C5a, C5i, 15s-E62.5 
and 30s- E62.5 between unexplained and other causes of chronic cough. For 15s-E62.5 
the difference almost approached statistical significance (p = 0.052); a type 2 error may 
have occurred due to insufficient statistical power due to missing data. 
E62.5, like Emax, might therefore reflect the underlying physiological and pathological 
processes in cough more accurately than C5 and C2.85 Comparison of E62.5 between 





6.4.7 Limitations  
This was a pilot study to explore potential differences between capsaicin challenge 
endpoints and numbers of patients were relatively small. Also, for 30s -E62.5, there were 
missing data.  
The study did not include healthy volunteers. Doing so may have allowed the potential 
discriminatory ability of the capsaicin challenge endpoints to be evaluated with more 
certainty. However, the main reference point for comparison with capsaicin endpoints 
in this study was 24-hour frequency, rather than the ability to discriminate between 
diagnostic categories. Cough frequency is more variable in disease than in health 
(Section 7.4.2),89 and it has been shown previously that although Emax correlates with 
24-hour cough frequency in chronic cough,85 this is not the case in healthy 
volunteers.246 Clearly the physiological processes governing cough in health are 
different from pathological mechanisms in disease. 
The data presented here suggest E62.5 might be a useful measurement in capsaicin 
cough challenges. Clearly though, this is a novel endpoint and more data are required 
for a fuller validation. In particular, repeatability of the test needs to be established, 
both in healthy volunteers and in disease. However, the same could be said for other 
endpoints used in capsaicin challenges, not only for measures such as Emax,85 but also 
established endpoints such as C2 and C5, which have only been explicitly tested for 
repeatability in healthy volunteers.242 
6.5 Conclusion 
C2 and C5 are not necessarily the most relevant endpoints in cough inhalational 
challenges for investigating mechanisms of cough.  Measuring the number of coughs 
evoked by a single relatively high concentration of capsaicin solution adds to the utility 
of this research tool. Further work is required in this area, also to establish the 
optimum duration over which coughs should be counted in inhalational challenges, 





7 Temporal patterns of coughing and 
respiratory disease 
7.1 Introduction and objectives 
The usually physiological and episodic phenomenon of coughing is increased in 
frequency in respiratory disease. Because of the only relatively recent development of 
portable cough monitors, temporal patterns of coughing in respiratory disease are only 
beginning to be investigated (Section 1.6.2.2). Very few studies have directly compared 
24-hour coughing patterns in more than one type of disease.89,91 There is no published 
work reporting 24-hour cough patterns in tuberculosis. Some of the varied underlying 
pathologies in other lung diseases are shared with TB (consolidation, granuloma 
formation, fibrosis and mucus hypersecretion) whilst others are not (bronchospasm 
and emphysema; Section 3.1). Further investigation in this area should reveal more 
about the mechanisms of cough, and whether this aspect of cough in TB is distinct or is 
similar to that in other disease.   
In this Chapter the following hypotheses are addressed: 
1. temporal cough patterns in respiratory disease are associated with general 
disease-independent factors related to participant (host) characteristics, such 
as sex, age and smoking; 
2. temporal cough patterns in respiratory disease are associated with specific 
disease-related factors, such as diagnosis itself, markers of disease severity 
and, in tuberculosis and other infections, microbial factors; 
3. cough in tuberculosis is less noticeable to the subject than in other conditions. 
7.2 Methods 
7.2.1 Patients 
Patients were recruited with a range of respiratory diagnoses and routine clinical data 





patients were recruited to the study by the author whilst running a clinic, a sample of 
those completing cough symptom questionnaires also underwent 24-hour cough 
monitoring, selected by convenience. 
7.2.2 Leicester Cough Monitor 
As previously outlined (Section 1.6.2.2.3.3), the recording component of the Leicester 
Cough Monitor (LCM) consisted of a commercially-available small battery-powered 
MP3 digital audio recorder (in this study Philips DVT 3000, DVT 5000 or LFH 0865) and 
a lapel free-field microphone (Olympus ME-15 or Philips LFH 9173). The equipment 
was worn as shown in Figure 7.1 and set to record sound continuously with a sampling 
frequency of 22 kHz (DVT 3000, DVT 5000) or 16 kHz (LFH 0865) and an encoding rate 
of 64 kbit/s (DVT 3000, DVT 5000) or 48 kbit/s (LFH 0865). The devices were powered 
by two AAA batteries, Duracell Rechargeable, which supplied >24 h of continuous 
recording, or Varta Industrial, which allowed for recordings lasting >48 h.  
 





The resulting digital audio files were transferred to a computer for analysis with the 
Leicester Cough Monitor software which, through an algorithm similar to that used in 
automated speech recognition, identified cough sounds.265 After initial automated 
analysis the software played back a selection of approximately 60-100 possible cough 
sounds for independent calibration by the operator (which in all cases was the author), 
before further refinement by the software. An automated report then displayed total 
cough frequency for each included 24-period, mean cough rate per hour, as well as 
similar data for cough bouts (defined as episodes of coughing in which the interval 
between individual cough sounds is <2 s).251 The timings of each detected cough sound 
cough could also be easily extracted. The software calculated nocturnal and daytime 
cough counts, from 22:00 to 08:00 h and 08:00 and 22:00 h, respectively. Data were 
derived  on cough clustering as proportions of all coughs distributed in bouts rather 
than ‘lone’ coughs (those separated from other cough sounds by ≥2 s), and numbers of 
coughs per ‘episode’ (i.e., a period of coughing consisting of either a either a lone 
cough or a bout of cough sounds separated by <2 s).  
The Leicester Cough Monitor software was kindly supplied by the developers, Dr. 
Surinder Birring (King’s College, London) and Dr. Sergio Matos (University of Aviero, 
Portugal). The developers and an independent investigator have evaluated the cough 
detection algorithm in isolated chronic cough and other diseases and reported it to be 
valid on comparison with auditory analysis as previously discussed (Section 
1.6.2.2.3.3).89,253,266 The cough monitor had not previously been used in tuberculosis.  
Although further formal validation of the Leicester Cough Monitor was not 
undertaken, automated cough monitoring was evaluated in two ways. First, for 
recordings which appeared to contain long periods during waking hours with 
substantially fewer reported coughs than at other times of the day, the quality of 
recording was checked. Using Audacity® audio editing software (Section 5.2.3), visual 
inspection of the audio trace verified that sounds had been recorded throughout the 





The LCM had the potential to detect background coughs and falsely attribute them to 
the subject undergoing cough monitoring, a particular problem on an open respiratory 
ward (Section 1.6.2.2.3.3). This potential was minimized during operator calibration of 
the cough detection algorithm by choosing to ignore coughs which either sounded 
distant to the microphone (due to their relative quiet volume and distinct quality 
compared to the majority of other coughs in a recording), or were ‘sex incongruent’, 
i.e. had a voiced quality of someone of the opposite sex to subject being studied. The 
cough monitoring process was also evaluated in this regard by making background 
recordings. To observe the potential impact of unwittingly detecting coughs of other 
people, the cough monitor was left running for 24 h at various locations on the 
respiratory ward and the acute admissions ward at Homerton University Hospital to 
measure background 24-hour cough frequency. 
7.2.3 Cough monitoring procedure 
On patient recruitment, or on repeat measurement, patients  were asked to wear the 
cough monitoring equipment for a period of at least 24 h. In individuals with acute 
respiratory disease, or early in the treatment of pulmonary tuberculosis, some 
recordings were made for 48 h. The LCM recorded sounds constantly throughout the 
period in which it was worn, during which patients were requested to continue normal 
activities (depending on the effects of the underlying disease) and to wear the monitor 
for the entire time, other than if showering or bathing. Study participants were either 
hospital inpatients or outpatients. If not hospitalized or not due to reattend hospital 
shortly after the monitoring period, subjects were asked to return the recording 
equipment by post at the end of the recording period in a pre-paid envelope. 
Patients were informed that the recording device would pick up normal conversation 
and other sounds as well as coughs but that, due to the nature of the semi-automated 
process of analysis, it would be only rarely necessary to listen to sections of recordings 





7.3 Analysis of data 
Temporal cough data (24-hour cough frequency and cough clustering) were compared 
across diagnostic groups with Kruskal-Wallis and one-way ANOVA tests for non-
parametric and parametric distributions, respectively. Both LTBI and pulmonary TB 
were used as individual comparator groups. Each group was also separately compared 
with every other, allowing for multiple comparisons with Dunn’s (non-parametric), or 
Dunnett’s (parametric) tests. 
For individual disease groups in which there were at least 15 participants, possible 
associations were explored between categorical disease-related variables and 24-hour 
cough frequency, initially with two-sample Wilcoxon rank-sum (Mann-Whitney) tests 
or, if >2 categories, Kruskal-Wallis tests. A Bonferroni correction was made for multiple 
two-sample comparisons if p ≤ 0.05. For single variables which had a statistical 
association with cough frequency of p ≤ 0.15, multivariate linear regression analysis 
was performed after log-transforming non-normally distributed data (Section 2.5). 
Cough frequency data were compared with continuous variables with Spearman rank 
correlation tests.  
7.4 Results 
7.4.1 Patients 
The study participants who underwent 24-hour cough monitoring are described in 
Chapter 3 (Section 3.5). For all disease groups other than chronic cough, the patients 
are the same. The characteristics of the 59 patients with isolated chronic cough who 





Characteristic All patients 
with isolated 
chronic cough 




(n = 59) 
p 
Female sex 98 (68.5) 38 (64.4) 0.622 
White ethnicity 54 (37.7) 25 (42.4) 0.635 
West European-born 64 (44.8) 28 (47.5) 0.758 
Age (y) 51 (39-65) 47 (38-61) 0.290 
Current smokers 5 (3.5) 0 0.324 
ACEi 13 (9.1) 2 (3.4) 0.239 
Opiate use 4 (2.8) 3 (4.5) 0.419 
Duration of cough (months) 
Diagnosis 
6 (3-12) 8 (5-27) 0.093 
asthma  44 (30.8) 10 (16.9) 0.054 
gastro-oesophageal reflux  23 (16.1) 10 (16.9) 1.000 
ACE inhibitor-associated 12 (8.4) 2 (3.4) 0.360 
upper airway pathology 10 (7.0) 2 (3.4) 0.515 
smoking 4 (2.8) 1 (1.7) 1.000 
voluntary coughing / throat clearing 1 (0.7) 1 (1.7) 0.500 
sarcoidosis 1 (0.7) 1 (1.7) 0.500 
unexplained chronic cough 23 (16.1) 20 (33.9) 0.004 
no diagnosis 18 (12.6) 15 (27.1) 0.035 
 
Va lues are n (%) or median (IQR). 
Note 3 patients (5.1%) had 2 diagnoses. 
Compared to the whole group of patients with isolated chronic cough, the subgroup 
undergoing cough monitoring were a representative sample except they were more 
likely to have unexplained chronic cough or no diagnosis due to ongoing follow-up in 
the clinic. There were also non-significant trends for a diagnosis of asthma and a     
longer duration of symptoms prior to the first clinic visit in the monitored sample. 
Table 7.1. Characteristics of patients with isolated chronic cough who underwent 24-hour cough monitoring  
7.4.2 Baseline 24-hour cough patterns in respiratory diseases 
Data on cough frequency, diurnal variation and cough clustering across disease groups 





Table 7.2. Cough frequency, diurnal variation and cough clustering in respiratory diseases. 
 
7.4.2.1 Cough frequency 
24-hour cough frequency across respiratory diseases was highly variable (Table 7.2; 
Figure 7.2). Median cough rates differed between disease groups overall (p < 0.0001) 
and cough frequency in TB was significantly lower than in chronic cough (p < 0.05), 
COPD exacerbations (p < 0.001) and pneumonia (p < 0.01). Cough frequency in the 
chronic diseases COPD, asthma, bronchiectasis, pulmonary fibrosis and lung cancer 
together was significantly lower than in the combined group of COPD exacerbations, 
acute asthma and pneumonia (median 305 [IQR 128-450] vs 559 [IQR 340-949] c/24h, 


























































































































































































Va lues are median (IQR) or mean (± SD). 
*% of coughs from 24 h period occurring between 22.00 and 08.00 
† bout: 2 or more coughs separated by < 2 s ; cough episode: coughing activity consisting of either a lone cough  







respectively, p < 0.0001). The highest cough frequency, 2,347 c/24h, was measured in 
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Figure 7.2. 24-hour cough frequency in respiratory diseases. 
 
There was very little coughing detected in participants with latent TB, which was 
significantly less frequent than in every disease group. However, the individual with 
LTBI who reported a cough of onset several days prior to study recruitment (Section 
3.2.11) coughed 120 times in 24 h.  
Common to almost all the patient groups was a pronounced skewed distribution of 













































































Va lues  are median (IQR). p' – Bonferroni -corrected va lue. 
7.4.2.1.1 Non-disease related factors and cough frequency 
Female sex was associated with cough frequency across disease groups (i.e. excluding 
LTBI); cough rates were almost 1.5 times higher in women than men. Cough frequency 
was higher in participants of white compared to other ethnicity, although this was not 
statistically significant following a Bonferroni correction for multiple comparisons  
(Table 7.3). There was overall no evidence for an effect of smoking, ACE inhibitor use, 
opiates or age (Figure 7.3). 
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Cough frequency va lues are median (IQR). p – va lues from Wilcoxon 
s igned rank tests, other than from Kruskal-Wallis test for final diagnosis. 
* ACE-inhibitor use (n=2), upper airway pathology alone (n=1), 
behavioural/ throat clearing (n=1), smoking (n=1), sarcoidosis (n=1), 
as thma and GORD (n=2), GORD and upper airways  pathology (n=1). 
n = 59. 
7.4.2.1.2 Isolated chronic cough 
No association was observed between final diagnosis, sex or ethnicity and 24-hour 
cough frequency in isolated chronic cough (Table 7.4). Statistical analysis of the effects 
of ACE inhibitor medications was not performed due to very small sample sizes, but 
the two participants currently taking these drugs had relatively very high cough rates 
(Table 7.4). There were only three patients currently taking codeine but no evidence 
for an effect on cough frequency. There was no association between age or symptom 
duration and 24-hour cough frequency in chronic cough (Spearman’s rho, ρ = 0.160, p 
= 0.226; ρ = 0.158, p = 0.397, respectively).   
Table 7.4. Cough frequency and other clinical variables in chronic cough. 
 
In patients of the subgroup unexplained chronic cough, there was a significantly higher 
cough frequency in women (n = 13, median 795 [IQR 539-1241] c/24h) than men (n = 





age on cough frequency (ρ = 0.212, p = 0.369), but a trend for higher cough 
frequencies in white (779 [587-1450] c/24/h) than non-white (398 [161-882] c/24h) 
individuals (p = 0.063). 
7.4.2.1.3 Stable COPD 
In COPD there was a trend towards higher cough frequencies in current smokers than 
non-smokers (p = 0.10) but no observed association with sex, ethnicity, ACE-inhibitor 
use (Table 7.5), age (Spearman’s rho, ρ = -0.202, p = 0.448), FEV1 (ρ = 0.407, p = 0.168) 
or number of exacerbations per year (ρ = 0.426, p = 0.129). Only one patient was 
currently taking codeine and had a very high cough frequency of 1237 c/24h. Cough 
rates were relatively lower in the small number of patients taking antimuscarinic 
medication (n = 3); no effect of inhaled corticosteroids or long-acting β-agonists was 
observed.  
































































































7.4.2.1.4 Pulmonary fibrosis 
No association of sex, ethnicity, current smoking, diagnosis or ACE inhibitor use with 
cough frequency in pulmonary fibrosis was observed (Table 7.6). Neither was there a 
correlation of age (Spearman’s rho, ρ = 0.167, p = 0.549), forced vital capacity (ρ = 
0.036, p = 0.899) or total lung capacity (ρ = 0.224, p = 0.533), with cough frequency. 
However, there was a trend for an inverse correlation of cough rates with total 
diffusing capacity of the lung for carbon monoxide (DLCO; ρ = -0.467, p = 0.108), and a 
significant inverse correlation between diffusing capacity of the lung for carbon 
monoxide per unit alveolar volume (KCO) and cough frequency (ρ = -0.666 [CI -0.888 to 
-0.193], p = 0.011; Figure 7.4). 
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Figure 7.4. Cough frequency and carbon monoxide transfer factor in pulmonary fibrosis. 
 
7.4.2.1.5 COPD exacerbations 
None of the examined categorical variables were significantly associated with cough 
frequency in COPD exacerbations (Table 7.7). Neither was there an observed effect of 
annual exacerbation frequency (Spearman’s rho, ρ = -0.229, p = 0.331), baseline FEV1 
(ρ = -0.179, p = 0.463) or CRP (ρ = 0.286, p = 0.175). There was a trend for higher cough 
frequencies in patients with a longer onset of symptoms prior to hospitalization (ρ = 
0.398 [95% CI -0.019 to 0.967], p = 0.054; Figure 7.5) and a significant association with 
age (ρ = 0.497 [0.094 to 0.760], p = 0.016). There was a trend for an association 





Table 7.7. Cough frequency and other clinical variables in COPD exacerbations 
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Figure 7.5. Cough frequency and duration of acute symptoms in COPD exacerbations. 
 
7.4.2.1.6 Acute asthma 
In acute asthma there was no evidence of an effect of admission peak expiratory flow 


















































































Va lues are median (IQR). 





hospital presentation (ρ = -0.124, p = 0.659) or annual number of exacerbations (ρ = 
0.137, p = 0.642) on 24-hour cough frequency. Neither was there a significant 
association of cough rates with the categorical variables examined (Table 7.8), or with 
age (ρ = 0.274, p = 0.302), although there was a trend for higher cough rates in women 
than men (p = 0.070). Only one patient was taking ACE inhibitor mediation and had a 
high cough rate of 1029 c/24h. 
Table 7.8. Cough frequency and other clinical variables in acute asthma. 
7.4.2.1.7 Community-acquired pneumonia 
No relationship was detected between CRP (Spearman’s rho, ρ = -0.357, p = 0.192), 
neutrophil count (ρ = -0.380, p = 0.169), or symptom duration (ρ = 0.118, p = 0.965) 
and cough frequency in pneumonia. Neither was there any observed association of 
cough frequency with age (ρ = -0.436, p = 0.091), sex, ethnicity, current smoking 
status, ACE inhibitor medication, time since hospital admission or other baseline 


























































Va lues are median (IQR). 





Table 7.9. Cough frequency and other clinical variables in pneumonia. 
7.4.2.1.8  Pulmonary tuberculosis 
On univariate analysis there was some evidence for an association between sputum 
smear positivity and 24-hour cough frequency in pulmonary TB (p = 0.056), and a trend 
for higher cough frequency in males than females (p = 0.132). 
There was, however, no evidence for an effect of the other documented clinical 
variables, including pulmonary cavitation, extent of radiographic disease involvement, 
and organism strain (Table 7.10). There were insufficient data to test for the effect of 
the Beijing strain alone, from only two patients, whose baseline cough frequencies 
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Va lues are median (IQR). 
* missing data for one patient. 





screening had substantially lower cough rates than patients who had been identified 
by other means. Both were sputum smear negative. Age and cough frequency were 
not correlated in TB (Spearman’s rho, ρ = 0.042, p = 0.787).  
7.4.2.1.9 Latent tuberculosis 
The 17 individuals with LTBI had a median cough frequency of 14 (8-53) coughs/ 24 h. 
The participant with the upper respiratory tract infection (URTI) coughed 120 times in 
24 h; cough rates in the remainder were 13 (8-45) c/24h. Cough rates in the two 















































































































































Va lues are median (IQR). 





smokers were 7 and 56 c/24h, respectively, and in the non-smokers without URTI, 13 
(IQR 8-41, geometric mean 16.5) c/24h. 
7.4.2.2 Diurnal variation  
Hourly cough frequency in all diagnostic groups was lower overnight than during the 
day. The pattern shown in Figure 7.6 for pulmonary TB was typical across diseases. On 
visual inspection there were no obvious peaks in coughing at particular times of day 
unique to certain diseases (Figure 7.7 compares the three acute respiratory diseases). 
However, a significantly larger proportion of total coughs occurred overnight in 
pneumonia than in TB, chronic cough or LTBI (p < 0.05), and in AECOPD than in TB or 
LTBI (p < 0.05; Table 7.2). The number of coughs between the hours of 22:00 and 08:00 
was strongly correlated with 24-hour cough frequency across diseases (Figure 7.8). 








































Error bars : median ± IQR 
 







7.4.2.3 Cough clustering  
Significantly fewer coughs were clustered into bouts in TB (mean 57.5 [±22.9] %) than 
in chronic cough (69.9 [±17.9] %, p < 0.05; Table 7.2). Coughs in LTBI were significantly 
less likely to be clustered into bouts than in all other groups except lung cancer. There 
was no other difference in this measure of cough clustering upon comparing each of 
the other groups to TB. The proportion of coughs in bouts and 24-hour cough 
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Figure 7.9. Correlations between nocturnal cough rates and 24-hour cough frequency. 
 





frequency were correlated across all participants (Spearman’s rho, ρ = 0.616 [0.520-
0.697], p < 0.0001).  
The median number of coughs per episode was variable within groups and not 
significantly different between diseases, although lower in LTBI than in all diseases 


































































































Figure 7.10. Cough clustering in respiratory diseases 
7.4.2.4 Power 
The log-transformed value for mean cough frequency in TB was 2.24 and standard 
deviation 1.91 coughs/24h. With 44 patients and two-sided statistical significance (α) 
0.05, the power to detect a difference in cough frequency of magnitude 15% from 
another disease group of a similar size was 82%. Amongst patients with TB, to compare 
24-hour cough frequency in any two equal-sized groups of 22 patients there was a 53% 
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Figure 7.11. Cough frequency and subjective cough severity in respiratory diseases. 
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7.4.3 Correlation between objectively-measured cough patterns and the subjective 
appreciation of cough 
Overall there was moderate correlation for 24-hour cough frequency with cough 
severity visual analogue scale (VAS) scores (Spearman’s rho, ρ = 0.48 [95% CI 0.35 to 
0.59], p < 0.0001; Figure 7.11), and weak correlation with Leicester Cough 
Questionnaire (LCQ) scores (Spearman’s ρ = -0.35 [-0.48 to -0.21], p < 0.0001; Figure 
7.12). 
Each of the domains of the LCQ was similarly correlated with cough frequency acros s 
diseases (Spearman’s rank correlation coefficients -0.321 [-0.451 to -0.278, p < 
0.0001], -0.318 [-0.448 to -0.174, p < 0.0001] and -0.345 [-0.473 to -0.204] for 
associations between CF24 and the physical, psychological and social domains, 
respectively).  
Table 7.11 shows that within diagnostic groups the strength of correlation between 
objective and subjective measures of cough varied and was perhaps stronger in COPD 
and pulmonary fibrosis than in other diseases, although there were wide confidence 
intervals for correlation coefficients. 
Table 7.11. Correlation between 24-hour cough frequency and patient-reported cough measures in respiratory 
diseases. 
 VAS score LCQ score 
Spearman’s  ρ (95% CI) p  Spearman’s  ρ (95% CI) p  
TB 0.588 (0.278 to 0.788) 0.0006 -0.337 (-0.643 to 0.061) 0.0853 
Chronic cough 0.351 (0.083 to 0.571) 0.009 -0.315 (-0.545 to -0.0403) 0.0217 
Stable  COPD 0.701 (0.193 to 0.912) 0.014 -0.609 (-0.8539 to -0.146) 0.0141 
Stable asthma 0.800* 0.333 -0.400* 0.750 
Bronchiectasis 0.095* 0.840 -0.452* 0.268 
Fibrosis 0.652 (0.194 to 0.877)   0.010 -0.643 (-0.873 to -0.179) 0.0116 
Lung cancer 0.150* 0.708 0.214* 0.662 
COPD 
exacerbations 
0.100 (-0.347 to 0.511) 0.657 0.117 (-0.383 to 0.564) 0.645 
Acute asthma 0.244 (-0.345 to 0.695) 0.397 -0.105 (-0.631 to 0.488) 0.727 
Pneumonia 0.517 (-0.037 to 0.827) 0.062 -0.354 (-0.741 to 0.210) 0.196 
ALL 0.479 (0.355 to 0.587) <0.0001 -0.350 (-0.476 to -0.208) <0.0001 
 





The relative physical, psychological and social burden of cough symptoms in relation to 
cough frequency in TB was similar to that observed in the other chronic disease groups 
for which there were adequate numbers of participants to make a comparison (Table 
7.12). The possible exception is in pulmonary fibrosis where LCQ physical domain 
scores were less well correlated than psychological and social domain scores with 
cough frequency, all though confidence intervals for Spearman’s ρ were wide. 
Overall, and within diagnosis groups, subjective cough scores were also correlated with 
24-hour cough episodes, to a similar degree as with the frequency of individual coughs 
(ρ = 0.44 [95% CI 0.31 to 0.56], p < 0.0001 for correlation of cough episodes/ 24 h 
across disease groups with cough severity VAS score; ρ = -0.29 [95% CI -0.43 to -0.13] 
for correlation with LCQ score, p = 0.0003). 
7.4.4 The Leicester Cough Monitor and background coughing 
All audio recordings from participants with COPD exacerbations, acute asthma and 
pneumonia were made during inpatient hospital admission, as were a number from 
patients with TB (n = 21), lung cancer (n = 7) and pulmonary fibrosis (n = 4). In TB all 
inpatient recordings were made in separate single patient side-rooms, whilst in acute 
asthma and COPD exacerbations, cough monitoring for the majority took place on 
open wards. In lung cancer and pulmonary fibrosis the numbers of patients in 
individual side-rooms was four and one, respectively. 
Table 7.12. Correlation between 24-hour cough frequency and domains of the Leicester Cough 
Questionnaire in TB and chronic respiratory diseases 
 Physical  Psychological  Social 
Spearman’s  ρ 
(95% CI) 
p  Spearman’s  ρ 
(95% CI) 
p  Spearman’s  ρ  
(95% CI) 
p  
TB -0.230  
(-0.569 to 0.176) 
0.249 -0.371  
(-0.665 to 0.023) 
0.057 -0.399  
(-0.683 to 0.011) 
0.039 
Chronic cough -0.295  
(-0.530 to -0.019) 
0.032 -0.268  
(-0.508 to -0.010) 
0.052 -0.357  
(-0.578 to -0.088) 
0.009 
Stable  COPD -0.629 
(-0.862 to -0.178) 
0.010 -0.636  
(-0.865 to -0.190) 
0.009 -0.653  
(-0.872 to 0.217) 
0.007 
Fibrosis -0.345 
(-0.736 to 0.219) 
0.204 -0.605  
(-0.857 to -0.118) 
0.018 -0.702 
(-0.897 to -0.281) 
0.004 







In pneumonia, 7 of 18 patients were in side-rooms and the remainder located on open 
wards during cough monitoring. Measured baseline cough frequency did not 
significantly differ between the two groups: 687 (396-959) vs. 731 (412-1140) c/24h, 
respectively, p = 0.535. 
Nine background 24-hour audio recordings were made, from six different locations on 
the respiratory and acute admissions wards at Homerton University Hospital. Median 
background cough frequencies detected by the Leicester Cough Monitor were 78 (35-
86) c/24h (3.3 [2.5-3.3] c/h). This compares with the median measured cough 
frequency for all patients of 559 (340-949) c/24h. There was no obvious differences 
between background cough counts on the two wards (p = 0.290).  
7.5 Discussion 
In this Chapter the temporal patterns of cough have been explored in a wide range of 
respiratory diseases to an extent that has not previously been reported.  I set out to 
investigate general and specific factors associated with objective measurements of 
coughing. General factors would be disease-independent, and specific factors would 
be related to pathology. In particular, the aim was to identify any host or micro-
organism-related variables associated with coughing in tuberculosis, which due to its 
role in transmission may have unique temporal characteristics compared to other 
diseases. 
Wide variation in 24-hour cough frequency in respiratory diseases was observed, and 
rates in TB were lower than in isolated chronic cough and acute respiratory diseases. 
Cough frequency across diseases was associated with female sex and, in TB, with 
sputum smear positivity (although p = 0.056). In pulmonary fibrosis cough frequency 
was associated with transfer factor for carbon monoxide, and in COPD exacerbation 
with duration of symptom onset, both novel findings.  In all diseases cough frequency 
reduced overnight, but less so in patients hospitalized with pneumonia or COPD 





in TB than in chronic cough, and in healthy individuals (with LTBI) the majority of the 
little coughing that occurred was as lone coughs rather than as bouts, the converse of 
the findings in disease.  
Across a range of respiratory diseases there was only a weak to moderate correlation 
between patient-reported cough symptom scores and objectively-measured cough 
frequency, and greater for the cough severity visual analogue scale than the Leicester 
Cough Questionnaire. 
7.5.1 Temporal cough patterns and respiratory disease 
There was wide variation in 24-hour cough frequency within all diagnostic categories 
and few differences between diseases. Cough frequencies were amongst the highest in 
isolated chronic cough, a condition defined solely on the basis of patient-reported 
excessive coughing,2 and lowest in latent TB, a group specifically chosen as a negative 
control. Patients in other disease groups were not selected on the basis of cough 
symptoms yet in some cases had cough frequencies as high as in isolated chronic 
cough. 
The pronounced skewed distribution of cough frequencies in almost all groups, which 
did not necessarily equate with markers of disease severity, suggests that small 
numbers of individuals are particularly prone to coughing in certain contexts for largely 
unknown, but presumably disease-independent (host-related) reasons. These 
individuals could perhaps be the super-spreaders or ‘tuberculosis disseminators’ in 
pulmonary TB.186  This phenomenon is also exemplified by the concept of unexplained 
chronic cough, or “cough hypersensitivity syndrome”, in which otherwise healthy 
individuals have very higher cough rates in response to seemingly innocuous stimuli.62 
7.5.1.1 ‘Normal’ cough frequency and latent tuberculosis  
‘Normal’ cough frequency has not been well defined. Latent tuberculosis, by definition, 
does not cause cough or any other clinical manifestations, but differentiating true 





assumed that the observed cough frequency in the participants with LTBI would reflect 
cough frequency in health, but comparisons with the literature are limited due to the 
paucity of evidence of what constitutes ‘normal’ cough frequency.  
Only three studies appear to have reported 24-hour cough frequency in healthy 
volunteers. Yousaf et al. reported a geometric mean cough frequency of 18.6 c/24h 
using the Leicester Cough Monitor in 44 healthy non-smokers,89 and in another small 
study using the LCM, mean cough rates in the included nine healthy volunteers were 2 
(SD ±1) per hour.84 The Manchester cough group reported median 24-hour cough 
frequencies in 12 healthy non-smokers using their Vitalojak cough monitor: 16.8 (range 
3-103) c/24h.78 They also investigated coughing frequency in another study which 
included healthy volunteers but quantified coughs as time spent coughing rather than 
numbers of coughs,76 complicating comparisons with the current study. The limited 
published data (from a total of 65 patients), therefore, reports very similar values for 
normal cough frequency to those observed in latent TB in the present study (16.5 
c/24h for the 14 non-smokers without URTI). 
The finding of normal cough frequencies in latent TB is valuable for two reasons. 
Firstly, it supports the notion that latent TB is a condition without clinical 
manifestations which can be recognized as such by experienced physicians. Secondly, 
it adds to the limited data available data on ‘normal’ 24-hour cough frequency. As 
stated by Robert Loudon in 1965, “the development of cough-counting devices 
measuring cough frequency in individual patients has made it important to es timate 
the frequency with which cough occurs in the general population”.6 This remains true 
50 years on: further data on cough frequency in health are needed to advance cough 
research. Normal ranges need to be established in different population groups in 
different situations to be able to interpret cough frequency values in disease and 
measure the effects of treatment.  For example, if cough frequency measurement 
were to be used to try and separate latent from active tuberculosis, no clear upper 





7.5.1.2 Demographic predictors of cough frequency 
7.5.1.2.1 Smoking 
It is evident anecdotally, from patient surveys,367,368 through direct observation of 
people smoking,72 and ambulatory cough monitoring,78,89 that smokers generally cough 
more frequently than non-smokers. This is probably due to the direct irritant effects of 
tobacco smoke, mucus hypersecretion and other mechanisms.78 However, despite the 
current observations of trends for associations between cough frequency and smoking 
in stable COPD (p = 0.104), COPD exacerbations (p = 0.149) and acute asthma (p = 
0.158), there was no observed association of smoking with cough frequency across all 
disease groups overall. As there were relatively few patients who were current 
smokers, it is possible that the study was underpowered in several cases to detect an 
effect of smoking. However, in pulmonary fibrosis, pneumonia and tuberculosis, cough 
frequencies were numerically lower in smokers than in non-smokers, with relatively 
large numbers in each group in TB (n = 20 vs. n = 24, respectively), which goes against 
an artefactual lack of effect of smoking in those conditions.  
In otherwise healthy volunteers, cough frequencies seem to be about twice those in 
smokers compared to non-smokers, although the evidence for this is only from two 
small studies, and the numerical difference in daily coughs in small (geometric mean 
33 vs. 19 c/24 h,89 or median [range] 5.3 [0.20–13.9] vs. 0.7 [0.13–4.3] c/h,78 
respectively). 24-hour cough frequency has very rarely been investigated in smokers, 
and only once before in patients with respiratory disease as far as I am aware; in COPD 
median cough frequency in current smokers was 9.0 c/h compared to 4.9 c/h in ex-
smokers.78 Current smokers have generally been excluded from other studies involving 
24-hour cough monitoring,75–77,79,80 so there are no other data on 24-hour cough rates 
in smokers with diseases other than COPD apart from those in the current study. 
However, on 8-hour overnight cough recordings, Loudon and Brown in the 1960’s 
observed no effect of usual smoking habit on cough frequency in pneumonia (n = 48) 





It could be the case that smoking is more likely to have an effect on cough frequency in 
diseases of the airways (COPD, asthma) than in diseases of the lung parenchyma 
(tuberculosis, fibrosis, pneumonia). This might be due to direct contact of cigarette 
smoke with the site of disease and amplification of the (largely unknown) mechanisms 
of cough in COPD and asthma, perhaps involving airway inflammation78,95 and sputum 
production.78 The reason that no effect of smoking on cough frequency was observed, 
either overall, or in tuberculosis, pneumonia  and pulmonary fibrosis individually, could 
be that any effect of smoking was small (perhaps equivalent to only an extra 14 coughs 
per day compared to non-smokers, as in healthy volunteers89), and dwarfed by the 
much larger effect on cough frequency of the underlying disease itself.  
Clearly, more data are needed to understand the role of smoking in the mechanism of 
cough in disease, but these, perhaps unexpected, findings have suggested that in 
disease of the lung parenchyma smoking may not always be an important determinant 
of cough frequency. This has implications in tuberculosis where, if not an important 
determinant of coughing, smoking might not affect infectiousness. Indeed Fennelly et 
al. have shown that when individuals with smear positive TB disease do cough there 
seems to be no effect of smoking status on the release of airborne bacilli.199 Also in 
isolated chronic cough, smoking is usually cited as an aetiological factor,9 yet there is 
no evidence as far as I am aware that it is usual for smoking on its own to cause cough 
frequencies in the pathological range. Just as gastroesophageal reflux probably does 
not cause significantly elevated cough rates in the majority, those that develop 
isolated chronic cough who are smokers may well have another reason for a 
significantly elevated cough frequency, for example hypersensitivity of airway nerves.62   
7.5.1.2.2 Sex 
Median cough frequencies were about 1.5 times higher in women than men across 
diagnostic groups overall. However, this difference was not statistically significant in 
any of the disease groups individually, apart from unexplained chronic cough and 





men than women (p = 0.13). Evidence for an effect of sex in stable asthma, 
bronchiectasis and lung cancer was not sought due to small sample sizes. 
Yousaf et al. using the LCM similarly showed higher cough frequencies in women than 
men overall across a range of (slightly different) diagnostic categories, a difference of 
1.9-fold.89 However, on overnight recordings in patients with COPD, pneumonia and  
pulmonary TB, Loudon and Brown observed no effect of sex.88 As in the current study, 
24-hour cough frequency has been reported elsewhere to be higher in women than 
men In unexplained chronic cough75 and asthma.76 Also in keeping with my findings, 
other work has similarly failed to show an effect of sex on cough rates in COPD,78 
idiopathic pulmonary fibrosis77 and isolated chronic cough due to a variety of 
causes.369 Data in URTI are conflicting.79,80  
Therefore, the current findings of sex and cough frequency are consistent with those in 
the literature. There may be no association between the two variables other than in 
idiopathic chronic cough, and perhaps asthma. In idiopathic chronic cough, reasons for 
a sex difference in cough frequency are not entirely clear and require further 
evaluation (Section 1.4), although differences in airway inflammation, peripheral 
neuronal sensitivity or central sensory processing between men and women may be 
important.9,75,81,340  
7.5.1.2.3 Other factors 
There was no significant effect of ACE inhibitor use on cough frequency in any disease 
group, although in isolated chronic cough there were only two patients taking the 
medication, both of whom had very high cough rates. ACE inhibitors are clearly a cause 
of isolated chronic cough,74 and appear to alter the threshold of the cough reflex in 
healthy individuals.14 However, cough reflex sensitivity (as it is usually measured) at 
best correlates only moderately with cough frequency,84 and there are very few data in 
the literature on objectively-measured 24-hour cough rates in individuals taking these 
medications, possibly from a maximum of five subjects.89,369 Although chronic cough 





unclear how frequently ACE inhibitors affect objectively-measured cough frequency in 
health and disease. Genotype may have an important influence.53 
In keeping with the lack of convincing evidence for codeine as an effective 
antitussive,17 no association of the use of the use of this medication with cough 
frequency was seen. Similarly, there is little convincing previous evidence on the action 
of methadone as an antitussive,370 and the current findings do not support an effect of 
this drug on cough frequency.   
The current study found no correlation of cough frequency with age across all 
participants as a whole, and a correlation within disease groups individually (which 
have different age profiles [Section 3.5]) only for COPD exacerbations. Previous work 
has not found an association of cough frequency with age in COPD,78 chronic cough 
due to a various causes,89,369 IPF,77 URTI,79 pneumonia and TB,88 although other studies 
in idiopathic chronic cough75 and asthma76 have reported higher cough rates in older 
individuals. The apparent correlation of cough frequency with age in the current onset 
might be due to the association of age with duration of pre-hospital symptom onset 
(Section 7.5.1.3.4), although why older individuals might have symptoms for more days 
prior to admission with a COPD exacerbation is unclear. The general question of how 
the tendency to cough through life might change remains unresolved.82  
Across all patients overall cough rates were higher in white than non-white 
participants. Although there was no evidence for a significant association of ethnicity 
with cough frequency within diagnostic groups individually, there was a trend towards 
higher cough frequencies amongst white participants in unexplained chronic cough. 
Part of the difference overall might have been due to an overrepresentation of white 
participants in the groups with COPD exacerbation and pneumonia (Section 3.5), both 
groups with relatively high cough rates. However, an effect of ethnicity on cough 
frequency cannot be excluded. There does not appear to be previous work examining 





one study found no difference between healthy volunteers of Indian, Chinese or 
European descent in capsaicin cough reflex sensitivity.371  
7.5.1.3  Baseline cough frequency and disease-related factors 
7.5.1.3.1 Isolated chronic cough 
None of the variables investigated, other than perhaps ethnicity and sex (as discussed 
above) were associated with cough frequency in isolated chronic cough. Only one 
other previous study appears to have looked at predictors of cough frequency in 
isolated chronic cough, all in patients with unexplained symptoms, and found sex and 
age to be important.75 As also discussed above, this correlation with age has not been 
supported by other work. Understanding of the direct causative mechanisms of 
coughing in chronic cough remains limited although neuronal hypersensitivity is 
increasingly thought to be important.62  
7.5.1.3.2 Stable COPD 
The Manchester cough group have looked in the most detail at cough frequency in 
COPD, finding current smoking, smoking history, reported sputum production, and 
sputum neutrophilia, but not lung function, to be predictors.78 Similarly, in the current 
work there was a trend for an association with current smoking and no evidence for an 
effect of FEV1.  
The observed association of cough frequency with long-acting muscarinic medication 
(tiotropium) could be a chance finding given small numbers involved. Alternatively, 
worse cough could have been a reason for an increased tendency to prescribe this 
commonly-used medication in COPD. However, there is some limited evidence for the 
beneficial effect of the short-acting anti-muscarinic agent ipratropium bromide on 
cough severity in isolated chronic cough,372 and tiotropium has been shown to reduce 
capsaicin-induced cough via action on TRPV1 receptors.373 An effect of tiotropium on 





7.5.1.3.3 Pulmonary fibrosis 
Only one study of which I am aware has looked at objective cough frequency in 
pulmonary fibrosis, again from the Manchester group, involving a total of 19 patients 
with IPF.77 Median (range) cough rates in the previous work were very similar to the 
current study, 226 (36-946) c/24h vs. 258 (110-859), respectively. The authors 
documented age, sex, body mass index, lung function, and current steroid use, and 
found no evidence for an influence of any of the variables on cough frequency. It is 
therefore of interest that in the current work there was a correlation between cough 
frequency and KCO, albeit in a group of mixed underlying diagnoses (n = 15). Lung 
function and other patient characteristics in the Manchester cohort seem very similar 
to those in the current study, although the former did not report ethnicity. The 
discrepancy between the two studies on KCO could reflect differences in underlying 
causes of fibrosis; further evaluation is required.  
The mechanisms of cough in pulmonary fibrosis, as in many disease are largely 
unknown.77,374,375 Changes in transfer factor could relate to cough frequency via an 
independent process indicating general progression of disease. Alternatively the 
alveolar destruction with which the loss of transfer factor is associated could in some 
way be accompanied by increased inflammation and activation of cough receptors in 
distal airways. Positron emission tomography studies have shown fibrotic lung tissue in 
ILD to be a lot more metabolically active than might have been assumed.376 Cough 
mechanoreceptors might also be more sensitive as a result of lung stretching following 
architectural distortion and traction bronchial dilatation. The airways can also be 
directly involved in both sarcoidosis and connective tissue disease which may more 
readily explain cough in these conditions,374 and perhaps an association with KCO as 
disease progresses.  
No attempt was made to measure the radiological extent of disease in patients with 





KCO and cough frequency although the scoring systems that exist for this purpose have 
not been extensively validated.377,378 
7.5.1.3.4 COPD exacerbations, acute asthma and pneumonia 
There are no published reports of 24-hour cough frequency in COPD exacerbations, 
acute asthma and pneumonia of which I am aware. In Loudon and Brown’s overnight 
cough recordings the authors did not look for any correlates with cough rates in 
patients hospitalized with COPD and pneumonia, other than with sex and smoking 
status, which were not found. 
In the current study there was a trend for higher cough frequencies, in COPD 
exacerbations, with duration of symptom onset, and, in acute asthma, with female sex, 
but no other predictors of cough frequency were identified in these conditions or in 
pneumonia, including markers of disease severity such as CRP and CURB-65 score, or 
peak expiratory flow in asthma. Other work has similarly failed to show an association 
between lung function measures and cough frequency in asthma, albeit in stable 
disease.76 Associations with sex have been discussed (section 7.5.1.2), but the possible 
association with symptom duration is novel. It is possible that there are ‘cough-
predominant’ COPD exacerbations, better tolerated in the outset than other 
exacerbations, perhaps related to certain viral aetiologies and less associated with 
systemic inflammation (CRP) than more severe types.379 Such exacerbations may start 
with cough and slowly build up before patients seek medical intervention for 
accompanying ‘major’ symptoms,380 by which time cough frequency has reached 
higher levels than in other, ‘dyspnoea-predominant’ episodes.  
The causes of excessive coughing in these three conditions have not been specifica lly 
investigated. In COPD exacerbations and acute asthma airway inflammation may be 
relevant, as has been shown in stable COPD,78 although not in stable asthma.76 COPD 
exacerbations have classically been termed ‘infective’ or ‘non-infective’, based mainly 
on the presence or absence, respectively, of increased sputum purulence, and the 





is difficult to make clinically, and no attempt was made to do so in the current study. 
Furthermore, molecular techniques have revealed viruses may be involved more 
frequently than previously recognized, in exacerbations of both COPD and asthma,382  
often acting in tandem with bacteria.383 Viral infections probably contribute to 
excessive coughing in a large proportion of exacerbations of airway disease, acting 
directly or indirectly on airway nerves.68,384  
7.5.1.3.5 Tuberculosis 
To my knowledge, this is the first work to have carried out 24-hour cough frequency 
measurement in pulmonary tuberculosis. Cough frequency was shown to be highly 
variable in TB, as in other diseases. The variable for which there was the best evidence 
for an association with 24-hour cough frequency was sputum smear status (p = 0.054). 
There was a suggestion that sex may also have been important (p = 0.132), but 
associations for none of the variables met the pre-specified level of statistical 
significance (p < 0.05). 
The only other studies of cough monitoring in TB of which I am aware are by Loudon 
from the 1960s, and owing to limitations of technology at the time, were constrained 
to overnight bedside recordings lasting up to 8 h.88,125 The authors made recordings in 
96 patients with pulmonary TB and reported a mean overnight cough frequency of 
approximately 8 c/h. This is about twice the median nocturnal rate for TB in the 
current study, although considerable variation was reported in the previous work, with 
rates <3 c/h in 50% of patients.88 The difference from the current study could reflect 
differences in patient characteristics. This is however difficult to ascertain as the ea rlier 
study report gives little detail other than that 35 patients had ‘far advanced’ disease, 
44 ‘moderately advanced’ and 17 ‘minimal pulmonary tuberculosis’, without defining 
these categories, which seem to refer to extent of radiographic change.88 Treatment 
and microbiological status was not stated. However, in keeping with the current work, 
cough frequency in TB was lower than in patients hospitalized with pneumonia and 





High variation of cough frequency in TB was therefore a common observation of the 
current work and the previous study of Loudon. All cough monitor recordings were 
started before commencing anti-tuberculous treatment in the current work, and even 
in smear-positive disease, 24-hour cough rates overlapped with those in latent TB.  
No other studies apart from that of Loudon and Brown88 have reported predictors of 
objectively-measured cough frequency in tuberculosis. In Chapter 4 an association of 
the presence of subjectively-reported cough in TB was reported with sputum smear 
positivity, absence of coincident extrapulmonary TB, and referral from screening . 
Associations with the severity and impact of cough symptoms were noted with 
absence of EPTB and possibly sputum smear and culture status  (Section 4.4.1.1). Other 
work has associated patient-reported cough with sputum and culture status, and 
radiological extent of disease in TB.305,349  
These observations on subjective and objective measures of cough in TB are therefore 
complementary but a weak correlation between the two fits with findings in other 
diseases. For example, the independent trend for an association of the presence of 
coexistent EPTB with better cough severity and cough-related quality of life (Section 
4.4.1.1.3) was not coupled with a correlation with lower objective cough frequency. It 
therefore seems that in the presence of coexistent extrapulmonary disease, cough 
frequencies in pulmonary TB are no lower than in the absence of EPTB (as reported 
here), but that coughing is less noticeable (as described in Chapter 2), presumably due 
to the presence of other symptoms of greater importance to the patient (e.g. neck 
lumps in lymph node disease or dyspnoea in pleural TB).   
Sex remains as a possible associated factor with cough frequency in TB, although there 
was only a trend for an association between the two variables (p = 0.13; Section 
7.5.1.2.2). This possible association is not explainable by sputum smear status or 
radiological extent of disease, which were not significantly different between the two 





There was no evidence to support the hypothesis that M. tuberculosis strain type 
might influence cough frequency, although there were only two patients with the 
Beijing strain (of particular interest due to reports of increased transmissibility182). 
Neither was there evidence for an association of the presence of visible cavities with 
cough frequency in TB. However, chest radiographs are insensitive to small cavities 
compared to computed tomography.385 Mechanistically, cavities could be important, 
as sites of high bacterial numbers and routes of access of M. tuberculosis to the 
airways,386 the location of the majority of cough receptors.   
An association passive rather than active case finding (screening), and possibly smear 
status, with cough frequency in TB, supports the idea that coughing becomes more 
prominent as the disease progresses.88,387 In general symptoms in pulmonary TB are 
probably more common and severe in sputum smear-positive compared to smear-
negative tuberculosis.388 The presence of larger numbers of bacteria in the sputum, 
and therefore the airways, presumably directly and indirectly triggers the cough reflex, 
by triggering inflammation involving neutrophils and other mediators ,389 possibly 
involving secreted TB antigens. There is further discussion about possible mechanisms 
of cough in TB in Section 8.5.2.  
The quantity and characteristics of sputum are also probably important in TB (Section 
4.5.2),102 but were not explored.  
 Other insights are reported in Chapter 8 with further discussion (Section 8.4.2), but 
the determinants of cough frequency in TB remain largely obscure. Because of 
implications for transmission of the disease this is a particular area in demand of 
further research.  
7.5.1.4 Diurnal variation in cough 
This is the first reported demonstration that objectively-measured cough frequency is 
reduced overnight in TB, lung cancer, COPD exacerbation, acute asthma and 
pneumonia. This has already been shown to be the case in isolated chronic cough,75,369 





unique patterns in any of the disease groups, in common with other work showing no 
significant differences in diurnal variation of cough between asthma, acute cough and 
chronic cough.91 However, overnight reductions in coughing were less pronounced in 
patients hospitalized with pneumonia and COPD exacerbations than in other study 
participants.  
Nocturnal cough rates were strongly correlated with total 24-hour cough frequencies 
across diseases. A similar finding has been reported elsewhere in chronic cough,369 but 
with perhaps a less strong association (Spearman’s ρ = 0.62, compared to ρ = 0.83 in 
the current study). I am unaware of other data on this in other diseases. If the current 
findings are replicated elsewhere, and indeed nocturnal cough counts are a strong 
predictor of cough frequency throughout the 24-hour period in respiratory diseases, 
then for patient convenience, cough monitoring for research and clinical purposes 
could be done overnight rather than during a whole day. This might increase the utility 
of cough monitoring, and would also reduce interference from background noise. 
Sleep appears to suppress coughing; the large majority of overnight coughs probably 
only occur during episodes of wakefullness.391 Patients were not specifically asked to 
record the approximate times of going to sleep and waking, but in one study of 
outpatient recordings in chronic cough, doing so did not make a significant difference 
to estimations of nocturnal cough rates compared to using the arbitrary times of night 
as 22:00 to 06:00 h as in the current study.369 Nocturnal cough rates were possibly 
relatively higher in patients with acute respiratory disease due to excessive noise and 
other factors in the hospital environment limiting sleep. Also the greater severity of 
accompanying symptoms (fever, dyspnoea, pain) compared to in chronic conditions 
presumably also affected sleep quality.   
Only one study (of 10 patients with COPD) appears to have coincided nocturnal cough 
monitoring with electroencephalogram data, showing coughs during true sleep to be 
rare;391 correlations between levels of central arousal and cough frequency have been 





to cough or whether the majority of nocturnal coughing occurs during periods where 
wakefulness has resulted from other causes. Sensitivity to an inhaled tussive agent has 
been shown to be suppressed during sleep.392 Investigating central mechanisms 
suppressing the cough reflex during sleep could lead to new insights for the 
development of antitussive therapies.393 
An overnight reduction of cough frequency in TB has implications for the transmission 
of disease. If coughing is infrequent overnight then sharing a bedroom with a potential 
source case of pulmonary tuberculosis may not represent any more of a significant risk 
for infection than other types of household contact. However, the risk may of course 
still be high depending on the duration of the total exposure and the nature of daytime 
contact. 
7.5.1.5 Cough clustering 
The temporal clustering of coughs was of interest as any difference between diseases 
may suggest differences in the mechanism or the purpose of coughing. Spacing of 
coughs closely together, for example, might increase the efficiency of clearing 
secretions,93 or aerosolizing pathogens (Section 1.4.2). This does not appear to have 
been investigated previously in any detail. In one study of spontaneous coughing in 
healthy individuals, the numbers of coughs per expiratory phase were counted and no 
differences were found based on smoking or sex.72 There were no differences between 
diseases in the current work other than a reduced proportion of clustering of coughs 
into bouts in TB compared to chronic cough. This is the opposite of what might be 
expected if cough clustering was strongly associated with the presence of sputum or 
bacterial aerosolization.  
The converse may therefore be the case, that a relatively lower number of cough 
bouts, and a high proportion of lone coughs for the same overall cough frequency 
could be associated with more efficient aerosolization of airway secretions. The first 
cough of an expiratory phase is usually the most powerful in terms of peak flow and 





to lower volumes of air remaining in the lungs.94 There may also remain a relatively 
much smaller amount of aerosolizable matter within in the airways after the first 
cough within a certain time period, meaning that second and subsequent coughs of a 
bout are less relevant for the expulsion of bacteria and other material into the air. As a 
consequence, the number of cough ‘episodes’, might be a better predictor of efficient 
aerosolization than the total number of coughs per se. Meanwhile the clustering of 
coughs into bouts might perhaps be more noticeable and therefore, as seen in the 
current work, more characteristic of isolated chronic cough, a condition defined by its 
irritating symptom, and associated with worse subjective scores than TB (Section 
4.4.1.1).  
Clustering of coughs and daily cough frequency are, however, correlated (Spearman’s 
ρ = 0.62 in the current study). In health (latent TB) only 26% of the few coughs were 
clustered into bouts compared to 72% in pneumonia, the disease with the highest 
median cough frequency. The only differences observed between diseases in 
clustering, between isolated chronic cough and TB, therefore are most probably a 
result only of differences in overall cough frequency between the conditions, and there 
is no evidence of independent variation between groups in cough clustering. 
The current study also provided no evidence that numbers of cough episodes are a 
better predictor of symptoms than numbers of individual coughs (although there were 
wide confidence intervals associated correlation coefficients). Other work in chronic 
cough has similarly shown numbers of cough bouts (or epochs) in chronic cough and 
the frequency of individual coughs to be closely correlated with one another and 
similarly related to quality of life.87  
7.5.2 Objective and subjective measures 
There was an overall weak to moderate correlation between objectively-measured 24-
hour cough frequency and subjective measures of cough (cough severity visual 
analogue scale score and Leicester Cough Questionnaire score). This has been noted 





coefficient -0.6 [ref 84], -0.53 [ref 87]), COPD (ρ = -0.64),78 asthma (ρ = -0.55 to -0.45),76 
bronchiectasis (ρ = -0.54)390 and pulmonary fibrosis (ρ = -0.80).77 Similar findings have 
been shown for correlations of cough frequency with VAS in chronic cough (Pearson’s r 
[for normalized data] = 0.45 [for daytime cough]; r = to 0.67 [nocturnal cough]),87 
COPD (ρ = 0.48 [nocturnal cough]; ρ = 0.66 [daytime]),78 asthma (ρ = 0.44),76 
bronchiectasis (ρ = 0.56)390 and pulmonary fibrosis (ρ = -0.80).77 No previous studies 
have looked at correlations of 24-hour cough counts with subjective measures in COPD 
exacerbations, acute asthma, pneumonia, cancer or tuberculosis as far as I am aware. 
However, on their study of overnight coughing in a mixture of patients, mainly with TB, 
pneumonia and COPD, Loudon and Brown found a very poor correlation between 
cough frequency and the response to the question “Do you have a cough at the 
present time?”, but did not present the findings by diagnosis.88 
As previously discussed, 24-hour cough frequency is probably a poor predictor of 
patients’ subjective appreciation of coughing for a number of reasons  (Section 1.6.1; 
Section 4.5.4). The findings did not support the hypothesis that cough might be less 
noticeable in tuberculosis than in other conditions, perhaps due to the action of the 
pathogen promoting its own transmission; correlation between objective and 
subjective measures of cough in TB was similar or stronger to that seen in the majority 
of other disease groups. Wide confidence intervals limited any meaningful 
comparisons of the relative social and psychological impacts of symptoms (based on 
LCQ domain scores) across disease in relation to cough frequency, which in TB would 
be relevant for social mixing and the spread of disease, but correlation coefficients 
were very similar in the two largest groups, TB and chronic cough (Table 7.3).  
The weakest correlations between objective and subjective measures of cough were in 
COPD exacerbations and acute asthma. The reasons for this are unclear, but perhaps 
reflect the relative lesser subjective importance of cough in these conditions compared 
to other symptoms, particularly acute breathlessness. For example in COPD 
exacerbations, increased cough is classed as a ‘minor’ symptom compared to the 





acute severe asthma, breathlessness is also probably the most important symptom, 
perhaps making the perception of coughing less troublesome. The novelty of cough in 
otherwise healthy patients with pneumonia might also make it more noticeable, 
compared to in acute asthma and COPD, where patients experience respiratory 
symptoms on a more frequent basis. 
Overall the Leicester Cough Questionnaire scores seemed to correlate less well with 
cough frequency than the visual analogue scale score, although confidence intervals in 
correlation coefficients overlapped. This is the largest study to perform this 
comparison. This finding is perhaps not unexpected. The VAS is a subjective marker 
specifically of the severity of cough, whereas the LCQ measures cough-related quality 
of life. The LCQ includes questions about concern of underlying illness, embarrassment 
of coughing and feelings of frustration, i.e. psychological and social impact rather than 
just physical effects, the latter of which might relate better to cough frequency. 
Subjective measures, although obviously very important for quantifying symptoms, are 
therefore poor surrogates for objective measurements. 24-hour cough frequency 
measurements are clearly more relevant for studying disease mechanisms, the efficacy 
of treatments and potential infectiousness in tuberculosis. 
7.5.3 The Leicester Cough Monitor 
The Leicester Cough Monitor was found to be useful. Although lacking previous 
evaluation in certain contexts, for example tuberculosis and acute respiratory disease, 
it provided meaningful data. It has probably been peer reviewed to a greater extent 
than any other cough monitoring system (Section 1.6.2.2.3.3).253,265,266 The 
demonstration of responsiveness in cough frequency data to treatment of tuberculosis 
presented in Chapter 8 (Section 8.4.2) provides further validation of the LCM in 
general, as well as specific validation in TB, as do the data correlating cough frequency 
with symptom scores in TB.  
There is no reason to suspect that the cough monitor should not be as accurate in TB 





between than within diseases.98,272 Furthermore, the correlations between measured 
nocturnal and 24-hour cough frequency were as strong in TB as in other conditions, 
and the comparisons to subjective measures of cough similar to in other diseases, 
suggesting the device performed equally across patient groups. 
The recording device was simple and unobtrusive, perhaps less so than other 
systems,90 and was acceptable to patients, with few refusing to undergo monitoring. 
Outpatient recordings were simplified by the ability to send digital recorders through 
the post, made possible by their small size and relative low cost (£40-50). As 
technology progresses, the recording component of the Leicester Cough Monitor 
should improve, perhaps involving smartphones and transfer of audio files by the 
internet. 
It is unlikely that any automated or semi-automated cough monitoring system would 
report all coughs with complete accuracy. As demonstrated in Chapter 5 (Section 
5.3.3), even the reference standard of auditory cough counting has a degree of error, 
perhaps due to classification of ‘atypical’ cough sounds. Compared to auditory cough 
counts, the sensitivity and specificity of the Leicester Cough Monitor has been 
reported to be 88 and 99%, respectively.256 There was therefore a small degree of 
error associated with cough frequency measurements in this study, as there would 
have been making measurements of any variable with any measurement tool. Because 
the inherent error of the LCM in most cases is probably random rather than systematic 
it should not qualitatively influence the findings.  
Table 7.13. Cough frequency measurements in disease from other studies. 
 24-hour cough frequency 
Leicester Cough Monitor Vi ta lojak 
current s tudy previous work 
Unexplained chronic cough 652 (216-1165) 480 (±0.5) 477 (±0.3)a 381 (206-552) b 
COPD 232 (112-385) 194 (±0.5) 213 (±0.3) a 170 (9.6-648) * c 
Pulmonary fibrosis 258 (110-859) 286 (±0.3) - 226 (36-946) d 
Healthy non-smokers 13 (8-14) 17 (±0.5) 19 (±0.5)a 17  (3-103) * c 
Va lues are: median (IQR or *range); geometric mean (±log10SD)  






The main shortcoming of the cough monitoring system was a potential inability to 
exclude background coughs. In most cases this should not be a significant problem, but 
it influences comparisons of absolute cough frequencies reported from different 
environments. A crude method of assessing the degree of ‘cough contamination’ on 
hospital ward recordings was used, and probably overestimated the number of 
background coughs (median 559 c/24 h) that would have been picked up during a 
routine patient recording. The background recordings included all captured coughs, a 
lot of which if present in patient recordings would have been filtered out by the LCM 
software. This would have occurred at the operator calibration stage by the ability to 
recognize background coughs as such by comparison to the louder, more frequent, and 
often qualitatively different cough sounds of the subject being studied. The lack of a 
significant difference in cough counts in pneumonia between patients in side rooms 
and on the open ward is reassuring that cough contamination might not be a 
significant problem in ward recordings. Also, it is less of a concern for measuring 
response to treatment in serial recordings made in similar conditions where relative 
change is more important than absolute change in numbers (Chapter 8).  
Table 7.13 shows other recent reports of 24-hour cough frequency in several diseases, 
using either Vitalojak, by the Manchester cough group, or the Leicester Cough 
Monitor. Comparisons between studies are of only limited value due to patient 
differences, but relative cough rates between diseases and variation within groups are 
similar between studies. This suggests that the two cough monitors produce very 
similar results. It would be of interest to compare these two systems directly, currently 
the two main cough monitors being used in clinical research.225 
7.5.4 Limitations 
The main limitation for at least some of the investigations described in this chapter 
was statistical power. The limited available data on variation on cough frequency 
across diseases made an a priori estimate of adequate sample sizes difficult. However, 





differences between diseases and large effects of particular variables on cough that 
might direct further investigation. In fact, the study was adequately powered to detect 
a 15% or greater difference in cough frequency between TB and isolated chronic 
cough, as was demonstrated. Conversely, the lack of statistically significant differences 
in cough frequencies between some groups despite numerical differences in medians 
(e.g. stable asthma and acute asthma) may well have been due to small numbers of 
patients.  
Sputum production was not measured, although, at least when assessed subjectively, 
it has been shown to be an important predictor of cough frequency in COPD.78 The 
measurement of sputum production was attempted, by responses to Question 2 of the 
Leicester Cough Questionnaire, as previously described, but the method was shown to 
be problematic (Section 4.5.2). The relationship between objectively-measured 
quantitative and qualitative characteristics of respiratory mucus and cough frequency 
awaits description, particularly in diseases of the airways (COPD, bronchiectasis and 
asthma).   
A further consideration is repeatability of 24-hour cough monitoring. Intra-individual 
day-to-day variability in cough frequency was not formally assessed, and could impact 
further on sample sizes required for detecting differences between diseases. This 
would be of most interest in the stable state (chronic cough, fibrosis, COPD, asthma, 
lung cancer and TB pre-treatment) in order to quantify differences due to the method 
of measuring cough frequency and random biological processes. Day-to-day 
differences in cough frequency in acute respiratory disease would also reflect the 
evolution of the underlying pathology and the response to treatment, and are 
addressed in Chapter 8. No other researcher seems to have explicitly assessed the 
repeatability of 24-hour cough monitoring in the stable state in the same patient. 
Some of the novel findings, such a possible effect of KCO on cough frequency in 
pulmonary fibrosis, and the association between symptom duration and cough 





absence of particular associations, such as that between organism strain and coughing 
in TB, also need confirmation.  
Sputum production was not measured, although, at least when assessed subjectively, 
it has been shown to be an important predictor of cough frequency in COPD.78 The 
measurement of sputum production was attempted, by responses to Question 2 of the 
Leicester Cough Questionnaire, as previously described, but the method was shown to 
be problematic (Section 4.5.2). The relationship between objectively-measured 
quantitative and qualitative characteristics of respiratory mucus and cough frequency 
awaits description, particularly in diseases of the airways (COPD, bronchiectasis and 
asthma).   
The negative control group in this Chapter was latent TB infection. The rationale for 
this was that participants in this category should be as similar to the principal group of 
interest as possible, pulmonary TB, but for the fact that they do not have the disease. 
As discussed above (Section 7.5.1.1), the assumption was that ‘latent’ infection would 
not cause coughing, but the possibility exists that some individuals could have had 
subclinical disease causing subtle effects on cough frequency. However, while this is of 
interest and warrants further investigation, such subtle effects would not impact on 
the observation presented here of a much lower cough frequency in LTBI than in 
respiratory disease. Although cough frequency in LTBI reported here was very similar 
to values reported elsewhere for healthy volunteers (Section 7.5.1.1), inferences from 
observed cough frequencies in the control group should also take account of the 
ethnic profile (minority white), relative young age and low smoking prevalence 
compared to other study groups (Table 3.1). 
7.6 Conclusion 
There was little evidence to support the hypothesis that temporal patterns of coughing 
vary with disease, and that any disease (particularly tuberculosis) might display a 
distinct pattern. However, the investigation of cough frequency in respiratory diseases 





unexplained variation in cough frequency in all diseases groups suggest ‘host’-related 
factors are important. At the same time, the differential impact of variables across 
diseases (e.g. sex, smoking) suggests different mechanisms are of different relative 
importance across conditions. Investigation of the differential rates in which cough 
resolves with treatment between and within diseases, might give further important 






8 The response of cough to the 
treatment of respiratory disease 
8.1 Introduction and objectives 
Cough is a prominent feature of respiratory disease and usually improves with 
resolution of the underlying cause. The rate of improvement is, however, unclear.   
Serial objective cough measurements have been made infrequently and in a limited 
number of contexts.79,80,125 Knowledge of the rate of improvement of cough in 
respiratory conditions would be of interest for several reasons. Firstly, it would provide 
clinicians with evidence to inform patients what to expect with treatment. Secondly, 
the relative rate of change in cough frequency in comparison to changes in other 
clinical parameters might add to research into the causes of cough. Differences in the 
timing of improvements between types of pathology (e.g. pathogen vs. host-related, 
airway-centred vs. parenchymal disease) might lead to further hypotheses about 
cough mechanisms. Thirdly, cough could be used as a novel biomarker of disease 
activity in respiratory disease with serial monitoring providing an objectively measure 
of clinical response to treatment. Finally, in TB, improvements in cough frequency 
might help with estimations of continued infectiousness and decisions regarding 
infection control.  
The following hypotheses were explored: 
1. The rate of change in 24-hour cough frequency in response to treatment of the 
underlying cause varies with respiratory disease; 
2. Improvements in cough frequency in respiratory conditions correlate with 
other markers of disease resolution.  
8.2 Methods 
Serial cough monitoring was performed with the Leicester Cough Monitor in study 





exacerbation, acute asthma and pneumonia; Section 3.5) as previously described 
(Section 7.2.2). Patients with the acute respiratory diseases were invited to participate 
in this part of the study if it was predicted they would remain hospitalized for >24 h 
after the initial cough monitoring period. Repeat monitoring was completed prior to 
hospital discharge.  
In TB, repeat cough monitoring was set up during initial hospitalization (where 
applicable) and later in treatment, by convenience to coincide with routine clinic 
attendance or directly observed therapy (DOT). Routine follow up clinic appointments 
in TB at HUH were scheduled for two weeks, two months and six months after 
initiation of therapy for uncomplicated cases. 
In order to magnify any overall responses of cough frequency to treatment in TB, 
patients were invited to undergo repeat cough monitoring only if the baseline cough 
rate was >100 coughs/24 h (c/24h), a cough frequency which probably coincides with 
the upper limit of the normal range for healthy non-smokers.78  
8.3 Analysis of data 
For the repeated measures analysis of the non-normally distributed cough frequency 
data, Wilcoxon matched-pairs signed rank tests were used. 
8.4 Results 
8.4.1 Acute respiratory disease 
In total, 26 patients with acute respiratory disease (COPD exacerbation, n = 10; acute 
asthma, n = 5; pneumonia, n = 11) underwent repeat cough monitoring during hospital 
admission, a median of 2 (IQR 1-4) days after the first. There was overall a non- 
significant trend for a reduction in cough frequency over this time, from a median of 
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8.4.1.1  COPD exacerbation 
Patients with COPD exacerbations demonstrated no change in overall cough frequency 
on repeat monitoring (from median 405 [315-705] c/24h to 507 [323-718] p = 0.92; 
Figure 8.1, bottom left). Two patients showed substantial rises, and two patients 
substantial decreases in cough frequency. There was no obvious differences between 
these two pairs of patients in terms of final outcome and duration of hospital 
admission, treatment, duration of symptoms prior to hospitalization, baseline numbers 
of exacerbations per year, smoking status, ACE inhibitor use, or interval between 
recordings (data not shown). However, the two patients who showed the most rapid 
improvement in cough frequency had amongst the least severe lung function deficits, 
FEV1 83 % and 82 % predicted, respectively.  
Over the same interval between repeated cough frequency measurements there was a 
trend for CRP to improve but missing data (n = 8; 45 [10-117] mg/L at baseline vs. 20 
[8-39] mg/L on repeated measurement; p = 0.078). There was no correlation between 
relative changes in cough frequency and CRP (ρ = -0.179, p = 0.713). 
8.4.1.2 Acute asthma  
Four of the five patients with acute asthma who underwent repeat cough monitoring 
showed an improvement in cough frequency (p = 0.125 for overall change in cough 
frequency in group). There was no obvious difference in the two patients who failed to 
improve in cough frequency by at least 20 % from those that did show an 
improvement (Figure 8.1, bottom middle), in terms of smoking status, duration of 
acute symptoms, timing of cough monitoring or PEFR at hospital presentation, 
treatment and final outcome (data not shown). However, the two non-responders 
were both female and both pregnant. 
8.4.1.3 Pneumonia  
All but three of the 11 patients with pneumonia and repeat cough monitoring data 
showed reductions in cough frequency (median 953 [IQR 410-1079] c/24h to 596 [252-
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Figure 8.2. Change in cough frequency and decline in CRP during 
treatment of pneumonia. 
 
compared to 4 of the other 8 patients with pneumonia, although this difference was 
not statistically significant (p = 0.236). There was a trend for a correlation between 
change in cough frequency and the fall in plasma CRP levels between the same time 
points: apart from one outlier, the percentage fall in CRP seemed predictive of the 
change in cough rate (overall ρ = 0.527, p = 0.123; Figure 8.2). There was an interval of 
6 days between cough monitoring periods for the patient with the largest rise in cough 
frequency, and a drop in CRP of only 233 to 181 mg/L over the same period. He 
subsequently required surgical intervention for a loculated empyema. The other two 
patients with pneumonia and rises in cough frequency were discharged from hospital 
two days after repeated monitoring and, as with all other patients with repeat cough 
frequency results, had good clinical outcomes. There was therefore no obvious reason 
for the increase in cough frequency despite a significant fall in CRP in the outlying 
patient in Figure 8.2. Time since admission, duration of symptoms, ACE inhibitor 
medication, initial CURB-65 score and radiological extent of disease had no obvious 






Table 8.1. Characteristics of patients with TB and baseline cough frequency >100 c/24h: 
comparison of participants undergoing serial cough monitoring with the rest of the group. 
Variable 
Participants with TB and baseline cough frequency >100 
c/24h 
 
without seria l  cough 
monitoring 
with serial  monitoring p 
n 10 22  
Sex (female) 3 (30%) 7 (32%) 1.00 
Age 40 (31-43) 41 (30-48) 0.83 
Current smokers 5 (50%) 13 (59%) 0.71 
Other resp dis 1 (1%) 0 0.31 
HIV  2 (20%) 1 (2%) 0.22 
Smear-positive 4 (40%) 18 (82%) 0.037 
Cavities 1 (10%) 12 (55%) 0.024 
Isoniazid-resistant 2 (20%) 3 (15%) 0.64 
 
Va lues are n (%) or median (IQR). 
8.4.2 Pulmonary tuberculosis 
Of the 44 patients with TB, baseline cough frequency was >100 c/24h in 32 (72.7%). 
Twenty-two were willing and available to undergo serial cough monitoring for at least 
48 h. In clinical and demographic characteristics, these individuals were comparable to 
the remaining 10 participants, apart from the fact that they were more likely to be 
sputum smear-positive and have evidence of cavitary disease (Table 8.1). All patients 
were eventually treated successfully. The median baseline cough frequency of these 22 
patients was 375 (222-695) c/24h. 
 
As shown in Figure 8.3, 24-hour cough frequency in the majority of patients with TB 
declined consistently during therapy with an overall significant improvement of 37.0% 
in the geometric mean value by one week (95% confidence interval 15.3 to 53.2%, p = 
0.034). However, there was substantial variation; at Week 2 and/or Week 8, five of the 
15 monitored patients had a higher cough frequency than at baseline. Amongst these 
slow responders there was poor adherence to medication with ongoing weight loss (n 
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Top - absolute cough frequency, bottom – relative cough frequency (% of baseline for patients included at time 
point).   Data points: geometric mean ± 95% confidence interval. 





(n = 1), extensive radiographic change at baseline (n = 1), and, in the patient with HIV, 
a persistently positive sputum smear at 8 weeks with minimal radiographic 
improvement. This was despite directly-observed therapy and a therapeutic peak 
blood rifampicin level (>5 mg/L [ref 394]). One other patient had a highly variable cough 
frequency during the first 8 weeks of treatment. There was no evidence for an effect of 
isoniazid resistance, cavitary disease, smear status or smoking on rates of cough 
resolution (data not shown).  
Due to a withdrawal of consent to repeatedly undergo cough monitoring and constraints 
on the time of the investigator, there was loss to follow up and missing data for certain 
time points as indicated in Figure 8.3. 
There was no evidence for a change in diurnal patterns of coughing with treatment in 
this sample but there was large variation: at baseline a median of 23.2 (13.5-43.0) % of 
coughs occurred overnight compared to 16.0 (2.7-53.4) % at week 2 (p = 0.844). 
8.5 Discussion 
Repeated 24-hour cough monitoring with treatment or natural resolution of 
respiratory disease has been only carried performed previously in isolated chronic 
cough43,66 and acute cough79,80 as far as I am aware. TB and acute respiratory diseases 
were chosen in the current study as they are tractable conditions in which a response 
to treatment was expected. This appears to be the first documentation of the 
resolution in 24-hour cough frequency during the entire course of treatment of 
pulmonary tuberculosis.  
In patients hospitalized with acute respiratory conditions, reductions in cough 
frequency after several days’ treatment were investigated and were shown to be more 
likely to occur in successfully-treated pneumonia than in acute asthma or COPD 





8.5.1 Acute asthma, COPD exacerbations and pneumonia 
Over a small time interval (median two days) a significant decrease in cough frequency 
was shown in pneumonia in patients with other indicators of response to treatment, 
an improvement in acute asthma in 3 of 5 patients, and overall no change in patients 
with COPD exacerbations, despite overall clinical improvements in the majority. Cough 
monitoring over this interval therefore seemed to be most useful as a predictor of 
overall treatment response in pneumonia. This was particularly demonstrated by the 
relative correlation of changes in cough frequency to response in CRP in pneumonia 
compared to COPD exacerbations, a marker which in both conditions has been shown 
to reflect disease activity.325,379,395  
The apparently more rapid response to treatment of cough in pneumonia compared to 
the other two acute respiratory diseases is of interest. Differences in the nature of the 
pathology might be important. For example, asthma and COPD are diseases of the 
airway, the site of cough receptors, whereas pneumonia causes parenchymal lung 
changes. Aetiological factors of the acute disease could also be of relevance to 
resolution of cough: bacteria are responsible for the large majority of community-
acquired pneumonia,325 whereas viruses are more frequently implicated in acute 
asthma and COPD exacerbations.68,382,396  
Of probable relevance is the fact that patients with pneumonia in this study otherwise 
had no other known lung disease. Conversely, patients with exacerbations of COPD 
and asthma by definition had chronic respiratory diseases, which in the stable state 
have been objectively shown to be associated with coughing (Section 0).76,78 The 
baseline physiological state in respect to cough will therefore be very different in COPD 
and asthma compared to individuals without chronic respiratory disease who develop 
pneumonia. In this regard it is noteworthy that two of the patients with only mild lung 
function deficits in COPD had the more rapid improvements in cough frequency. 
There were too few patients with acute asthma (n = 5) to make any meaningful 





improvement in cough frequency in the two pregnant women, despite an overall 
clinical response to treatment is of interest. The relationship between asthma and 
pregnancy is complex,397 and the frequency of exacerbations is probably increased.398 
Asthma exacerbations have also been reported to be prolonged in pregnancy, 
although this may have been a result of unnecessary excessive caution with the use of 
corticosteroid treatment in pregnant women in previous practice.399 There was no 
evidence of this in the current study. It has been suggested that the cough reflex may 
be increased in pregnancy, as an adaptation to prevent aspiration.340 Alternatively 
coughing might be more frequent in pregnancy because of (micro-) aspiration and 
gastro-oesophageal reflux. This does not appear to have been investigated, but it may 
be relevant to these current observations. 
The sample size was too small to detect whether current smoking habit was associated 
with a lack of improvement in cough frequency in pneumonia with treatment. 
However, as well as being a risk factor for pneumonia, current smoking is also 
associated with a negative outcome of the disease, independently of disease severity 
and comorbidities.400 The mechanism through which this occurs could also influence 
cough. In the current study it is possible that some of the current smokers with 
pneumonia also had undiagnosed COPD, with an additional influence on cough 
frequency resolution. 
There are no other data on objectively-measured serial cough counts in these three 
conditions with which to compare the current data. Reports of the resolution of 
subjectively-reported cough symptoms in acute respiratory disease are few and varied. 
The duration and resolution of symptom-defined COPD exacerbations has been 
investigated,315,401–403 although cough, classed as a ‘minor’ symptom,380 appears to 
have been researched infrequently in this context. The median time for symptom 
scores to return to baseline following a COPD exacerbation in the community is 
probably 7 or 8 days.315,404 From daily diary cards, cough symptoms (rated by patients 
as ‘increased’ or ‘not increased’,315 or on a severity scale of 0-3 [ref 403]) probably take 





corticosteroids symptoms seem to take 7-10 days to fully resolve,405 but there do not 
appear to be studies looking at resolution of cough in asthma specifically. 
In community-acquired pneumonia a small number of studies, reviewed elsewhere,324 
have prospectively documented the persistence of symptoms following the initial 
diagnosis and appropriate treatment. In one study which regularly assessed symptoms 
following diagnosis in a mix patients who had been either hospitalized or treated in the 
community for pneumonia, cough was reported to take a median of 14 (range, 7-21) 
days to resolve.406 In other series cough persisted in 50% at 30 days,407 and in 32% of 
patients at 90 days.408 The relative severity of cough at particular time points following 
treatment of pneumonia was not reported in any of these studies. 
The limited literature on patient-reported cough therefore suggest a more protracted 
course of symptoms in pneumonia than acute asthma or COPD exacerbations. This 
difference was not reflected in the results of cough monitoring over the first few days. 
Early changes in cough frequency may not reflect the total duration of excessive 
coughing. However, as discussed in Chapter 7, symptoms correlate poorly with 
objective cough frequency in these conditions, particularly acute asthma and COPD 
exacerbations. Patients with no chronic lung disease recovering from pneumonia may 
be more likely to notice frequent coughing which, for them, is a comparatively novel 
symptom. More data from serial cough monitoring in acute respiratory disease over 
multiple time points could be very informative.  
8.5.2 Tuberculosis 
In pulmonary tuberculosis Loudon and Spohn investigated the effect of treatment on 
overnight cough frequency (Section 1.6.4).125 Comparisons between the current study 
and this earlier work are limited by differences in cough monitoring technology and 
the omission of patient characteristics from the short study report.125 However, the 
current study has shown that objective 24-hour cough counts respond to treatment of 





8.4). Cough frequency improved at a similar rate in both studies (by approximately 
40% and 80% after 1 and 8 weeks, respectively).  
Although there was variability, nocturnal cough rates maintained a relatively constant 
relationship to 24-hour cough frequency after two weeks of TB treatment in the 
current work. As was shown in Chapter 7 for measuring baseline cough frequency 
(Section 7.4.2.2), cough recordings overnight in TB might therefore be a more 
convenient surrogate for 24-hour cough frequency measurement to monitor response 
to treatment.  
8.5.2.1 Stability in cough frequency during days 0-2 
No significant change in cough frequency was observed from the first monitoring 
period, started before commencing treatment, and the second period, completed 
within 48 h of receiving the first TB medications, where this occurred. This has two 
implications. The first is practical; for serial cough monitoring a baseline, ‘pre-
treatment’ cough frequency measurement could probably be made at any point within 
the first 48 h of starting treatment with similar results. The fact that the cough 
recording device does not have to be available at the precise point of receiving the first 
dose of medication might increase the utility of serial cough monitoring as a clinical 
 
Left: current s tudy; data points are geometric mean. Right: from Loudon and Spohn (ref 125). Data points are 
means.  
Figure 8.4. Rate of resolution of cough frequency during treatment of TB in current study compared to 
previous work. 
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and research tool in tuberculosis, as long as a recording can be made within the first 
two days.  
The second implication is mechanistic; the lack of change in cough within the first 48 h 
suggests that numbers of live bacteria might not be necessarily directly related to 
coughing in TB. Serial sputum early bactericidal activity analyses during initial 
treatment in drug-sensitive disease,409,410 and the rapid drop in infectiousness 
immediately following the start of treatment118,218 suggest that the majority of 
mycobacteria are killed with the first 24-48 h of TB medication. If Mtb is isoniazid-
sensitive, approximately >90% are probably killed within the first two days (although 
the rate of killing slows down over the following 12 days).411,412 Physical and chemical 
components of bacteria, or substances they release before and after death, along with 
the lung’s inflammatory response might therefore be more important in the 
(unknown) mechanisms of cough in tuberculosis than the direct action of live bacteria.  
Consistent with this idea was the observation that cough resolution was no slower in 
individuals with isoniazid-resistant TB than in those who were isoniazid-sensitive, 
despite a presumably slower decline in numbers of live bacteria without the action of 
this highly bactericidal agent.409 Furthermore, the drug with the most potent 
bactericidal action in standard current regimens during the third to fifth days of 
treatment is rifampicin.411 The availability of this drug in the current study seemed to 
make little difference to the rate of cough resolution over the first week of treatment 
compared to that seen in the older work from the pre-rifampicin era.125 
A large number of secreted proteins and other molecules have been shown to be 
produced by Mycobacterium tuberculosis.413,414 The role of many of these is unknown 
and a role in cough is possible. Secreted antigenic peptides would be of greater 
interest due to a longer half-life than volatile organic compounds given the relatively 
slow resolution of cough in TB compared to the time frame demonstrated here for 





Markers of pulmonary or systemic inflammation were not routinely measured in TB in 
the current study. Although the data in pneumonia showed that the decline in CRP and 
cough frequency might occur over a similar time frame (Section 8.4.1.3), more detailed 
observations would clearly be required to test for a direct role of the host response in 
the mechanism of cough in TB.  
The more rapid decline in cough frequency observed here in pneumonia than in TB 
suggests different mechanisms for cough in the two conditions. Live bacteria, for 
example, may have a greater (direct or indirect) effect on triggering the cough reflex in 
pneumonia. 
8.5.2.2 Variability in cough frequency resolution  
A delayed improvement of cough frequency was seen in some patients with TB in the 
current work (e.g. a third of the monitored individuals had a cough frequency higher 
than at baseline by Week 2 and/or Week 8), and possible reasons for this were 
identified. Loudon and Spohn, in the only other similar previous work to the current 
study, did not discuss possible causes of variation in improvements in objectively-
measured cough frequency with treatment of TB.125 However, a previous retrospective 
study of subjectively-reported cough involving close to 2,000 patients found that 
almost 20% of patients still complained of a productive cough after 24 weeks of 
treatment for pulmonary TB.305 Some had failed treatment or later relapsed, but the 
authors speculate that in the majority this was due to smoking, coexistent chronic 
respiratory disease or irreversible TB-related lung damage. In the current work there 
was no evidence for smoking as either a predictor of baseline cough frequency in TB 
(Section 7.5.1.2.1), or of a cough frequency response to treatment.  
The same previous study estimated the rate of improvement of cough symptoms, 
complete resolution in 50 % of patients after about six weeks.305 Elsewhere, the 
median time to disappearance of subject-reported cough was about 70 days.349 This 
figure fits with an extrapolation from Figure 8.3 in this Chapter; by 70 days, median 





healthy individuals (7.4.2.1.9). However, comparing the two studies is problematic 
given the limited correlation that exists between subjective and objective descriptions 
of coughing (Section 7.4.3). 
8.5.2.3 Further implications of rates of improvement in cough 
There is an urgent need for new biomarkers in tuberculosis, for use as endpoints in 
clinical trials of new tuberculosis drugs and regimens,415 and for individualizing 
treatment, particularly in drug resistant-TB.416 Cough frequency measurement could be 
a useful laboratory-free method of measuring the response to treatment.259 It seems 
to detect resolving disease a lot more quickly than the currently most frequently-used 
clinical measures of treatment response, weight gain,417 radiographic improvement418 
and  sputum microbiological conversion.304 Cough frequency in the current study was 
also sensitive to poor treatment adherence.  
More data are required to correlate changes in cough frequency with other 
established markers of treatment response. A limitation of cough monitoring is that 
not all patients with tuberculosis cough more frequently than would be expected in 
health (only 73% in the current study). However, serial cough frequency might still be 
valuable form a lower baseline, but day-to-day random variation and the performance 
of the cough detection algorithm would become relatively more important. From a 
public health perspective, patients with the highest cough frequencies would in any 
case be the priority for measuring treatment response. Due to increased coughing 
itself, and the possible association with sputum smear positive disease (Section 
7.5.1.3.5), these patients are presumably the most infectious.  
8.5.3 The serial measurement of cough frequency 
Repeated cough monitoring could be a useful and novel tool for measuring responses 
to treatment in respiratory disease. More data are required to take this forward. One 
of the next steps will be to establish variability in day-to-day cough frequency in the 
stable state. This appears to have been done rarely in any context, including isolated 





individual variation in cough frequency in a group of inpatients with tuberculosis, 
pneumonia or chronic bronchitis. On overnight cough recordings on three consecutive 
nights there was much less variation within than between patients, although it was 
more marked in COPD.  These data are however of limited value, being from only 
overnight recordings, and presumably not reflecting a stable state as the participants 
were hospitalized for treatment of their acute lung disease. From baseline variability it 
will also be necessary to establish the minimal important difference in cough 
frequency in lung diseases that correlate with meaningful clinical improvements, as 
has been done in acute cough (by correlation with the main endpoint of symptom 
scores in that context).80 
8.5.4 Limitations 
The need to establish the repeatability of cough monitoring in the stable state before 
embarking on larger investigations of changes in cough frequency with treatment has 
been discussed (Section 8.5.3).  
This exploratory work is limited by small sample sizes in the strengths of its 
conclusions, particularly for acute asthma with only 5 patients. The missing data from 
serial cough monitoring in with TB also precluded more than a speculative 
consideration of reasons for the apparent variability in the rate of change in cough 
frequency. However, an acknowledgement of expected loss to follow up will be useful 
in future studies investigating improvement in cough in TB and other contexts.  
8.6 Conclusion 
Serial cough monitoring could be a useful novel approach to measuring treatment 
response. The varying timeframes over which cough improves with treatment of 






9 TRPV1 polymorphism and phenotype 
in chronic cough 
9.1 Background and aim 
The previous chapters have demonstrated significant variation in objectively measured 
cough frequency and cough reflex sensitivity between individuals, within as much as 
between disease groups. This strongly suggests the presence of as yet uncertain 
factors influencing cough independent of pathological processes. One such factor 
could relate to inherent genetic differences between people. 
The genetic influences on cough patterns have been investigated rarely. Angiotensin 
converting enzyme receptor polymorphism may be important for developing ACE 
inhibitor-induced cough51,419,420 but probably not for chronic cough of other causes,52 
although it may affect cough reflex sensitivity.53  Polymorphism in the tachykinin gene 
NK-2R has been associated with cough reflex sensitivity to capsaicin but not with 
symptoms of chronic cough.54 There do not appear to have been other studies 
comparing objectively-measured cough to genetic variation.  
There has been interest in the TRPV1 (transient receptor potential vannilloid 1) 
channel for its role in the cough reflex (Section 1.3).9,27 The pro-tussive compound 
capsaicin acts through this channel and TRPV1 antagonists reduces sensitivity of the 
cough reflex in human studies.29,30,40 A recent study has identified single nucleotide 
polymorphisms (SNPs) of TRPV1 associated with cough symptoms in a large multi-
centre population.55 Six SNPs located on chromosome 17p13.3 appeared to be of 
particular interest (rs161365, rs17706630, rs2277675, rs222741, rs150854 and 
rs224498): all but two were associated with chronic cough (defined as coughing during 
the day or night on most days for as much as 3 months per year, rs161365 and 
rs224498 were associated only with nocturnal cough), and all but rs222741 were 
associated with cough independently in each of the two large adult cohorts included in 





EGEA,421 and the European Community Respiratory Health Survey, ECRHS422). The 
putative effects of these polymorphisms in objectively-measured cough is not known. 
This Chapter will address the hypothesis that SNPs of TRPV1 are associated with cough 
reflex sensitivity and 24-hour cough frequency in chronic cough.  
9.2 Methods 
This was an observational cross-sectional study carried out at King’s College Hospital, 
London. Participants were patients with chronic cough who had been referred to a 
tertiary care cough clinic by other respiratory specialists or a general  practitioner; 
recruitment criteria and routine demographic measurements are described in Section 
6.3.1. 
The primary outcome variable was cough reflex sensitivity to capsaicin. This was 
measured as C5, the minimum concentration of capsaicin solution required to elicit 
five coughs (C5). Secondary outcome variables were cough reflex sensitivity measured 
as the number of coughs produced following inhalation of 62.5 µM capsaicin solution 
(E62.5; Section 6.1), 24-hour cough frequency (CF-24) and cough symptoms (Leicester 
Cough Questionnaire [LCQ] score and cough visual analogue scale [VAS], score). The 
key predictor variable was TRPV1 genotype. 
9.2.1 TRPV1 genotype 
A saliva sample of approximately 2 ml was taken from each study participant and 
stored at room temperature using Oragene® collection kits (DNA Genotek, Ottowa, 
Canada).423 DNA extraction and analysis were carried out by the Barts and the London 
Genome Centre (London, UK) in order to genotype the six SNPs of TRPV1 of interest, 
rs161365, rs17706630, rs2277675, rs222741, rs150854 and rs224498.55  
DNA extraction was carried out according to the Genome Centre’s protocol, following 
the recommendations of DNA Genotek.424 Oragene/saliva samples were incubated at 
50 °C before a 1000-µL aliquot was taken from each to be mixed with Oragene Purifier. 





ethanol to precipitate out DNA, which was separated out by further centrifugation 
before being dissolved in standard buffer solution. 
For SNP genotyping, purified DNA was run through TaqMan® probe-based polymerase 
chain reaction (PCR) amplification and allelic discrimination assays in accordance with 
the manufacturer’s instructions (Applied Biosystems, Foster City, California).425 A 
fluorogenic 5’ nuclease chemistry technique was used to detect specific PCR product 
following its accumulation during PCR cycles with the use of sequence-specific primers 
and probes corresponding to the five TRPV1 SNPs.426 Automated fluorescence 
measurements from PCR wells revealed the identity of alleles within in each sample.  
9.2.2 Cough variables  
Capsaicin inhalation cough challenge was carried out following international 
guidelines,5 and as described in Section 6.2.2). The values of C5 were calculated by the 
method of interpolation. 24-hour cough frequency (CF24) was measured with the 
Leicester Cough Monitor (LCM), worn by each patient for 24 h (Section 7.2.2), starting 
after the capsaicin challenge. Before capsaicin challenge testing, participants 
completed the LCQ (for measurement of cough-related quality of life) and rated the 
severity of their cough in the previous two weeks with a visual analogue scale (Section 
4.2.2).  
9.2.3 Statistical methods 
A priori estimation of sample sizes for detecting an association between TRPV1 
polymorphism and cough sensitivity and frequency was difficult without knowledge of 
the expected effect of allele frequency on cough characteristics. From previous work 
the background minor allele frequency for all the SNPs of interest was assumed to be 
approximately 0.35.55 In accordance with the Hardy-Weinberg principle, homozygotes 
for the minor allele genotype for each SNP were assumed to be present at a frequency 
of 0.12, heterozygotes 0.46,  and major allele homozygotes 0.42 in the background 





null hypothesis that the TRPV1 SNP genotype distribution in patients with chronic 
cough is no different from that in the background population, it was therefore 
estimated that about 28 major allele homozygotes for each SNP would be recruited, a 
total of 32 individuals with the two other genotypes (heterozygous or minor allele 
homozygous).  
The minimally clinically important difference in C5 has not been explicitly defined. 
Despite this, on repeat testing with a standard capsaicin challenge protocol of s erial 
doubling concentrations of solution, 85% of healthy individuals produce values for C5 
within one doubling concentration of the initial value.242 A difference of >1 doubling 
concentration is therefore probably clinically important. Practically, due to the way in 
which the test is performed, a difference of less than this would be difficult to detect in 
any case. 
The mean and SD of C5 in isolated chronic cough were not explicit in the existing 
literature, but other studies using C5 as an outcome variable in chronic cough have 
used sample sizes of 20-30 in each comparator group.40,267,427 The power of the study 
to detect a difference in C5 between genotypes for each SNP was therefore unknown a 
priori. The sample size of 60 was chosen primarily because of feasibility, time and 
resources for this pilot study. 
Univariate analysis was performed for each SNP in two ways. For a between-group 
comparison, patients were divided into three groups according to genotype (minor 
allele homozygous, heterozygous or major allele homozygous), and the non-normally 
distributed outcome variables were compared to look for differences with Kruskal-
Wallis tests. Univariate linear regression analysis was also performed for each SNP 
after normalising data (where necessary) with either a square root or logarithmic 
transformation, as appropriate.  This tested for a dose response of numbers of copies 
of the minor allele for each SNP under the assumption their effects were additive.55 A 
possible confounding effect of ethnicity was tested by including this variable (white vs. 





Values are median (IQR). 
After genotype data had been provided by the Barts and the London Genome Centre, 
all further data analysis was carried out by the author. 
9.3 Results 
57 patients were recruited with chronic cough; 38 with unexplained chronic cough and 
19 with cough secondary to other diagnoses. Participant characteristics are described 
further in Chapter 6 (Section 6.3.1, Table 6.1). 
The process of saliva collection, DNA purification and genotyping on the whole was 
successful. All 57 study participants donated saliva; adequate DNA samples were 
extracted for analysis of at least the majority of SNPs from 54 patients. Genotyping 
results were achieved for the following numbers of individuals for each SNP: rs161365, 
54; rs17706630, 54; rs2277675, 54; rs222741, 53; rs150854, 51 and rs224498, 54.  
Table 9.1. Capsaicin sensitivity, 24-hour cough frequency TRPV1 genotype; between-group analysis. 






























































































































































































































9.3.1 Genotype and objective measures of cough 
There was no evidence for an association between TRPV1 polymorphism and either 
the primary endpoint, C5, or the secondary objective endpoints, E62.5 or CF24. This was 
the case both for Kruskal-Wallis analyses of differences between pairs of genotypes at 
an individual locus (Table 9.1), and regression analyses to test for a dose response of 
number of copies of each minor allele (Table 9.2). There were trends for lower cough 
reflex threshold and higher CF24 in women than men (Table 9.1). Similar results were 
observed by including ethnicity in the regression analyses.  
Table 9.2.Capsaicin sensitivity, 24-hour cough frequency and TRPV1 minor allele status; regression analysis. 
SNP 

















(-1.07 to  0.31) 
0.277 -0.05 
(-0.24 to 0.14) 
0.601 -0.24  





(-1.31 to 0.63) 
0.487 -0.14  









(-0.68 to 0.89) 
0.795 -0.005 
(-0.22 to 0.21) 
0.964 -0.25  





(-0.31 to 1.08) 
0.274 -0.06  
(-0.24 to 0.12) 
0.58 -0.14  





(-1.18 to 0.61) 
0.525 0.04 













(0.11 to 0.28) 
0.401 0.10  
(-0.38 to 0.57) 
0.684 
 
9.3.2 Genotype and cough symptoms 
There was no evidence for an association between TRPV1 polymorphism and cough-




Values from logistic regression analyses testing for relationships between each variable and the number of copies of each 





Table 9.3. LCQ scores, VAS scores and TRPV1 genotype; between-group analysis. 





































































































































































Table 9.4. Cough symptom scores and TRPV1 minor allele status; regression analysis. 
SNP 













(-18.58 to 5.17) 
0.261 0.41 





(-20.98 to 13.72) 
0.676 -0.14  





(-8.31 to 18.66) 
0.443 -0.23  
(-1.92 to 1.46) 
0.788 
rs222741 -1.58 
(-12.5 to 9.31) 
0.771 0.86  





(-19.4 to 9.08) 
0.469 0.46  





(-17.3 to 5.02) 
0.274 0.49  




Values are median (IQR). 
Va lues from logistic regression analyses testing for relationships between each variable and the number of 






These data do not support the hypothesis that TRPV1 polymorphisms influences either 
cough reflex sensitivity to capsaicin, 24-hour cough frequency or cough symptoms in 
patients with chronic cough. However, the findings need to be examined in view of the 
power of the study. 
9.4.1 Statistical power 
Mean and SD log10 C5 values of all patients in the current study were 0.901 and 0.502, 
respectively (corresponding to 7.96 and 3.18 µM). For a two-sided α value of 0.05 and 
a power of 0.80, 44 patients would be required in each comparator group to detect a 
difference at least as large as one doubling concentration of C5 between them.309  
The mean frequency of minor allele homozygotes in the current study was 0.09. 
Therefore, on the assumption that the current study sample was representative of all 
patients with chronic cough, in order to expect approximately 44 patients to be minor 
allele homozygous for each of the TRPV1 SNPs of interest, 489 study participants with 
chronic cough would be required. However, based on the observed overall mean 
minor allele frequency of 0.41 and assumptions of the Hardy-Weinberg principle, the 
expected frequency of minor allele homozygotes was 0.16 (not statistically different 
from that observed; Fisher’s exact test, p = 0.391). This would suggest a minimum 
necessary total sample size of 275 participants.309 
Therefore for simple statistical tests of comparisons between groups, the current study 
was underpowered to exclude the possibility of an association between C5 and the 
minor allele homozygous state for each of the SNPs. For the mean sample size of 5 
minor allele homozygous the power was 0.05 for α = 0.05, although 0.40 for α = 0.23 
(corresponding to the lowest value of p from Kruskal-Wallis tests of differences in C5 
according to genotype).309 
Despite this, due to the high mean p-values (α = 0.23) for tests of differences in C5 





adequate to compare the major allele dominant homozygous with the heterozygous 
genotype for each SNP: 0.79 for the mean group sample size of 24.309)  
Similar conclusions can be made for the other study endpoints – despite relatively 
small sample sizes, the large p-values suggest that a clinically meaningful difference in 
E62.5, 24 cough-frequency, LCQ and VAS scores between heterozygotes and individuals 
homozygous for each of the major alleles of the SNPs studied is unlikely, but very small 
numbers limit interpretation of the possible effects of the minor allele homozygous 
states.  
However, if the assumptions of other authors are followed that any phenotypic effects 
of TRP minor alleles are additive,55,428,429 the current study does give evidence against a 
large effect of the minor allele homozygous states; the confidence intervals associated 
with the regression coefficients on testing for an additive dose effect of each minor 
allele on cough measurements were wide and all include zero (Table 9.2, Table 9.4) 
9.4.2 TRPV1 polymorphism and cough 
Why an association between subjectively-assessed cough and TRPV1 genotype was 
observed in the previous study but not in the current work may be either due to either 
limitations of statistical power, differences in the study samples, or differences in the 
methods of assessing symptoms. The study of Smit et al. included a large population 
sample made up of a mixture of individuals with asthma and healthy volunteers in 
whom chronic cough was relatively rare,55 compared to a relatively small number of 
patients from a hospital clinic who all had chronic cough in the current work.  
Several simple binary measures were the outcome for symptoms in the previous study; 
the presence or absence of ‘usual’ cough, nocturnal cough and chronic cough. The 
presence of chronic cough was defined as a positive response to the question “Do you 
cough first thing in the morning on most days for as much as three months each 
year?”.55 Such a question would have produced a positive response in the large 





questionnaire (the LCQ226) and a cough visual analogue scale to quantify the personal 
impact and severity of cough symptoms. 
Although the current findings are constrained by small sample sizes, inherent reasons 
why TRPV1 variation may not be associated with objectively-measured characteristics 
of cough, at least amongst patients with chronic cough, should be considered, 
particularly in light of an association with the presence or absence of cough symptoms 
in a large population study.55 
Firstly, cough symptoms have been noted for a long time to have a weak correlation 
with objectively-measured characteristics of coughing (Section 4.5.4). It was reported 
almost 50 years ago that there was poor association between cough frequency in 
respiratory disease and response to the question “do you have a cough at the present 
time?”.88 TRPV1 polymorphism may therefore affect the noticeability or memorability 
of coughing in a manner that is independent of the objective variables measured in the 
current study. TRPV1 polymorphism may, for example, impact on the force of 
coughing, or may even have no impact on the physical characteristics of coughing at 
all, only on the subjective awareness of cough. The absence of any observed 
association between genotype and the severity of symptoms however makes this 
unlikely. 
Alternatively, TRPV1 polymorphism could affect cough in manner which is subtle. Such 
effects may not be detectable in a group of individuals who experience cough on a 
frequent basis, due to other underlying influences on cough, but may only become 
apparent in general population cohorts. 
A problem with studying genetic influences on cough is that phenotypes are not static 
over time. Isolated chronic cough usually responds to treatment335 and can resolve 
spontaneously64 or in response to placebo67 and behavioural training.65 TRPV1 
receptors are upregulated in chronic cough,28 but also in response to rhinovirus34 and 





measured over multiple time points in the investigation of potential genetic influences 
on the response of the cough reflex to different stimuli and respiratory insults. 
There has recently been a decline in the interest of several years ago into the role of 
TRPV1 in the cough reflex.31 Although TRPV1 antagonists appear to reduce cough 
reflex sensitivity to capsaicin in patients with chronic cough, this has not been coupled 
with an effect on cough symptoms or objectively-measured cough frequency.40 Despite 
the fact that TRPV1 receptors are involved in the cough reflex, at least when triggered 
experimentally, their exact role in the complexity of spontaneous coughing is unclear.   
Angiotensin-converting enzyme receptor polymorphism seems to be important for 
developing ACE-inhibitor-induced cough.51,419,420 Other genetic influences on cough 
have been demonstrated rarely, although effects on cough reflex sensitivity to 
capsaicin are similarly not necessarily associated with differences in the amount of 
noticeable coughing.54 Study of the genetic variation in cough is  important as it may 
lead to improved understanding of mechanisms and novel approaches to controlling 
cough. The study of Smit et al. is the only of which I am aware which has attempted to 
compare polymorphisms affecting known components of the cough reflex to reported 
cough in a large population cohort. SNPs in TRPV4 and TRPA1 were also investigated in 
the same study but were shown not to be associated with the reported presence of 
cough.55  
Further large epidemiological studies of potentially important polymorphisms should 
be undertaken to identify other SNPs which could be tested against objective cough 
measures in smaller clinical studies. One gene of interest might be P2X3, coding for an 
ATP-gated ion channel, the blocking of which appears to be very effective in reducing 
coughing in some, but not all patients with unexplained chronic cough.43,431 
Alternatively, large case-control genome-wide association studies could be performed 







Small sample size has been discussed, which led to a paucity of individuals in the study 
homozygous for the minor allele variants of each of the TRPV1 SNPs, and therefore a 
limitation on any conclusion about associations with these genotypes.  
The inclusion only of patients with isolated chronic cough was also a limitation. Cough 
in other diseases, such as tuberculosis, may have different underlying mechanisms, 
perhaps of much greater relevance for TRPV1 polymorphism. It is possible that 
secreted antigens from Mycobacterium tuberculosis (Section 8.5.2.3) act via the TRPV1 
receptor, although this has not been investigated. Performing cough challenges in 
tuberculosis would be more complicated due to problems of infection control, and the 
need to account for any effects of treatment on cough in TB.  
The inclusion of healthy volunteers may have added power to the study and would 
have allowed the presence of cough to be used as a binary outcome variable, as in the 
earlier population study.55 However due to predicted very low 24-hour cough 
frequency, a very large sample would be required to test for influences on this 
outcome variable in healthy subjects. 
Although C5 has been used as an outcome variable in many other studies, is 
recommended for this purpose by guidelines,5 and is stable over time in healthy 
volunteers242 its use is limited by a lack of evaluation of repeatability in chronic cough, 
and it has been criticised for a lack of discrimination between health and disease 
(Section 6.1).85 24-hour cough frequency as an endpoint similarly does not appear to 
have been assessed for repeatability over time in the stable state in chronic cough and 
chronic cough (Section 8.5.3). E62.5 is a novel study endpoint introduced in this thesis 
with possible advantages over C5 but awaits further evaluation (Section 6.3.2).  
Technical problems led to an inability to obtain any genetic data from the samples of 
three study participants and a partial lack of data from a further four. However, this 
yield is probably similar or higher than might have been expected if blood or buccal 





Compared to sampling blood, collecting saliva is convenient and painless and has been 
reported to result in extracted DNA of similar quality and quantity to that from 
sampling blood.434 
9.5 Conclusion 
This is the first study to compare TRPV1 polymorphism to objectively-measured cough 
variables, and one of very few pieces of work to investigate the genetic determinants 
of cough. Although the number of participants was small, in chronic cough no 
relationship was observed between each of six SNPs of TRPV1 and objectively-
measured cough phenotypes. TRPV1 polymorphism is unlikely to have a large clinically 
important effect amongst patients with isolated chronic cough. This pilot work should 
be repeated in a further study involving a larger number of participants with and 













10 The measurement of airborne 
particle concentrations during 
coughing and other respiratory 
actions 
10.1 Background and aims 
Tuberculosis is the archetypical aerially-transmitted infectious disease and coughing is 
assumed to be the way in which the majority of infectious particles are produced. 
However, the comparison of coughing with other respiratory actions has been rarely 
investigated in the same study. Comparing studies is difficult due to the variety of 
techniques used for particle measurement (Section 1.5.2). The pattern of coughing 
may also be relevant, for example whether coughs occur singly or as part of a 
prolonged coughing bout, as may physiological parameters, in particular peak 
expiratory flow rates and the duration of the expiratory cough phase. These variables 
have not previously been assessed in relation to the generation of exhaled particles as 
far as I am aware.   
The particle size of interest is 0.5-10 μm as this is the theoretical diameter required to 
access the alveoli upon inhalation and is also thought to be the size that will remain in 
airborne suspension without being affected by gravity (Section 1.5.2.1).  
For logistical and ethical reasons, the direct observation of the aerosolization of 
Mycobacterium tuberculosis from the respiratory tract in patients with pulmonary 
tuberculosis is difficult as previously discussed (Section 1.6.2.5). Apart from the 
complexity of directly detecting airborne Mtb,202 studying this phenomenon would 
need to involve patients with untreated smear-positive pulmonary tuberculosis since 
effective antibiotics seem to render TB non-infectious very quickly.435,436 Although 
possible,126 involving such patients entails a risk of cross infection, and deliberately 





large majority of studies on the production of airborne respiratory droplets or droplet 
nuclei (from here on together referred to as particles)involve healthy volunteers only, 
on the assumption that in infectious disease at least some of these particles would 
contain microbes.127 
Various methods have been employed to attempt to measure airborne particles 
expelled from the mouth, but among the most reliable seem to be modern techniques 
which involve laser particle counting equipment (Section 1.6.2.5.4).127 A simple 
method recently used by Lai et al. used a handheld laser particle counter (Lighthouse 
5016) in a room to demonstrate that far higher numbers of airborne particles are 
produced by blowing on a vuvuzela, a type of plastic horn, than by shouting.163  
The objectives were, 
1. to investigate the potential of a simple technique for measuring airborne 
particles produced during respiratory actions which would be applicable to a 
normal clinical environment and,  
2. if meeting the first objective, to compare the concentrations of particles 
released from the mouth during coughing, and from different types of cough, 
with those released during other actions at different distances form the 
subject.  
The key hypothesis being tested was that coughing releases more respiratory particles 
than other actions. 
10.2 Methods 
10.2.1 Study design, setting and participants 
This was an observational pilot study carried out at Homerton University Hospital, 






The concentration of airborne particles measured at a controlled distance from the 
mouth of diameter >0.3 μm was the outcome variable. The main explanatory variable 
was nature of the expiratory activity: silent breathing, speech at normal conversational 
volume and at high volume, and several patterns of coughing. Potential confounding 
variables were sex, age, smoking and lung function. 
10.2.3 Data sources 
10.2.3.1 Particle counter 
Airborne particles were measured with a portable laser diffraction counter, Lighthouse 
3016 (Lighthouse Worldwide Solutions, California, USA). The apparatus met the 
International Organization for Standardization standard ISO 21501-4 concerning the 
detection and sizing of particles measuring 0.1-10.0 μm.437 It measured in the range 
0.3-25.0 μm using the following diameter range categories: ≥0.3 to <0.5, ≥0.5 to <1.0, 
≥1.0 to <3.0, ≥3.0 to <5.0, ≥5.0 to <10.0, and ≥10 μm. Although the device was used 
routinely for measuring the level of airborne particulate contamination in industrial 
cleanrooms, a very similar piece of equipment (Lighthouse 5016) has been used in a 
previous study for measuring exhaled particles close to the subject during shouting 
and blowing on a vuvuzela as mentioned above.163 The Lighthouse 3016 and 5016 are 
identical pieces of equipment apart from the fact that the 3016 has a lower minimum 
particle detection limit, 0.3 compared to 0.5 μm for the 5016. To my knowledge there 
has been no comparison of this device with other methods of measuring particles 
produced during respiratory activities.  
10.2.3.2 Room particle measurement 
The particle counter was placed at a sitting head height in the centre of a clinic room of 
length, width and height 4.28, 2.30 and 2.62 m, respectively, with the study subject 
(this author) sitting facing the machine at a distance of 1.7 m from it (Figure 10.1). This 
distance was chosen to exclude larger droplets released from the mouth which should 





the cough air jet, assuming a cough velocity of approximately 10 m/s, and the other 
conditions discussed in Section 1.5.4, including RH 50% and ambient temperature 20 
°C (Section 1.5.4.2). The machine took measurements every 2 s over a one-minute (30-
cycle) period on three occasions whilst the subject carried out the following actions: 
1. silently sitting with mouth closed;  
2. silently walking around room;  
3. loudly talking (counting) whilst seated; 
4. openly coughing repeatedly into room;  
5. coughing repeatedly into his hand;  
6. coughing repeatedly whilst wearing a surgical mask;  
7. coughing repeatedly while wearing a filtering face protector (FFP)-3 mask. 
Between each one-minute measurement period the total room air volume was 
changed by vacating the room and running the negative pressure ventilation 
(operating at 12 air changes/h) for 5 min. The subject repeated all the actions once. As 
control measurements, particle counts were also taken from the empty room (after 
changing the room air volume), and during the nebulization of normal saline, using a 
Medix AC2000 nebulizer (Clement Clarke International, England). According to the 
manufacturer,438 the median aerodynamic diameter of nebulized particles was 3.4 μm 





with 72% of particles <5 μm. Repeat measurements were taken from the empty room 
several hours after the first. Mean room particle concentrations were calculated for 
each corresponding activity. 
10.2.3.3 Near-subject particle measurement 
Whilst seated, participants carried out each of the actions listed below for 5 s. On 
every occasion, the participant held up the smaller end of a horizontal truncated 
hollow paper cone to their mouth. The particle counter was positioned at the other 
end of the cone and it took one measurement every second. In between actions the 
subject removed the cone from the mouth for several seconds. After reviewing interim 
data, the size of the cone was changed part way through this study in order to try and 
amplify any differences between activities. The first was of length 45.0 cm, diameter of 
smaller opening 10.0 cm, and diameter of wider opening 26.0 cm, the second cone had 
dimensions 14.0 x 1.6 x 5.0 cm, respectively (Figure 10.2).  
The cycle of actions was performed three times for each subject, maintaining the cone 
configuration the same throughout. Particle measurements were also taken for 5 s 
from the end of the empty cone in between cycles. The instructions to the participants 
were as follows:   
1. sit silently and breathe through your nose (for larger cone) or mouth (for 
smaller cone); 
2. count upwards from one at a normal speaking volume; 
3. count upwards from one at a loud speaking volume; 





5. cough four times in one full breath. 
 
Figure 10.2. Positioning of truncated cone and particle counter during near-subject measurement of airborne 
particles from respiratory actions. 
The peak, rather than the mean, airborne particle count during each action was taken 
for analysis. This was on the basis that the mean particle concentration during the 5 s 
activity may have included measurements, particularly at the beginning of the of the 
episode during nasal or mouth breathing, which did not include particles released from 
the respiratory tract, due to the time taken to travel down the cone. 
10.2.3.4 Other measurements 
Study participants wore a digital audio recorder and microphone during particle 
measurement in order to count the number of coughs. Subjects’ peak expiratory flow 
rate (PEFR) and peak cough flow rate (PCFR) were measured with a portable peak flow 
meter (Mini-Wright Standard Range EU Scale, Clement Clarke International, 
England)439,440 before proceeding with the particle measurements. The ambient 
temperature and relative humidity were also recorded with the in-built thermometer 
and hygrometer of the particle counter. 
10.2.3.5 Bias 
Blinding the participants to the type of activity they were performing was not possible, 





10.2.3.6 Study size 
There were few data on which to estimate variation for calculating a minimum 
necessary sample size for this part of the study. Based on the closest similar study to 
this163 I planned to involve a minimum of eight participants. 
10.2.3.7 Statistical methods 
For the data from room particle measurement, particle counts for pairs of scenarios 
were compared with two-sample t-tests, after verifying that data were normally 
distributed. 
For near-subject particle measurements, the mean peak readings from the three 
attempts at each activity were taken in each subject for each cone. The mean 
difference in this value between pairs of actions across participants was ca lculated and 
tested for a statistically significant difference from zero in each case with one sample t-
tests after testing for a normal distribution in the data.  
10.3 Results  
10.3.1 Room particle measurement 
Comparing room particle concentrations during open coughing and quiet sitting there 
was no difference for three of the particle size ranges (Figure 10.3, Table 10.1). For 
each of the ranges >0.3 to ≤0.5 μm, >0.5 to ≤1.0 μm and >1.0 to ≤3.0 μm, however, 
airborne particle counts were significantly lower during open coughing to quiet sitting. 
There was no significant difference in counts on comparing coughing to talking for two 
size ranges. For each of the >3.0 to ≤5.0 μm, >5.0 to ≤10.0 μm and >10 μm size ranges, 
however, room particles counts were lower during coughing, and for >0.3 to ≤0.5 μm 
counts, were higher whilst the subject was coughing compared to during talking. 
For all size ranges, measured room particle concentrations were significantly lower in 
the presence of the sitting subject compared to in the empty room. Wearing a surgical 





- ≤0.5 μm and >0.5 - ≤1.0 μm particles and higher concentrations for all other particle 
size ranges compared to coughing openly into the room (Table 10.1, Figure 10.3). 
Counts were substantially raised during the nebulisation of sal ine for all particle sizes 
(p < 0.001, Table 10.1).  Repeat measurements from the empty room several hours 
after the first revealed a large increase in particle concentrations (p < 0.001; Table 
10.1). The room temperature ranged from 23.0 to 24.6 °C. Ambient humidity also 
varied, from 39.8%, when the room was empty, to 50.0% during the nebulisation of 
saline. The peak cough flow rate of the subject was 410 L/min (6,833 cm3/s). As the 
cylindrical mouthpiece of the peak flow meter was of diameter 2.8 cm, the 
corresponding cough flow velocity through the mouthpiece was 11.1 m/s. 
The variation in room particle measurements was high during each activity. This was 
particularly the case for particle ranges ≥1.0 µm, where the relative standard deviation 






 Table 10.1. Room particle counts during expiratory manoeuvres by one subject. 
Values are mean (±SD) particle counts /L. 
 
Figure 10.3. Mean (SD) Room particle counts during expiratory manoeuvres from one subject. 















































































































































































10.3.2 Near-subject particle measurement 
The larger cone was used by 11 participants (2 current smokers; 4 female) and the 
smaller cone by 8 (no current smokers; 5 female). For the participants using the larger 
cone, median (IQR) age was 31 (27-33) years, mean (SD) PEFR 591 (155) L/min and 
PCFR 390 (124) L/min. For the smaller cone experiments these values were 37 (31-54) 
years, 523 (217) L/min and 322 (135) L/min, respectively.  Measured mean PCFR was 
lower than PEFR (p = 0.0005 and 0.004, for subjects using the large cone and small 
cone, respectively). The mean peak particle counts at the exit of the cones are shown 
in Table 10.2 and Table 10.3. A crude visual inspection of the data gives no indication 
of a difference in the distribution of particle sizes between respiratory activities. Only a 
small minority of the observed differences in mean peak particle counts between 
activities were statistically significant (Figure 10.4). For example, counts were lower for 





compared to counting loudly through the larger cone, and significantly fewer particles 
were counted for half of the size ranges during counting at normal volume than during 
breathing into the smaller cone.  
Table 10.2. Peak airborne particle counts at exit of larger cone during respiratory actions. 
 
   
Values are mean (±SD) particle counts /L from measurements in 11 volunteers. Bars on right correspond to the 
same particle size ranges as in the columns and ordered in the same sequence with a logarithmic scale on the 











Table 10.3. Peak airborne particle counts at exit of smaller cone during respiratory actions. 
Values are mean (±SD) particle counts /L from measurements in 8 volunteers. Bars on right correspond 
to the same particle size ranges as in the columns and ordered in the same sequence with a logarithmic 













Figure 10.4. Mean (SD) differences in peak airborne particle counts at exit of cone during selected pairs of 






10.4.1 Room particle measurement 
The significant differences observed in room particle concentrations at different times 
are difficult to explain by considering only the type of action performed by the subject. 
The finding that concentrations of particles measuring <3.0 μm decreased during 
coughing compared to sitting in silence was unexpected. On comparing coughing to 
talking, there was either a reduction or no significant difference in particle 
concentrations; only for the ≥0.3 to <0.5 μm range was coughing associated with 
higher particle concentrations. This also appears counter-intuitive, although Morawska 
et al. found exhaled particle concentrations to be higher during talking to coughing.150 
However, in that study the type of cough was described as a mild throat clearing rather 
than a loud open cough, as in the current work.   
Wearing a surgical mask was associated with a statistically significant increase in room 
particle counts during coughing for the four larger particle size ranges. I would not 
necessarily expect surgical masks to affect the release of particles of a smaller size, as 
they are carried in air leaks around the edge of the mask,290,441 but surgical masks 
should eliminate some of the larger particles released while coughing, as they have 
been proven to reduce the transmission of tuberculosis from infectious source 
cases.222  
Compared to readings taken from the empty room, the observed drop in the 
concentration of airborne particles associated with the presence of the subject could 
have been due to electrostatic attraction between particles and the subject or his 
clothes.442 Electrostatic forces could also be relevant specifically for the aerial 
movement of microorganisms yet have received little attention.443,444 For example, the 
amount of clothing worn and types of fabric used might have an impact on the 
airborne transmission of infection, in turn influenced by climate, housing, socio-






These apparent paradoxical findings could all be explained by fluctuations in the 
background particle count, rather than by the nature of the activity performed. The 
large increase in particle counts with nebulized saline supports the reliability of the 
measurement device, yet the difference in particle counts in the empty room at 
different times suggests large variability in ambient particle concentrations. The clinic 
room in which the measurements were taken was situated at the front of the hospital 
near the car park in a large city. Changing the air in the room in between activities 
during the study with the negative pressure ventilation, although intended to remove 
any particles generated by the subject, would have accelerated the movement of 
particles into the room. Airborne particles generated by vehicles and other sources 
outside the room therefore presumably had a strong influence on the observed wide 
variability in particle counts.  
The method of attempting to measure particles released from the mouth in a clinic 
room at a distance of 1.7 m away therefore seems to have been flawed, mainly due to 
the dilution by the much larger concentrations of particles already in the room, which 
appeared to fluctuate due to external influences.  
10.4.2 Near-subject particle measurement 
Attempting to measure released airborne particles  closer to a subject should have 
been a more sensitive method due to greater concentrations compared to 
measurements taken further away. However, few significant differences in peak 
concentrations of any airborne particle size range close to the mouth were detected 
when comparing pairs of respiratory actions across a group of volunteers. The majority 
of these significant differences were also counterintuitive. For example, it appeared 
that, for most size ranges, fewer particles were released from the larger cone when 
counting loudly compared to counting at normal volume, and that fewer particles were 
released from the smaller cone when counting at normal volume than during quiet 
breathing. Also, for the smaller cone, the highest counts of particles of diameter >1.0 





during breathing. However, due to a lack of adjustment for multiple statistical 
comparisons (e.g. with a Bonferroni correction), it would be expected that some of the 
observed differences would have appeared significantly different at the 5% level by 
chance alone.  
These findings are in contrast to other recent work, most notably that of Morawska et 
al.,150 but also of others,127,153,163 who have shown talking and coughing to produce 
higher particle concentrations than breathing.  The methodology used in the current 
study was different to the majority of other work. In particular, background aerosol 
particles were not eliminated. This has been done in other work using high-efficiency 
particulate arrestance (HEPA)-filtered air,445 a specially-constructed experimental 
rig,150 a biological safety cabinet,153 or a clean room.283 Consequently, particle 
concentrations of diameter 0.3-20 μm measured during coughing by Morawska et 
al.150 were almost 60 times lower than those measured in one part of the current study 
for the same size range (c. 460/L  compared to 27,070/L at the exit of the larger cone). 
As with the room measurements, the near-patient airborne particle counts would have 
been influenced by fluctuations in background particle concentrations. 
However, other work which has not eliminated background air particle counts has 
achieved positive results. In particular, the study of Lai et al. used a technique almost 
identical to the current work with a very similar particle counter (Lighthouse 5016) for 
measuring peak particle concentrations whilst shouting into a paper cone compared to 
blowing through a vuvuzela.163 The study environment was a ‘closed room free from 
drafts’, with no mention of removing background particulate matter with a HEPA filter, 
and the laser particle counter was placed at the exit of the vuvuzela or cone. It was this 
earlier study which inspired to the methodology for the current work. Mean peak 
particle concentrations in the size range 0.5-25.0 μm were >175 times greater when 
participants blew on the vuvuzela than when shouting (658,000 vs. 3,700/L).163  The 
reason that the methodology worked for Lai et al. was presumably simply because the 
number of particles produced by the vuvuzela was so great that the method of 





the current study actually add weight to the findings of Lai et al. by suggesting that the 
vuvuzela can produce more particles than coughing or shouting; the same method 
which showed a large difference in particle production between shouting and blowing 
the vuvuzela failed to show a difference between loud talking and coughing. By 
contrast, in order to demonstrate differences in particle productions between simpler 
respiratory actions, a more sensitive measurement technique is presumably required, 
namely one that accounts for background aerial room particles . For example the 
difference in airborne particle counts released into a rig containing HEPA-filtered air 
from nasal breathing and coughing  was approximately 30 vs. 460/L in the study of 
Morawska et al.150 (a factor of 15.3), whereas the total background airborne particle 
count in one part of the current study was almost 27,000/L with a standard deviation 
of 6,750/L.   
Because the initial objective of the study was not met, to validate the handheld 
particle counter for measuring particles released from the respiratory tract in a normal 
clinical environment, I did not attempt to investigate the effects of cough flow rate, 
participant gender, age and smoking on particle production. Other methodology, such 
as the HEPA-filtered experimental rig of Morawska’s et al., would be more suitable for 
this purpose.150 As that system is enclosed from the surrounding environment it also 
has the advantage of having fewer problems with infection control than an open room 
if directly studying potentially transmissible disease. The same research group have 
used the apparatus on patients as well as healthy volunteers, specifically to observe 
the aerosolization of Pseudomonas aeruginosa in cystic fibrosis.446 This could serve as a 
very useful model for studying the patterns of cough and other respiratory actions in 
relation to the aerial release of other pathogens, and could potentially be adapted 
directly to study tuberculosis, although airborne Mtb is more difficult to detect than 
Pseudomonas,202,447 particularly when the average rate of airborne release infectious 






In contrast to other work with healthy volunteers, peak cough flow rates in this study 
appeared lower than peak expiratory flows rather than the other way round.448 This is 
probably an artefact of the measurement technique; recent work has suggested that 
hand-held peak flow meters underestimate cough flow peak rates when compared to 
readings made with a pneumotachograph.440  Accelerations in flow rates during the 
expulsion of air are greater during a cough than during forced expiration.440,448 The 
inertia and friction acting against movement of the sliding pointer of the Mini Wright 
peak flow meters is therefore more likely to be a problem during a cough than during 
forced expiration.   
The results of this study, in common with a number of others investigating airborne 
particle production during respiratory actions, are only applicable to healthy 
volunteers. However, this does not detract from my main conclusion that a detailed 
investigation of this type should attempt to eliminate background aerial particles, 
whether using patients or healthy controls. 
10.5 Conclusions 
In the majority of circumstances, a simple hand-held laser counter was not suited for 
the measurement of particles released from the respiratory tract into ambient air by 
healthy volunteers. For further investigation into the role of respiratory activities on 
the aerosolization of material from the respiratory tract, closed systems which 






11 Cough in pulmonary tuberculosis 
and household infection 
11.1 Background and objectives 
The transmission of tuberculosis is determined by a complex interaction between a 
number of factors affecting the infectiousness of the source case, the chance of the 
environment permitting the aerial transit of viable M. tuberculosis (Mtb), and the 
susceptibility of others to new infection. Other than the bacterial status of the sputum, 
data relating to the determinants of source case infectiousness are few.200 The subject 
of this thesis, coughing, is assumed to be important in the transmission of TB, but this 
has not been directly proven. The single previous study involving cough frequency 
monitoring was limited by measuring only nocturnal cough counts. It found only a 
statistically insignificant trend for a measure of infectiousness with cough frequency 
which was not necessarily independent of the stronger predictors of infectiousness, 
sputum smear and culture status, and radiological extent of disease.125 Another study 
has shown that subjectively more severe coughing is associated with Mtb 
transmission.234 However, as has been demonstrated in earlier chapters  (Section 7.4.3) 
subjective interpretations of coughing correlate poorly with objective measurements. 
This chapter with describe the investigation of the following hypotheses: 
- index case-reported cough in TB is a predictor of Mtb exposure amongst household 
contacts; 
- 24-hour cough frequency is a determinant of the infectiousness of tuberculosis. 
11.2 Methods 
This was an observational study, part retrospective and part prospective, carried out at 





11.2.1 Household contacts 
The household contacts of patients notified with TB were screened for Mtb infection at 
Homerton University Hospital as part of routine care as recommended by national 
guidelines.327 Their data were extracted from medical records retrospectively. 
Household contacts were defined as individuals living in the same house as the index 
case and sharing a bedroom, kitchen, bathroom or sitting room.327 Demographic 
characteristics were noted, particularly those with previously-reported associations 
with risk of acquiring Mtb infection, including ethnicity, age, country of birth, HIV 
infection, and BCG vaccination status.449 Age was categorized as <5 y, 5–14 y and ≥15 y 
in line with other work,196,450 and corresponding to differences in TB epidemiology.451 
Country of birth was classified as high or low TB incidence as defined by the World 
Health Organization with a cut off national incidence of 40 cases per 100,000 
population.452,453  
Mtb infection status was estimated by the response to Mantoux testing and/ or 
interferon-γ release assay (IGRA; usually QuantiFERON® [QFT; Cellestis, Australia]), the 
tests performed according to standard procedures.327,328 Routine practice at the 
Homerton University Hospital TB clinic was for both tests to be carried out in contacts 
aged 14-35 yrs. Children <14 years were usually tested with Mantoux alone, followed 
by IGRA if positive. Individuals >35 y were offered an IGRA and a chest x-ray without 
Mantoux testing. Because of the usual delay in developing immune sensitivity 
following Mtb infection, tests were repeated after 6 weeks if negative at baseline in 
case of recent transmission events. The Mantoux test was considered positive if the 
skin induration diameter measured ≥5 mm 48-72 h after tuberculin administration in 
BCG-naïve individuals or  ≥15 mm following previous BCG vaccination, or had increased 
by >5 mm on re-testing.327 Indication of infection with Mtb was followed by 








All patients notified to Public Health England (formerly the Health Protection 
Authority) as cases of tuberculosis at Homerton University Hospital during 2012 and 
2013 were included. 
Prospective data 
Patients with tuberculosis were prospectively recruited for 24-hour cough monitoring 
before or on starting anti-TB medication.  In order to increase the probability of 
observing recent TB transmission events, only patients with sputum smear-positive 
pulmonary disease were included. Routine clinical, radiological and microbiological 
data were collected for all patients as previously described (Section 3.3). 
11.3 Analysis of data 
The primary outcome measure was presumed infection with Mtb as determined by 
Mantoux and/or IGRA as just described. Univariate analysis of candidate categorical 
and continuous predictor variables was performed with Mantel-Haenszel tests and 
logistic regression, respectively. Variables possibly associated with Mtb infection (p < 
0.15) were entered into multivariate logistic regression models as previously described 
(Chapter 2), fitted using a generalized estimating equation in Stata to control for 
clustering of subjects within households. It was decided a priori to add the presence of 
cough (retrospective dataset) or cough frequency (prospective data) to the models, 
being the main variables of interest. Adjusted odds ratios were derived from the logit 
models by raising e to the power of the logistic coefficient. This was done separately 





11.4 Results  
11.4.1 Retrospective data 
470 individuals were screened for Mtb infection as contacts of 299 notified cases of TB 
during 2012-13. Associations of characteristics of these individuals and the index cases 
are shown in Table 11.1 and Table 11.2. On adjusted univariate analysis, contact 
characteristics associated with Mtb infection were TB incidence in the country of birth 
and age. Insufficient data on smoking in contacts were collected for analysis and there 
were only five patients with HIV to investigate its role as a risk factor for Mtb infection. 
Index characteristics associated with infection in contacts included site of disease 
(pulmonary, as opposed to extra-pulmonary tuberculosis). Amongst contacts of 
pulmonary TB, on adjusted analysis the presence of cough in the index case, sputum 
smear status of the index case, and index disease due to a Haarlem strain of organism 
appeared important. There were also independent trends for associations of index 
case sputum smear grade, radiological extent of disease, and the presence of visible 
cavities with Mtb infection in contacts.  
On multi-variate analysis of all contacts, TB incidence in contact country of birth (OR 
1.9 [1.1-3.1], p = 0.02) and site of index case disease (pulmonary vs. extrapulmonary, 
OR 2.0 [1.2-3.4], p = 0.01) were the only variables with an independent significant 
association with Mtb infection. For Mtb infection in contacts of pulmonary TB, only TB 
incidence in contact country of birth and sputum smear status appeared independent 
important explanatory variables (Table 11.2), with the presence of cough not being 
significant. Similarly, reported cough was not an independent predictor of Mtb 
infection looking only at contacts of smear positive pulmonary TB (data not shown). 
Amongst the screened household contacts there were 10 co-prevalent cases of 
tuberculosis. Only two of these had smear-positive pulmonary disease; both were 
contacts of different cases of smear positive index TB. One was the only screened 
contact of the associated index case, whereas the other was one of four screened 





Table 11.1. Univariate analysis of variables associated with M. tuberculosis infection in household contacts of 
tuberculosis (retrospective cohort). 
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INDEX CASE CHARACTERISTICS – CONTACTS OF ALL PATIENTS   























































































Sputum smear grade  










































































































































Table 11.2. Multivariate analysis of variables associated with M. tuberculosis infection in household contacts of 
pulmonary tuberculosis (retrospective cohort). 
 
CONTACTS Multivariate adjusted analysis 
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TB incidence in country 


















































Background rates of Mtb infection amongst the individuals screened can be estimated 
from rates of infection in contacts of extrapulmonary TB and of denotified cases, 
18.2% and 17.9%, respectively. 
11.4.2 Prospective data 
There were 28 patients with smear positive tuberculosis who underwent 24-hour 
cough monitoring at or before starting treatment (Section 3.5.10). 16 had household 
contacts who attended for screening at Homerton University Hospital. There were a 
total of 63 screened contacts, a median of 4 per index case (range 1-10). 23 screened 
contacts (37.1%) were deemed to have been infected with Mtb on the basis of 
Mantoux testing and/or IGRA. A Mantoux-/IGRA+ was considered significant in an 
adult and two Mantoux+/IGRA- were considered positive in children; the remainder 
were concordant.  There were no cases of co-prevalent active TB. 
There were only two contacts with HIV, one of whom was infected with Mtb. Only one 
had diabetes. There were no specific data on features of the housing type or proximity 







Table 11.3. Univariate analysis of variables associated with M. tuberculosis infection in household contacts of 
smear positive tuberculosis (prospective cohort). 
 
CONTACTS Univariate unadjusted analysis Univariate adjusted analysis 
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On univariate analyses there were trends (p < 0.15) for associations of sputum smear 
grade and cough frequency with household Mtb infection (Table 11.3). No other 
variables appeared to be important. There was no evidence that clustering of contacts 
within households affected these associations; adjusted statistical analysis revealed 
very similar results. However, on multivariate analysis, both sputum smear grade and 
baseline cough frequency (Figure 11.1) of the index case were both associated 
independently and significantly with Mtb infection in contacts (Table 11.4). 
1 0 1 0 0 1 0 0 0
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c o n ta c ts  in fe c te d
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Figure 11.1. Cough frequency in smear positive tuberculosis and TB infection in household contacts.  
Table 11.4. The association of index case cough frequency and sputum bacillary with M. tuberculosis infection in 
contacts on logistic regression analysis. 
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This is the first work to show an association of 24-hour cough frequency in TB with 
rates of Mtb infection amongst contacts. It is also the first work to show a significant 
association of objective cough frequency measured over any duration with Mtb 
infection.  In contrast the subjectively-reported presence of cough was not 
independently associated with this measure of transmission. 
11.5.1 Retrospective data: the presence of cough and household infection 
Coughing has long been assumed to be important for the transmission of tuberculosis 
but direct data supporting this have been mainly circumstantial  (Section 1.5).119 Few 
studies appear to have investigated patient-reported cough as an independent risk 
factor for infectiousness.234  
Although apparently important on univariate analysis, the current work did not find 
reported cough in the index case to be an independent risk factor for Mtb infection in 
household contacts.234 This is in contrast to the recent study of Jones-López which 
measured cough symptoms in TB and Mtb infection in households.234 However, in that 
study, symptoms were measured quantitatively (visual analogue scale and the 
Leicester Cough Questionnaire), rather than by the simple approach of cough present 
vs. cough absent, presumably resulting in greater power to detect an effect of cough 
symptoms.234 There were relatively few index cases of pulmonary TB in the 
retrospective part of the study here who denied cough; information on the severity of 
cough symptoms was not available. In the (relatively small) prospective part of the 
study I chose not to investigate an association between cough symptoms and 
household Mtb infection due to the limited correlation that exists between subjective 
assessments of cough and the variable of interest, objectively-determined cough 
frequency in TB (Section 7.4.3). 
Reported cough duration in the source case was not shown to be associated with Mtb 
infection in household contacts. This appears to have been rarely examined,454,455 but 





and commencing treatment will presumably have given rise to more opportunities for 
transmission of infection. The current study may have been underpowered to detect 
this effect. However, as well as there being a poor correlation between objective 
cough frequency and the subjective appreciation of coughing, recall of onset of 
symptoms is probably variable. Patient-reported estimates of duration of cough might 
therefore not be an accurate representation of the objectively-measured time for 
which cough frequency has been increased. 
In the retrospective dataset, the Haarlem strain of organism in the index case was 
associated with higher rates of presumed infection in household contacts. This was not 
supported by the prospective findings. Neither am I aware of reports from the 
literature suggesting an association of increased infectiousness with the Haarlem 
clade. Conversely, Jones-López et al. reported that a genetic cluster corresponding to 
the Haarlem spoligotype was associated with households in which there was a lower 
prevalence of Mtb infection on contact tracing.234 There is clearly a need for further 
investigation into the potential role of Mtb strain type in transmission of infection.184 
11.5.2 Prospective data: objectively-measured cough frequency and household TB 
infection 
Regarding objective cough frequency in TB, the only previous relevant study involved 
130 childhood household contacts, including 88 contacts of smear positive disease. In 
contrast to the current work which found a significant association between index case 
cough frequency and household rates of Mtb infection, the relationship between these 
two variables in the previous study was not statistically significant (p < 0.20).125 
A reason for the discrepancies between the findings of the current work and this 
previous study might relate to the duration of cough monitoring. As previously 
discussed (Section 1.5.3.3), Loudon and Spohn performed only overnight recordings 
lasting 8 h,125 as opposed to 24-hour recordings in the current work. However, 
although 24-hour monitoring produces a full picture of the amount of coughing on a 





nocturnal cough counts are a good surrogate for 24-hour monitoring. Other 
differences between the current work and that of Loudon and Spohn include the 
method of determining infection with Mtb, the age of the contact cases, and, possibly, 
patient characteristics, strains of Mtb, and environmental factors. The earlier study 
used only the tuberculin skin test (TST) for determining infection, having taken place 
several decades prior to the introduction of IGRAs. A positive test was defined as a 
resulting skin induration of diameter ≥10 mm, as opposed ≥5 or ≥15 mm in the current 
study, depending on BCG vaccination status. The sensitivity of the test decreases with 
a larger minimum induration size.297  
Previous BCG vaccination status affects interpretation of the result and was not stated 
in the previous paper, although few or no contacts are likely to have been vaccinated, 
the study having taken place in the USA, where routine BCG vaccination has never 
been recommended.456,457 The performance of the TST in the earlier study may also 
have been adversely affected by the relatively very high levels of exposure to non-TB 
mycobacterial antigens which occur in Texas and other Southern States .366,458 One of 
the shortcomings of the TST is its low specificity compared to currently available 
IGRAs.459 
Unlike in the current study, Loudon recruited only children aged ≤14 years for 
estimating recent household Mtb transmission, to reduce the chance that a presumed 
infection had occurred at some other point in time, the opportunities for such events 
being lower with younger age. In the current work, like any using immunological 
markers as a surrogate for recent transmission, there was no way of confirming that 
the sources of presumed infection were the TB index cases of interest.  
However, several additional findings add weight to assumption of additional 
transmission events amongst the screened contacts. Firstly, the rate of Mtb infection 
amongst this group (37%) was higher than the local background prevalence of 18% 
amongst contacts of presumed non-infectious individuals (p = 0.007, Fisher’s exact 





microscopy were also associated with rates of Mtb infection amongst household 
contacts suggests the occurrence of transmission from the source cases of interest, 
sputum smear status being the most commonly-used predictor of infectiousness in 
pulmonary TB (Section 1.5.3.1).119,200 Thirdly, 50% of children aged <5 years 
demonstrated immune responses to Mtb antigen, and, finally, birth in a high TB-
incidence country was not associated with LTBI amongst household contacts in the 
prospective cohort. These observations are all difficult to explain without recent 
transmission events, at least some of which were presumably associated with the 
index cases of interest.  
There had presumably been far fewer recent transmission events amongst the 
retrospective cohort of household contacts; a large proportion of the index cases were 
likely to have been non-infectious, having either smear negative pulmonary disease, 
extra-pulmonary TB or no TB diagnosis at all (denotified cases; Table 11.1). As a 
consequence, in that cohort, only 16% of children aged <5 years demonstrated 
evidence of TB infection, and birth in a high TB-incidence was the strongest predictor 
of Mtb infection amongst all contacts overall, a likely result of a the relative 
importance of distant over recent transmission.  
It is not possible to comment on differences between individual characteristics of the 
index cases and household contacts between the current work and that of Loudon, nor 
on differences in environmental characteristics as they were either not measured or 
not reported in one or both studies.  
Although sputum bacterial content of the index case has repeatedly been shown to 
predict rates of infection in household contacts,119 relatively few studies have 
specifically investigated the effect of sputum smear grade amongst smear positive 
source cases of TB.460,461 In this context, the findings reported here of an association 
between smear grade and household transmission is of particular interest.  
There was no evidence for an association between Mtb infection and any 





other than cough frequency and sputum smear grade. This included two of the 
apparently strongest risks for infection, contact birth place in a high TB-prevalence 
country,450 and visible cavities on the chest x-ray of the index case. However, it is 
unclear whether the presence of cavities is a risk factor for transmission independent 
of smear positivity (Section 1.5.3.1). And it is possible that relatively high rates of 
recent infection were more important than previous background Mtb transmission 
events, masking the apparent effect of country of birth. Larger studies with more 
statistical power would be required for this to be explored further. 
11.5.3 Limitations 
There were no data on several variables which may have been relevant for 
transmission, for example details of the nature and duration of  contact between index 
case and contacts,119 and environmental features such as household ventilation.181 
However, this study was essentially exploratory and to control for other potentially 
important variables would have required a larger investigation.  
The role of exposure to cases of TB other than the index case of interest was taken into 
account only by documenting co-prevalent smear positive pulmonary tuberculosis. 
However, there were no such cases in the prospective cohort, and only one of 
relevance (where there were other household contacts) in the retrospective series. 
Household co-prevalent active TB was therefore not a significant problem for the 
current work. The elimination of all other, possibly unknown, relevant source cases of 
Mtb infection, over a longer period for older screened individuals, is of course 
impossible. It is a general limitation of using immune responses as a marker of 
transmission, and has been discussed (previous Section and Section 1.6.2.5.5).  
However, none of the variables potentially associated with observed rates of Mtb 
infection was likely to have been also related to coughing, so should not have 






Because only smear positive TB was studied no comment can be made on the role of 
cough frequency on infectiousness in patients who were sputum smear negative for 
AFB. Owing to the much lower likelihood of transmission with smear-negative 
disease,462 a larger study would be needed to investigate this. 
Cough monitoring covered only one 24-hour period prior to starting treatment. This is 
only a surrogate for estimating the rates of aerosolization of TB bacilli during the total 
period of infectiousness prior to treatment. It would be difficult, ethically and 
logistically, to organize a study involving multiple periods of 24-hour cough monitoring 
before starting treatment in a potentially infectious source case. However, as observed 
in Chapter 8 (Section 8.5.2.1), the lack of change in 24-cough frequency within the first 
48 h of TB treatment suggests relatively stability in cough counts for at least several 
days prior to the cough monitoring period. 
11.6  Conclusions 
The demonstration of an association between 24-hour cough frequency in smear 
positive tuberculosis and rates of household infection is novel. Any method of 
estimating the infectiousness of TB should be welcome for directing infection control 
measures and contact tracing efforts, particularly with drug-resistant disease in areas 












12 Summary, conclusions and final 
remarks 
From an initial idea of researching coughing in tuberculosis it soon became apparent 
that there were many gaps in knowledge about cough, not only in TB, but in 
respiratory disease in general. Some of these uncertainties were fundamental and 
seemingly basic, such as how to best define a cough. Identification of the gaps in the 
literature, led to a series of specific interlinking research questions. 
I started by assessing whether cough impacts on patients to a greater or lesser degree 
in some respiratory conditions than others, i.e. whether there are subjective 
differences in cough between diseases (Chapter 4). Wide variation was observed both 
within as well as between respiratory conditions, with few significant differences 
overall between diseases. In the process of doing this I validated the Leicester cough 
Questionnaire for use in tuberculosis. 
Following this confirmation that a reliance on subjective measures would be 
insufficient for research into cough, I addressed how best to measure cough frequency 
objectively (Chapter 5). I confirmed that coughs are easily recognizable by the human 
ear, providing justification for counting coughs based on their ‘characteristic sound’.2 
This also provided a method for evaluating an automated cough monitor. In contrast 
with an earlier report,262 PulmoTrackTM showed poor agreement with the human ear, 
and was not be suited for the remainder of the study (Chapter 5). I therefore used the 
Leicester Cough Monitor from then on which, although like any cough monitor 
currently used in research has limitations, has been more extensively validated than 
any other device. 
Chapter 6 addressed the other common approach to the objective clinical evaluation 
of cough, the capsaicin cough challenge. In particular I provided further data to suggest 





cough reflex sensitivity, and show that a novel measure, E62.5, could have merit due to 
a correlation with 24-hour cough frequency. 
Chapter 7 compared 24-hour temporal cough patterns in a large group of patients with 
different diseases, including several in which no such measurements have been 
reported previously. There was much variation in cough frequency within and between 
diseases, and nothing to suggest a unique temporal pattern of cough in any disease. In 
particular, nocturnal suppression of coughing appears universal across respiratory 
conditions, and there was a remarkably constant relationship between nocturnal 
cough rates and those during the day. This strongly suggests the existence of common 
basic mechanisms driving cough across varying contexts.  
Chapter 7 also examined variables associated with coughing in respiratory diseases 
which have not been investigated previously. While some of the novel findings are 
probably merely hypothesis-generating due to small sample sizes, others have 
corroborated those of earlier work from overnight monitoring. Such findings include 
an association (albeit with p = 0.054) sputum smear status and 24-cough frequency in 
TB, and a (perhaps surprising) lack of general overall correlation between current 
smoking and cough frequency in respiratory disease. 
The improvement in 24-hour cough frequency during treatment of acute respiratory 
conditions and tuberculosis was the rarely-studied subject of Chapter 8. Although only 
relatively small numbers of patients were included, the s lower rates of decrease in 
coughing in acute asthma and COPD exacerbations compared to pneumonia despite 
otherwise successful recovery from illness were of interest and led to speculation 
about mechanistic factors. The pilot data on the rates of improvement in 24-hour 
cough frequency with treatment of pulmonary tuberculosis  were remarkably similar to 
observations made almost 50 years ago in the pre-rifampicin era with overnight cough 
recordings. A slower response to treatment was associated with explanatory clinical 
factors, suggesting that 24-hour cough frequency might be a novel biomarker of 





An attempt to explain some of the poorly understood variability in baseline cough 
patterns in respiratory disease was made in Chapter 9 by measuring TRPV1 
polymorphism. Despite much interest in TRPV1, there was no evidence that such 
genetic variability substantially affects objectively-measured features of chronic cough.  
The following chapters addressed the potential infectiousness of coughing in 
tuberculosis. Section 1.5.4 had taken a theoretical approach to discuss the movement 
of respiratory droplets on leaving the mouth and made predictions based on variables 
including droplet velocity, size and composition and ambient conditions including 
temperature and relative humidity. Chapter 10 attempted to measure such droplets 
with the aims of testing these predictions on comparing different respiratory actions 
and types of cough in aerosolizing respiratory secretions. Unfortunately the device 
tested was shown to be not sufficiently sensitive for this purpose. Finally, Chapter 11 
assessed 24-cough frequency in tuberculosis along with other variables to try and 
explain variation in rates of household infection. I demonstrated, for probably the first 
time, a significant independent association between cough frequency and rates of 
household infection. Objectively-measured cough seemed a much more sensitive 
predictor of infectiousness than the documented presence or absence of coughing. 
Any piece of clinical research has constraints, due to time, resources, expertise, and 
availability of study subjects. This is particularly the case with a doctoral thesis. The 
main limitation in the current work has been patient sample sizes, which, as a 
consequence, mean that many of the findings presented here should be seen as 
preliminary. The novel conclusions in particular should be confirmed in other contexts 
and in larger studies.  
Another limitation of this research has been the lack of scope to explore other areas 
initially identified in Chapter 1 as being worthy of study. This includes the issue of 
whether cough sounds are different depending on underlying pathology, which 
remains unresolved. Initial data which I have not yet reported, in keeping with those of 





as between diagnostic groups. I did not perform analysis of the sound frequency 
composition of coughs. Only one study seems to suggest that cough sounds may have 
diagnostic value,100 and should be replicated. 
Much still remains to be discovered about the mechanisms of cough. Genetic 
influences may still be important, if not involving TRPV1, then perhaps involving other 
cough receptors (such as P2X3), mucus production, the central processing of cough, or 
other complex determinants of coughing. The measurement of volatile organic 
compounds in exhaled breath in health and disease and during treatment may reveal 
novel mediators for cough.463,464   
The interaction between taste sensation and the cough reflex is worthy of study. 
Observations made in the process of this research, but not reported, suggest the 
ability to taste phenylthiocarbamide (PTC) was not related to cough. However, a more 
detailed examination of the pathways involved in detecting taste in the context of 
cough would now seem to be even more fruitful following the recent demonstration of 
the efficacy of a P2X3 antagonist in chronic cough,43,431 P2X receptors being integral to 
gustation.50  
Finally, a much more detailed assessment of how coughing produces infectious 
airborne particles should be undertaken, in TB and other contexts. This will require a 
complicated approach, both to measure particles283 and to study the mechanics of 
coughing. 
Few pieces of research are definitive. The minimum I hope to have achieved in working 
towards this thesis is to have better defined areas of ignorance that exist within the 
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